Heterocyclic compounds for imaging aggregated alpha synuclein in the synucleinopathies
Heterocyclic compounds specifically bind to alpha-synuclein, addressing the challenge of imaging and treating alpha-synuclein aggregation in neurodegenerative diseases by enabling precise brain imaging and aggregate clearance, thus offering a promising approach for managing conditions like Parkinson's disease and multiple system atrophy.
Patent Information
- Application Number
- PCT/US2024/028910
- Authority / Receiving Office
- WO · WO
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2023-05-10
- Filing Date
- 2024-05-10
- Publication Date
- 2024-11-14
AI Technical Summary
Current methods for monitoring and treating neurodegenerative diseases associated with alpha-synuclein aggregation, such as Parkinson's disease and multiple system atrophy, lack effective strategies for imaging and clearing pathological alpha-synuclein aggregates from the brain.
Development of heterocyclic compounds that bind specifically to alpha-synuclein with high affinity, allowing for effective modulation and imaging of alpha-synuclein aggregates in the brain, while minimizing off-target binding to Abeta, which can interfere with imaging.
The compounds enable precise imaging and potential treatment of neurodegenerative disorders by targeting and clearing alpha-synuclein aggregates, as demonstrated by their high brain uptake and specificity in positron emission tomography imaging and their ability to modulate alpha-synuclein in preclinical studies.
Smart Images

Figure US2024028910_14112024_PF_FP_ABST
Abstract
Description
HETEROCYCLIC COMPOUNDS FOR IMAGING AGGREGATED ALPHA SYNUCLEIN IN THE SYNUCLEINOPATHIESCROSS-REFERENCE TO RELATED APPLICATIONS
[0001] This application claims the benefit of the priority of U.S. Provisional Patent Application No. 63 / 501,345, filed May 10, 2023, the disclosure of which is incorporated by reference herein.GOVERNMENT RIGHTS
[0002] This invention was made with government support under NS 110456 awarded by the National Institutes of Health. The government has certain rights in the invention.TECHNICAL FIELD
[0003] The present disclosure provides heterocyclic compounds and uses thereof.BACKGROUND
[0004] Alpha-synuclein is a 140 amino acid protein whose function in cell biology is poorly understood. Post-translational modification and abnormal aggregation of this protein is an event in a family of neurodegenerative disorders referred to as the “synucleinopathies.” The most common synucleinopathy is Parkinson’s disease (PD), which is characterized by the insoluble aggregates of alpha-synuclein (Asyn or asyn) in the form of Lewy bodies (LBs) and Lewy neurites (LNs). Another synucleinopathy is multiple system atrophy (MSA), which is characterized by alpha-synuclein aggregates in the form of glial cell inclusions (GCIs) in the oligodendrocytes largely in the cerebellum, pons and medulla. Since the abnormal aggregation of alpha-synuclein is believed to play a causal role in PD and MSA, there has been a major effort to develop novel therapeutic strategies aimed at preventing or removing pathological forms of this protein from brain.
[0005] What is needed are alternate methods for monitoring and treatment neurodegenerative diseases.SUMMARY
[0006] In some aspects, the disclosure provides compounds of Formula I or a pharmaceutically acceptable salt or isotopic variant thereof, wherein R1to R7, Xi and X2 are defined herein.
[0007] In other embodiments, the disclosure provides compounds of Formula II, or a pharmaceutically acceptable salt or isotopic variant thereof, wherein R20-R25, R31-R34, Zi, Z2, and a-e are defined herein.
[0008] In further embodiments, the disclosure provides methods of modulating alpha-synuclein in a patient in need thereof, comprising administering an effective amount of a compound described herein to the patient. In certain aspects, the compound binds to alpha- synuclein.
[0009] In yet other embodiments, the disclosure provides methods of treating a neurodegenerative disorder in a patient in need thereof, comprising administering a pharmaceutical agent that clears aggregated alpha-synuclein from the brain of the patient; administering an effective amount of a compound described herein to the patient; and performing positron emission tomography imaging on the patient. In certain aspects, the compound has a low affinity for Ap.BRIEF DESCRIPTION OF THE DRAWINGS
[0010] FIGs. 1A and 1C are nuclear emulsion autoradiography images of a postmortem brain samples (A-not PD brain; C-MSA brain) after administration of3H- Compound 103. FIGs. IB and ID are the same samples from FIGs. 1A and 1C after incubating sequentially with anti-phospho-a-syn (SI 29) antibody (p-syn / 81A, BioLegend) and Alexa Fluor 488 goat anti-mouse secondary antibody to immunostain LBs and LNs.FIGs. IE and 1G are nuclear emulsion autoradiography images of postmortem brain samples of (E-PD brain; G-not MSA brain) with3H-Compound 43. FIGs. IF and 1H are the same samples from FIGs. IE and 1G after incubating sequentially with anti-phospho-a-syn (SI 29) antibody (p-syn / 81A, BioLegend) and Alexa Fluor 488 goat anti-mouse secondary antibody to immunostain LBs and LNs.
[0011] FIG. 2 are dynamic whole body PET images of1^-compound 103 in a nonhuman primate 1-90 minutes after administration1’C-compound 103. This figure shows the high brain uptake and rapid washout of [nC]-Compound 103.
[0012] FIG. 3 are autoradiography images in tissue sections of3H-Compound 103 and3H-Compound 43 in PD, MSA and control brain. Neuropathological scores for Abeta, tau and Asyn are shown for each tissue section. FIG. 3 (top) shows the ability of [3H]- Compound 103 to image alpha synuclein in human postmortem samples of MSA and not PD and age-matched control. FIG. 3 (bottom) shows the ability of [3H]-Compound 43 to image alpha synuclein in human postmortem samples of PD and not MSA and age-matched control.
[0013] FIG. 4 is a dot plot showing the ratio of the specific binding signal for ■’El- Compound 103 of pathology case (PD or MSA) vs. control for each radioligand. (PD : Control and MSA : Control). This figure shows the specificity of the radiotracers shown in Figure 3.
[0014] FIG. 5 is a dot plot showing the ratio of the specific binding signal for ■’El- Compound 43 of pathology case (PD or MSA) vs. control for each radioligand. (PD : Control and MSA : Control). This figure shows the specificity of the radiotracers shown in Figure 3.
[0015] FIG. 6 are dynamic PET images (top) and time-activity curves for whole brain and different brain regions (bottom) ofnC-compound 103 in a non-human primate and show the high uptake and rapid washout of [nC]-compound 103.
[0016] FIG. 7 are dynamic PET images (top) and time-activity curves (bottom) ofnC-compound 43 in a non-human primate and show the high uptake and rapid washout of [nC]-compound 43.DETAILED DESCRIPTION OF ILLUSTRATIVE EMBODIMENTS
[0017] Described herein is the radiosynthesis, in vitro binding, and in vivo evaluation of compounds that bind with high affinity to Asyn. Advantageously, thecompounds disclosed herein have a low affinity for Abeta. Abeta is an off-target binding site that may interfere with imaging alpha synuclein aggregates in the synucleinopathies.
[0018] In the present disclosure the singular forms “a,” “an” and “the” include the plural reference, and reference to a particular numerical value includes at least that particular value, unless the context clearly indicates otherwise. Thus, for example, a reference to “a material” is a reference to at least one of such materials and equivalents thereof known to those skilled in the art, and so forth.
[0019] When a value is expressed as an approximation by use of the descriptor “about” it will be understood that the particular value forms another embodiment. In general, use of the term “about” indicates approximations that can vary depending on the desired properties sought to be obtained by the disclosed subject matter and is to be interpreted in the specific context in which it is used, based on its function. The person skilled in the art will be able to interpret this as a matter of routine. In some cases, the number of significant figures used for a particular value may be one non-limiting method of determining the extent of the word “about.” In other cases, the gradations used in a series of values may be used to determine the intended range available to the term “about.” Where present, all ranges are inclusive and combinable. That is, references to values stated in ranges include every value within that range.
[0020] When a list is presented, unless stated otherwise, it is to be understood that each individual element of that list and every combination of that list is to be interpreted as a separate embodiment. For example, a list of embodiments presented as “A, B, or C” is to be interpreted as including the embodiments, “A,” “B,” “C,” “A or B,” “A or C,” “B or C,” or “A, B, or C.”
[0021] It is to be appreciated that certain features which are, for clarity, described herein in the context of separate embodiments, may also be provided in combination in a single embodiment. That is, unless obviously incompatible or excluded, each individual embodiment is deemed to be combinable with any other embodiment(s) and such a combination is considered to be another embodiment. Conversely, various features of the invention that are, for brevity, described in the context of a single embodiment, may also be provided separately or in any sub-combination. It is further noted that the claims may be drafted to exclude any optional element. As such, this statement is intended to serve as antecedent basis for use of such exclusive terminology as “solely,” “only” and the like in connection with the recitation of claim elements, or use of a “negative” limitation. Finally,while an embodiment may be described as part of a series of steps or part of a more general structure, each said step may also be considered an independent embodiment in itself.
[0022] As used herein, the term “administering” means providing a pharmaceutical agent, z.e., a compound described herein, or composition, z.e., a pharmaceutical compositions described herein, to a subject, and includes, but is not limited to, administering by a medical professional and self-administering.
[0023] As used herein, the phrase “pharmaceutically acceptable” refers to compounds, compositions, and / or dosage forms which are, within the scope of sound medical judgment, suitable for use in contact with the tissues of human beings and animals without excessive toxicity, irritation, allergic response, or other problem or complication, commensurate with a reasonable benefit / risk ratio.
[0024] As used herein, the term :compound(s) of formula I” includes those compounds of “formula I,” as well as compounds of any of the formula I subgenera. The term “compound(s) of formula II” includes those compounds of “formula II,” as well as compounds of any of the formula I) subgenera.
[0025] As used herein, the term “subject” or “patient” means a human or nonhuman animal selected for treatment or therapy.
[0026] As used herein, the term “treating” a disease in a subject or “treating” a subject having or suspected of having a disease refers to subjecting the subject to a pharmaceutical treatment, e.g., the administration of an agent, such that at least one symptom of the disease is decreased or prevented from worsening.
[0027] As used herein, the term “isotopic variant” refers to a compound that contains unnatural proportions of isotopes at one or more of the atoms that constitute such compound. In some embodiments, an “isotopic variant” of a compound can be radiolabeled, that is, contain one or more non-radioactive isotopes and / or one radioactive isotope. It will be understood that, in a compound where such isotopic substitution is made, the following atoms, where present, may vary, so that for example, any hydrogen may be2H / D, any carbon may be13C, or any nitrogen may be15N, and that the presence and placement of such atoms may be determined within the skill of the art. In other embodiments, the compounds are radiolabeled with a non-radioactive isotope such as for example, deuterium (2H or D), carbon- 13 (13C), nitrogen- 15 (15N), or the like. In other embodiments, the compounds are, additionally or alternatively, labeled with one radioactive isotope. In some embodiments, the radioactive isotopes emit electrons, alpha (a), gamma (y) or beta (P‘ or p+) particles.Radioactive labels include, without limitation, tritium (3H), carbon-11 (nC), carbon-14 (14C), fluorine-18 (18F), iodine-123 (123I), iodine-124 (124I), iodine-125 (125I), iodine-131 (131I), bromine-76 (76Br), bromine-77 (77Br), oxygen-15 (15O), nitrogen-13 (13N), or astatine-211 (211At) or combinations thereof. Thus, radiolabeled compounds of the disclosure can be used in diagnostic methods such imaging. Imaging methods include, without limitation, singlephoton emission computed tomography (SPECT) or Positron Emission Topography (PET) studies. In some embodiments, the radiolabel is3H or14C. In further embodiments, the compound is radiolabeled with3H,14C, and / or123I and may be used in SPECT. In other embodiments, the compound is radiolabeled with a P+emitting isotopes, such asnC,18F,15O,13N,124I, or76Br and may be useful in PET. In further embodiments, the compound is radiolabeled with18F ornC and may be useful in PET. In yet other embodiments, the compound is labeled with123I and may be useful in SPECT. In further embodiments, the compounds may be radiolabeled with electron emitting isotopes, such as123I, or77Br. In yet other embodiments, the compounds are radiolabeled with alpha particle emitting radiolabels such as211At. In still further embodiments, the compounds are radiolabeled with P' emitting isotopes such as131I.
[0028] All isotopic variants of the compounds of the disclosure, radioactive or not, are intended to be encompassed within the scope of the disclosure.
[0029] It is also to be understood that compounds that have the same molecular formula but differ in the nature or sequence of bonding of their atoms or the arrangement of their atoms in space are termed “isomers.” Isomers that differ in the arrangement of their atoms in space are termed “stereoisomers,” for example, diastereomers, enantiomers, and atropisomers. The compounds of this disclosure may possess one or more asymmetric centers; such compounds can therefore be produced as individual (R)- or (S)-stereoisomers or as mixtures thereof.
[0030] Unless indicated otherwise, the description or naming of a particular compound in the specification and claims is intended to include both individual enantiomers and mixtures, racemic or otherwise, thereof. Within the present disclosure, any open valency appearing on a carbon, oxygen, or nitrogen atom in any structure described herein indicates the presence of a hydrogen atom. Where a chiral center exists in a structure, but no specific stereochemistry is shown for that center, both enantiomers, separately or as a mixture, are encompassed by that structure. The methods for the determination of stereochemistry and the separation of stereoisomers are well-known in the art.
[0031] The term “alkyl” as used herein, alone or in combination, refers to an aliphatic or cyclic hydrocarbon radical containing from 1 to about 20 carbon atoms, preferably from 2 to 6, more preferably from 2 to 4, carbon atoms. Representative examples of alkyl include, but are not limited to, methyl, ethyl, n-propyl, iso-propyl, n-butyl, sec-butyl, iso-butyl, tert-butyl, n-pentyl, isopentyl, neopentyl, n-hexyl, 2-methylcyclopentyl, and 1- cy cl ohexyl ethyl. An alkyl described herein may be substituted as described herein.
[0032] The term “alkynyl,” as used herein, alone or in combination, refers to a straight-chain or branched chain hydrocarbon radical having one or more triple bonds and containing from 2 to 20, preferably from 2 to 6, more preferably from 2 to 4, carbon atoms. Examples of alkynyl radicals include, without limitation, ethynyl, propynyl, hydroxypropynyl, butyn-l-yl, butyn-2-yl, pentyn-l-yl, 3-methylbutyn-l-yl, hexyn-2-yl, and the like. An alkynyl described herein may be substituted as described herein.
[0033] The term “amino,” as used herein, alone or in combination, refers to -NRR,’ wherein R and R,’ are, independently, hydrogen, alkyl, acyl, heteroalkyl, aryl, cycloalkyl, heteroaryl, or heterocycloalkyl, any of which can themselves be optionally substituted.
[0034] The term “aryl,” as used herein, alone or in combination, means a carbocyclic aromatic system containing one, two or three rings wherein such rings can be attached together in a pendant manner or can be fused. The term “aryl” embraces aromatic radicals such as phenyl, naphthyl, anthracenyl, phenanthryl, indanyl, indenyl, annulenyl, azulenyl, tetrahydronaphthyl, and biphenyl. An aryl may be substituted as described herein.
[0035] The term “heteroaryl,” as used herein, alone or in combination, refers to 3- to 7-membered, unsaturated heteromonocyclic rings, or fused polycyclic rings in which at least one of the fused rings is unsaturated, wherein at least one atom is selected from the group consisting of O, S, and N. The term also embraces fused polycyclic groups wherein heterocyclic radicals are fused with aryl radicals, wherein heteroaryl radicals are fused with other heteroaryl radicals, or wherein heteroaryl radicals are fused with cycloalkyl radicals. Examples of heteroaryl groups include pyrrolyl, pyrrolinyl, imidazolyl, pyrazolyl, pyridyl, pyrimidinyl, pyrazinyl, pyridazinyl, triazolyl, pyranyl, furyl, thienyl, oxazolyl, isoxazolyl, oxadiazolyl, thiazolyl, thiadiazolyl, isothiazolyl, indolyl, isoindolyl, indolizinyl, benzimidazolyl, quinolyl, isoquinolyl, quinoxalinyl, quinazolinyl, indazolyl, benzotriazolyl, benzodi oxolyl, benzopyranyl, benzoxazolyl, benzoxadiazolyl, benzothiazolyl, benzothiadiazolyl, benzofuryl, benzothienyl, chromonyl, coumarinyl, benzopyranyl, tetrahydroquinolinyl, tetrazolopyridazinyl, tetrahydroisoquinolinyl, thienopyridinyl,furopyridinyl, pyrrolopyridinyl and the like. Exemplary tricyclic heterocyclic groups include carbazolyl, benzidolyl, phenanthrolinyl, dibenzofuranyl, acridinyl, phenanthridinyl, xanthenyl and the like. A heteroaryl may be substituted as described herein.
[0036] The term “halogen,” “halo,” or “hal,” as used herein, alone or in combination, refers to fluorine, chlorine, bromine, or iodine.
[0037] The term “optionally substituted” means the anteceding group can be substituted or unsubstituted. When substituted, the substituents of an “optionally substituted” group can include, for example, one or more substituents independently selected from the following groups or a particular designated set of groups, alone or in combination: alkyl, alkenyl, alkynyl, cycloalkyl, aryl, alkoxy (such as methoxy), hydroxyalkyl, oxo, cyano, halogen, hydroxy, amino, nitro (NO2), or thiol (SH). In some embodiments, the substituent is Ci-ealkyl. In other embodiments, the substituent is C2-ealkenyl. In further embodiments, the substituent is C2-ealkynyl. In yet other embodiments, the substituent is Cs-scycloalkyl. In still further embodiments, the substituent is aryl. In other embodiments, the substituent is Ci- ealkoxy (such as methoxy). In further embodiments, the substituent is hydroxyalkyl, such as CH2OH or CH2CH2OH. In yet other embodiments, the substituent is oxo. In still further embodiments, the substituent is cyano (CN). In other embodiments, the substituent is halo (F, or Cl, or Br). In further embodiments, the substituent is hydroxy (OH). In still other embodiments, the substituent is amino (NH2). In yet further embodiments, the substituent is nitro (NO2). In other embodiments, the substituent is thiol (SH).Compounds of Formula I
[0038] According to the disclosure, compounds of Formula I are described:
[0039] According to the disclosure, n is 1 or 2. In some embodiments, n is 1. In other embodiments, n is 2.
[0040] According to the disclosure, R1to R4are H. In some embodiments, R1and R3are H and R2and R4are joined to form -Ci-ealk-. In other embodiments, R2and R4are joined to form -CH2-. In further embodiments, R2and R4are joined to form -CH2CH2-.among others. In yet other embodiments, R2and R4are H and R1and R3are joined to form - Ci-ealk-. In still further embodiments, R1and R3are joined to form -CH2-. In other embodiments, R1and R3are joined to form -CH2CH2-. In further embodiments, R1to R4are H.
[0041] According to the disclosure, R5is optionally substituted aryl or optionally substituted heteroaryl. In some embodiments, R5is optionally substituted aryl. In further embodiments, R5is optionally substituted phenyl. In further embodiments, R5is optionally substituted heteroaryl. In yet other embodiments, R5is optionally substituted N-containing heteroaryl. In still further embodiments, R5is optionally substituted pyridyl, optionally substituted isoquinolinyl, optionally substituted benzoxazolyl, optionally substituted benzthiazolyl, or optionally substituted quinoxalinyl. In other embodiments, R5is optionally substituted pyridyl. In further embodiments, R5is optionally substituted isoquinolinyl. In yet other embodiments, R5is optionally substituted benzoxazolyl. In still further embodiments, R5is optionally substituted benzthiazolyl. In other embodiments, R5is optionally substituted quinoxalinyl. In further embodiments, R5is substituted with alkoxy such as methoxy.
[0042] According to the disclosure, X1is absent or -C(O)-. In some embodiments, X1is absent. In other embodiments, X1is -C(O)-.
[0043] According to the disclosure, X2absent, O, or NH. In some embodiments, X2is absent. In other embodiments, X2is O. In further embodiments, X2is NH.
[0044] According to the disclosure R6is H, CN, Ci-ealkyl, Ci-ealk-OH, or optionally substituted phenyl. In some embodiments, R6is H. In other embodiments, R6is CN. In further embodiments, R6is Ci-ealkyl. In yet other embodiments, R6is methyl, ethyl, propyl, butyl, pentyl, or hexyl. In still further embodiments, R6is methyl. In other embodiments, R6is Ci-ealkOH. In further embodiments, R6is CH2OH, CH2CH2OH, propyl-OH, butyl-OH, pentyl-OH, or hexyl-OH. In yet other embodiments, R6is optionally substituted phenyl. In further embodiments, R6is, wherein R9is optionally substituted Ci-ealkyl, optionally substituted Ci-ealkoxy, halo, optionally substituted Ci-ehaloalkyl, or optionally substituted Ci-ehaloalkoxy. In some aspects, R9is optionally substituted Ci-ealkyl such as methyl, ethyl, propyl, butyl, pentyl, or hexyl, or such as CH3. In other aspects, R9is optionally substituted Ci-ealkoxy such as methoxy, ethoxy, propoxy, butoxy, pentoxy, or hexoxy, or such as methoxy. In further aspects, R9is halo such as Br, Cl, or F, or such as F. In still further aspects, R9is optionally substituted Ci-ehaloalkyl such as CF3. In yet otheraspects, R9is optionally substituted Ci-ehaloalkoxy such as OCF3, OCH2CH2F, or OCH2CH(OH)CH2F.
[0045] According to the disclosure, R7and R8are, independently, H, halo, or NH2. In some embodiments, R7is H. In other embodiments, R7is halo such as Cl, F, or Br. In further embodiments, R7is F. In further embodiments, R7is NH2. In yet other embodiments, R8is H. In still further embodiments, R8is halo such as Cl, F, or Br. In other embodiments, R8is F. In further embodiments, R8is NH2.
[0046] In some aspects, the compound is of Formula I-A, or a pharmaceutically acceptable salt or isotopic variant thereof, wherein R'-R8, X2, and n are defined herein:
[0047] In other aspects, the compound is of Formula I-B, or a pharmaceutically acceptable salt or isotopic variant thereof, wherein R'-R5, R7, R8, and n are defined herein:
[0048] In further aspects, the compound is of Formula I-C, or a pharmaceutically acceptable salt or isotopic variant thereof, wherein R'-R8and n are defined herein:
[0049] In yet other aspects, the compound is of Formula I-D, or a pharmaceutically acceptable salt or isotopic variant thereof, wherein R'-R8and n are defined herein:
[0050] In still other aspects, the compound is of Formula I-E, or a pharmaceutically acceptable salt or isotopic variant thereof, wherein RJ-R5, R7, R8, and n are defined herein:In this structure, R10is Ci-ealkoxy such as methoxy, ethoxy, propoxy, butoxy, pentoxy, or hexoxy, or such as methoxy. In further aspects, R10is halo such as Br, Cl, or F, or such as F. In still further aspects, R10is Ci-ehaloalkyl such as CF3. In yet other aspects, R10is Ci- ehaloalkoxy such as OCF3, OCH2CH2F, or OCH2CH(OH)CH2F.
[0051] According to the disclosure, the compound is: ethyl 4-amino-2-(3-(pyridin-2-yl)-3,8-diazabicyclo[3.2.1]octan-8-yl)pyrimidine-5- carb oxy late (1); ethyl 4-amino-2-(3-(isoquinolin-3-yl)-3,8-diazabicyclo[3.2.1]octan-8-yl)pyrimidine- 5-carboxylate (2); ethyl 4-amino-2-(3-(quinolin-3-yl)-3,8-diazabicyclo[3.2.1]octan-8-yl)pyrimidine-5- carb oxy late (3); ethyl 4-amino-2-(8-(pyridin-2-yl)-3,8-diazabicyclo[3.2.1]octan-3-yl)pyrimidine-5- carb oxy late (4); ethyl 4-amino-2-(8-(isoquinolin-3-yl)-3,8-diazabicyclo[3.2.1]octan-3-yl)pyrimidine- 5-carboxylate (5); ethyl 4-amino-2-(8-(quinolin-3-yl)-3,8-diazabicyclo[3.2.1]octan-3-yl)pyrimidine-5- carb oxy late (6); ethyl 4-amino-2-(4-(pyridin-2-yl)- 1 ,4-diazepan- 1 -yl)pyrimidine-5-carboxylate (7); ethyl 4-amino-2-(4-(quinolin-3-yl)-l,4-diazepan-l-yl)pyrimidine-5-carboxylate (8); ethyl 4-amino-2-(4-(pyridin-2-yl)piperazin-l-yl)pyrimidine-5 -carboxylate (9); ethyl 4-amino-2-(4-(benzo[d]oxazol-2-yl)piperazin-l-yl)pyrimidine-5-carboxylate(10); ethyl 4-amino-2-(4-(benzo[d]thiazol-2-yl)piperazin-l-yl)pyrimidine-5-carboxylate(11); ethyl 4-amino-2-(3-(benzo[d]thiazol-2-yl)-3,8-diazabicyclo[3.2.1]octan-8- yl)pyrimidine-5-carboxylate (12);ethyl 4-amino-2-(4-(isoquinolin-3-yl)piperazin-l-yl)pyrimidine-5-carboxylate (13); ethyl 4-amino-2-(4-(quinolin-3-yl)piperazin-l-yl)pyrimidine-5-carboxylate (14); ethyl 4-amino-2-(4-(quinolin-2-yl)piperazin-l-yl)pyrimidine-5-carboxylate (15); ethyl 4-amino-2-(4-(quinoxalin-2-yl)piperazin-l-yl)pyrimidine-5-carboxylate (16); ethyl 4-amino-2-(4-(4-methoxyphenyl)piperazin-l-yl)pyrimidine-5-carboxylate (17);4-amino-N-(4-methoxyphenyl)-2-(3-(pyridin-2-yl)-3,8-diazabicyclo[3.2.1]octan-8- yl)pyrimidine-5-carboxamide (18);4-amino-2-(3-(isoquinolin-3-yl)-3,8-diazabicyclo[3.2.1]octan-8-yl)-N-(4- methoxyphenyl)pyrimidine-5-carboxamide (19);4-amino-N-(4-methoxyphenyl)-2-(3-(quinolin-3-yl)-3,8-diazabicyclo[3.2.1]octan-8- yl)pyrimidine-5-carboxamide (20);4-amino-2-(8-(isoquinolin-3-yl)-3,8-diazabicyclo[3.2.1]octan-3-yl)-N-(4- methoxyphenyl)pyrimidine-5-carboxamide (21);4-amino-N-(4-methoxyphenyl)-2-(8-(quinolin-3-yl)-3,8-diazabicyclo[3.2.1]octan-3- yl)pyrimidine-5-carboxamide (22);4-amino-N-(4-methoxyphenyl)-2-(4-(pyridin-2-yl)- 1 ,4-diazepan- 1 -yl)pyrimidine-5- carboxamide (23);4-amino-2-(4-(isoquinolin-3 -yl)- 1 ,4-diazepan- 1 -yl)-N-(4-methoxyphenyl)pyrimidine- 5-carboxamide (24);4-amino-N-(4-methoxyphenyl)-2-(4-(quinolin-3 -yl)- 1 ,4-diazepan- 1 -yl)pyrimidine-5- carb oxami de (25);4-amino-2-(4-(benzo[d]oxazol-2-yl)piperazin-l-yl)-N-(4-methoxyphenyl)pyrimidine- 5-carboxamide (26);4-amino-2-(4-(benzo[d]thiazol-2-yl)piperazin-l-yl)-N-(4-methoxyphenyl)pyrimidine- 5-carboxamide (27);4-amino-N-(4-methoxyphenyl)-2-(4-(pyridin-2-yl)piperazin-l-yl)pyrimidine-5- carboxamide (28);4-amino-2-(4-(isoquinolin-3-yl)piperazin-l-yl)-N-(4-methoxyphenyl)pyrimidine-5- carboxamide (29);4-amino-N-(4-methoxyphenyl)-2-(4-(quinolin-3-yl)piperazin-l-yl)pyrimidine-5- carboxamide (30);4-amino-N-(4-methoxyphenyl)-2-(4-(quinolin-2-yl)piperazin-l-yl)pyrimidine-5- carboxamide (31);4-amino-N-(4-methoxyphenyl)-2-(4-(quinoxalin-2-yl)piperazin-l-yl)pyrimidine-5- carboxamide (32);4-amino-N-(4-methoxyphenyl)-2-(4-(4-methoxyphenyl)piperazin-l-yl)pyrimidine-5- carb oxami de (33);4-amino-N-(4-fluorophenyl)-2-(4-(pyridin-2-yl)piperazin-l-yl)pyrimidine-5- carb oxami de (34);4-amino-2-(4-(pyri din-2 -yl)piperazin-l-yl)-N-(4-(trifluoromethyl)phenyl)pyrimidine- 5-carboxamide (35);4-amino-2-(4-(pyri din-2 -yl)piperazin- 1 -yl)-N-(4-(trifluoromethoxy)phenyl)pyrimidine-5-carboxamide (36);2-hydroxy ethyl 4-amino-2-(4-(pyridin-2-yl)piperazin-l-yl)pyrimidine-5-carboxylate (37);(4-amino-2-(4-(pyridin-2-yl)piperazin-l-yl)pyrimidin-5-yl)methanol (38);5-methyl-2-(4-(pyridin-2-yl)piperazin-l-yl)pyrimidin-4-amine (39);2-(4-(pyridin-2-yl)piperazin- 1 -yl)pyrimidin-4-amine (40);4-amino-2-(4-(pyridin-2-yl)piperazin-l-yl)pyrimidine-5-carbonitrile (41);N-(4-methoxyphenyl)-2-(4-(pyridin-2-yl)piperazin-l-yl)pyrimidine-5-carboxamide (42); ethyl 4-amino-2-(4-(pyridin-4-yl)piperazin-l-yl)pyrimidine-5 -carboxylate (117);4-amino-N-(4-methoxyphenyl)-2-(4-(pyridin-3-yl)piperazin-l-yl)pyrimidine-5- carboxamide (118); ethyl 4-amino-2-(4-(pyrimidin-2-yl)piperazin-l-yl)pyrimidine-5-carboxylate (119);4-amino-N-(4-methoxyphenyl)-2-(4-(pyrimidin-2-yl)piperazin-l-yl)pyrimidine-5- carboxamide (120); ethyl 4-amino-2-(4-(pyrazin-2-yl)piperazin-l-yl)pyrimidine-5-carboxylate (121);4-amino-N-(4-methoxyphenyl)-2-(4-(pyrazin-2-yl)piperazin-l-yl)pyrimidine-5- carboxamide (122); ethyl 4-amino-2-(4-(thiazol-2-yl)piperazin-l-yl)pyrimidine-5 -carboxylate (123);4-amino-N-(4-methoxyphenyl)-2-(4-(thiazol-2-yl)piperazin-l-yl)pyrimidine-5- carboxamide (124); ethyl 4-amino-2-(3-(benzo[d]thiazol-2-yl)-3,8-diazabicyclo[3.2.1]octan-8- yl)pyrimidine-5-carboxylate (125);4-amino-N-(4-methoxyphenyl)-2-(8-(quinolin-3-yl)-3,8-diazabicyclo[3.2.1]octan-3- yl)pyrimidine-5-carboxamide (126);4-amino-N-(2-fluoro-4-methoxyphenyl)-2-(4-(pyri din-2 -yl)piperazin-l-yl)pyrimidine- 5-carboxamide (127);4-amino-N-(3-fluoro-4-methoxyphenyl)-2-(4-(pyri din-2 -yl)piperazin-l -yl)pyrimidine- 5-carboxamide (128);2-hydroxy ethyl 4-amino-2-(4-(pyridin-2-yl)piperazin-l-yl)pyrimidine-5-carboxylate(129);N-(4-methoxyphenyl)-2-(4-(pyridin-2-yl)piperazin-l-yl)pyrimidine-5-carboxamide(130);4-amino-N-(4-hydroxyphenyl)-2-(4-(pyridin-2-yl)piperazin-l-yl)pyrimidine-5- carboxamide (131);4-amino-N-(4-(2-fluoroethoxy)phenyl)-2-(4-(pyridin-2-yl)piperazin-l-yl)pyrimidine-5-carboxamide (132); or4-amino-2-(4-(benzo[d]oxazol-2-yl)piperazin-l-yl)-N-(4-(2- fluoroethoxy)phenyl)pyrimidine-5-carboxamide (133); or a pharmaceutically acceptable salt or isotopic variant thereof.Compounds of Formula II
[0052] According to the disclosure, compounds of Formula II, or pharmaceutically acceptable salts or isotopic variants thereof are provided.:
[0053] According to the disclosure, R20is optionally substituted Ci-ealkoxy or optionally substituted Ci-ehaloalkoxy. In some embodiments, R20is Ci-ealkoxy, such as methoxy, ethoxy, propoxy, butoxy, pentoxy or hexoxy. In other embodiments, R20is OCH3. In further embodiments, R20is Ci-ehaloalkoxy, such as Ci-efluoroalkoxy. In yet other embodiments, R20is OCH2F or OCH2CH2F.
[0054] According to the disclosure, R21is H, optionally substituted Ci-ealkyl, optionally substituted Ci-ealkoxy, optionally substituted heteroaryl or optionally substituted aryl. In some embodiments, R21is H. In other embodiments, R21is Ci-ealkyl, such asmethyl, ethyl, propyl, butyl, pentyl, or hexyl. In further embodiments, R21is methyl. In yet other embodiments, R21is Ci-ealkoxy, such as methoxy, ethoxy, propoxy, butoxy, pentoxy or hexoxy. In still further embodiments, R21is methoxy. In other embodiments, R21is optionally substituted aryl, such as aryl, naphthyl, anthracenyl, phenanthryl, indanyl, indenyl, annulenyl, azulenyl, tetrahydronaphthyl, and biphenyl. In further embodiments, R21is phenyl. In yet other embodiments, R21is optionally substituted heteroaryl. In still further embodiments, R21is a N-containing heteroaryl. In other embodiments, R21is optionally substituted pyridyl, optionally substituted quinolinyl, or optionally substituted quinoxalinyl.In other embodiments,, wherein e is 1 or 2. In some aspects, e is 1. In other aspects, e is 2. In further embodiments, Z1isIn still other embodiments,
[0056] According to the disclosure, Z2is CH or N. In some embodiments, Z2is CH. In other embodiments, Z2is N.
[0057] According to the disclosure, a, b, c, d, and e are, independently, 1 or 2. In some embodiments, a is 1. In other embodiments a is 2. In further embodiments, b is 1. In yet other embodiments, b is 2. In still further embodiments, c is 1. In other embodiments, c is 2. In further embodiments, d is 1. In yet other embodiments, d is 2. In still furtherembodiments, a, b, c, and d are 1. In other embodiments, a and b are 1 and c and d are 2. In further embodiments, a and c are 1 and b and d are 2. In still other embodiments, a, b, and d are 2 and c is 1.
[0058] According to the disclosure, R22, R23, R24, and R25are H; or R23and R24are H and R22and R25are joined to form -Ci-ealk-; or R23and R25are H and R22and R24are joined to form -Ci-ealk-; or R22and R24are H and R23and R25are joined to form -Ci-ealk-. In some embodiments, R22, R23, R24, and R25are H. In further embodiments, R22and R25are H and R23and R24are joined to form -Ci-ealk-, such as -CH2-, -CH2CH2-, or CH2CH2CH2-. In other embodiments, R23and R24are H and R22and R25are joined to form -Ci-ealk-, such as - CH2-, -CH2CH2-, or CH2CH2CH2-. In further embodiments, R23and R25are H and R22and R24are joined to form -Ci-ealk-, such as -CH2-, -CH2CH2-, or CH2CH2CH2-. In yet other embodiments, R22and R24are H and R23and R25are joined to form -Ci-ealk-, such as -CH2-, - CH2CH2-, or CH2CH2CH2-. In still further embodiments, R22and R25are H and R23and R24are joined to form -Ci-ealk-, such as -CH2-, -CH2CH2-, or CH2CH2CH2-.
[0059] According to the disclosure, R31, R32, R33, and R34are H; or R33and R34are H and R31and R32are joined to form a Cs-scycloalkyl; or R31and R32are H and R33and R34are joined to form a Cs-scycloalkyl. In some embodiments, R31, R32, R33, and R34are H. In other embodiments, R33and R34are H and R31and R32are joined to form a Cs-scycloalkyl, such as cyclopropyl, cyclobutyl, cyclopentyl, or cyclohexyl. In further embodiments, R33and R34are H and R31and R32are joined to form cyclopropyl. In yet other embodiments, R33and R34are H and R31and R32are joined to form a cyclobutyl. In still further embodiments, R33and R34are H and R31and R32are joined to form cyclopentyl. In other embodiments, R33and R34are H and R31and R32are joined to form cyclohexyl. In further embodiments, R31and R32are H and R33and R34are joined to form a Cs-scycloalkyl, such as cyclopropyl, cyclobutyl, cyclopentyl, or cyclohexyl. In yet other embodiments, R31and R32are H and R33and R34are joined to form cyclopropyl. In still further embodiments, R31and R32are H and R33and R34are joined to form cyclobutyl. In other embodiments, R31and R32are H and R33and R34are joined to form cyclopentyl. In further embodiments, R31and R32are H and R33and R34are joined to form cyclohexyl.
[0060] In some embodiments, the compound is of formula II-A, wherein R20, R21, and a-d are defined herein:
[0061] In other embodiments, the compound is of formula II-B, wherein R20-R25and e are defined herein:
[0062] In further embodiments, the compound is of formula II-C:
[0063] In yet other embodiments, the compound is:4-methoxy-N-(4-(6-(pyridin-2-yl)-2,6-diazaspiro[3.3]heptan-2-yl)phenyl)benzamide(H7);4-methoxy-N-(4-(7-(pyridin-2-yl)-2,7-diazaspiro[3.5]nonan-2-yl)phenyl)benzamide (H8);4-methoxy-N-(4-(7-(3-nitrophenyl)-2,7-diazaspiro[3.5]nonan-2-yl)phenyl)benzamide (H9);4-methoxy-N-(4-(7-(pyridin-2-yl)-2,7-diazaspiro[4.4]nonan-2-yl)phenyl)benzamide (120);4-methoxy-N-(4-(5-(pyridin-2-yl)hexahydropyrrolo[3,4-b]pyrrol-l(2H)- yl)phenyl)benzamide (100);4-methoxy-N-(4-(2-(pyridin-2-yl)-2,8-diazaspiro[4.5]decan-8-yl)phenyl)benzamide (ioi);4-methoxy-N-(4-(5-(pyridin-2-yl)-2,5-diazabicyclo[2.2.1]heptan-2- yl)phenyl)benzamide (102);4-methoxy-N-(4-(3-(pyridin-2-yl)-3,8-diazabicyclo[3.2.1]octan-8- yl)phenyl)benzamide (103);4-methoxy-N-(4-(3-(quinolin-3-yl)-3,8-diazabicyclo[3.2.1]octan-8- yl)phenyl)benzamide (104);4-methoxy-N-(4-(3-(quinoxalin-2-yl)-3,8-diazabicyclo[3.2.1]octan-8- yl)phenyl)benzamide (105);4-methoxy-N-(4-(3-(pyridin-2-yl)-3,9-diazabicyclo[3.3.1]nonan-9- yl)phenyl)benzamide (106);4-methoxy-N-(4-(4-(pyridin-2-yl)- 1 ,4-diazepan- 1 -yl)phenyl)benzamide ( 107);N-(4-(4-(5-chloropyridin-2-yl)piperazin-l-yl)phenyl)-4-methoxybenzamide (108); 4-methoxy-N-(5-(4-(pyridin-2-yl)piperazin-l-yl)pyridin-2-yl)benzamide (109); 4-methoxy-N-(5-(3-(pyridin-2-yl)-3,8-diazabicyclo[3.2.1]octan-8-yl)pyridin-2- yl)benzamide (110);4-methoxy-N-(5-(4-(pyridin-2-yl)-l,4-diazepan-l-yl)pyridin-2-yl)benzamide (111);4-methoxy-N-(6-(3-(pyridin-2-yl)-3,8-diazabicyclo[3.2.1]octan-8-yl)pyridin-3- yl)benzamide (112);4-methoxy-N-(4-(4-methylpiperazin-l-yl)phenyl)benzamide (113);N-(4-(l-azaspiro[3.5]nonan-l-yl)phenyl)-4-methoxybenzamide (114); 4-methoxy-N-(4-(3-methoxyazetidin-l-yl)phenyl)benzamide (115); or 4-(2-fluoroethoxy)-N-(4-(3-(pyridin-2-yl)-3,8-diazabicyclo[3.2.1]octan-8- yl)phenyl)benzamide (116); or a pharmaceutically acceptable salt or isotopic variant thereof.Pharmaceutically Acceptable Salts of the Compounds
[0064] The compounds described herein can exist as salts, such as therapeutically acceptable salts. In some embodiments, the salt is an acid addition salts. Suitable salts include those formed with both organic and inorganic acids. Such acid addition salts will normally be pharmaceutically acceptable. However, salts of non-pharmaceutically acceptable salts can be of utility in the preparation and purification of the compound in question. For a more complete discussion of the preparation and selection of salts, refer to Pharmaceutical Salts: Properties, Selection, and Use (Stahl, P. Heinrich. Wiley-VCHA, Zurich, Switzerland, 2002).
[0065] As used herein, the phrase “salts” refers to the inorganic and organic salts of compounds. Some salts of the disclosure may be pharmaceutically acceptable salts, which are generally non-toxic inorganic and organic salts of compounds. Acid addition salts include, but are not limited to hydrochloride, hydrobromide, hydroiodide, nitrate, sulfate, bi sulfate,phosphate, acid phosphate, isonicotinate, carbonate, bicarbonate, acetate, lactate, salicylate, citrate, tartrate, propionate, butyrate, pyruvate, oxalate, malonate, pantothenate, bitartrate, ascorbate, succinate, maleate, gentisinate, fumarate, gluconate, glucuronate, saccharate, formate, benzoate, glutamate, methanesulfonate, ethanesulfonate, benzenesulfonate, p- toluenesulfonate, trifluoromethanesulfonate, and pamoate (i.e., l,l'-methylene-bis-(2- hydroxy-3 -naphthoate)) salts.
[0066] The term “therapeutically acceptable salt,” as used herein, represents salts or zwitterionic forms of the compounds of the present invention which are water or oil-soluble or dispersible and therapeutically acceptable. The salts can be prepared during the final isolation and purification of the compounds or separately by reacting the appropriate compound in the form of the free base with a suitable acid. Representative acid addition salts include acetate, adipate, alginate, L-ascorbate, aspartate, benzoate, benzenesulfonate (besylate), bisulfate, butyrate, camphorate, camphorsulfonate, citrate, digluconate, formate, fumarate, gentisate, glutarate, glycerophosphate, glycolate, hemisulfate, heptanoate, hexanoate, hippurate, hydrochloride, hydrobromide, hydroiodide, 2-hydroxyethansulfonate (isethionate), lactate, maleate, malonate, DL-mandelate, mesitylenesulfonate, methanesulfonate, naphthylenesulfonate, nicotinate, 2-naphthalenesulfonate, oxalate, pamoate, pectinate, persulfate, 3-phenylproprionate, phosphonate, picrate, pivalate, propionate, pyroglutamate, succinate, sulfonate, tartrate, L-tartrate, trichloroacetate, trifluoroacetate, phosphate, glutamate, bicarbonate, para-toluenesulfonate (p-tosylate), and undecanoate. Also, basic groups can be quatemized with methyl, ethyl, propyl, and butyl chlorides, bromides, and iodides; dimethyl, diethyl, dibutyl, and diamyl sulfates; decyl, lauryl, myristyl, and steryl chlorides, bromides, and iodides; and benzyl and phenethyl bromides. Examples of acids which can be employed to form therapeutically acceptable addition salts include inorganic acids such as hydrochloric, hydrobromic, sulfuric, and phosphoric, and organic acids such as oxalic, maleic, succinic, and citric.Pharmaceutical Compositions
[0067] While it is possible for compounds described herein to be administered as the raw chemical, it is also possible to include them in pharmaceutical compositions. Accordingly, pharmaceutical compositions are provided and comprise a compound or a pharmaceutically acceptable salt or isotopic variant thereof, together with one or more pharmaceutically acceptable excipient thereof. The excipient must be “acceptable,” i.e.,compatible with other components of the pharmaceutical composition and not deleterious to the recipient thereof. Any of the well-known techniques, excipients, and excipients can be used as the excipient and as understood in the art. See, e.g., Remington's Pharmaceutical Sciences. The pharmaceutical compositions can be manufactured in a manner that is itself known, e.g., by means of conventional mixing, dissolving, granulating, dragee-making, levigating, emulsifying, encapsulating, entrapping or compression processes, for example.
[0068] In some embodiments, “pharmaceutically acceptable excipient” is a pharmaceutically-acceptable material, composition or vehicle involved in carrying or transporting an agent from one organ, or portion of the body, to another organ, or portion of the body. Each excipient must be “acceptable,” z.e., compatible with other components of the composition. Some examples of excipients include: (1) sugars, such as lactose, glucose and sucrose; (2) starches, such as com starch and potato starch; (3) cellulose, and its derivatives, such as sodium carboxymethyl cellulose, ethyl cellulose and cellulose acetate; (4) powdered tragacanth; (5) malt; (6) gelatin; (7) talc; (8) excipients, such as cocoa butter and suppository waxes; (9) oils, such as peanut oil, cottonseed oil, safflower oil, sesame oil, olive oil, com oil and soybean oil; (10) glycols, such as propylene glycol; (11) polyols, such as glycerin, sorbitol, mannitol and polyethylene glycol; (12) esters, such as ethyl oleate and ethyl laurate; (13) agar; (14) buffering agents, such as magnesium hydroxide and aluminum hydroxide; (15) alginic acid; (16) pyrogen-free water; (17) isotonic saline; (18) Ringer's solution; (19) ethyl alcohol; (20) pH buffered solutions; (21) polyesters, polycarbonates and / or polyanhydrides; and (22) other non-toxic compatible substances employed in pharmaceutical formulations.
[0069] The pharmaceutical compositions include those suitable for oral, parenteral (including subcutaneous, intradermal, intramuscular, intravenous, intraarticular, and intramedullary), intraperitoneal, transmucosal, transdermal, rectal or topical (including dermal, buccal, sublingual and intraocular) administration. The pharmaceutical compositions can be presented in unit dosage form and can be prepared by any of the methods well known in the art.
[0070] Pharmaceutical compositions suitable for oral administration can be presented as discrete units such as capsules (e.g., push-fit, soft, sealed), sachets, tablets, powders, granules, solutions, suspensions, emulsions, bolus, or pastes.
[0071] The pharmaceutical compositions can be formulated for parenteral administration by injection, e.g., by bolus injection or continuous infusion. Thepharmaceutical compositions can take such forms as suspensions, solutions or emulsions in oily or aqueous vehicles, and can contain formulatory agents such as suspending, stabilizing and / or dispersing agents. The formulations can be presented in unit-dose or multi-dose containers, e.g., sealed ampoules and vials, and can be stored in powder form or in a freeze- dried (lyophilized).
[0072] Pharmaceutical compositions for parenteral administration include aqueous and non-aqueous (oily) sterile injection solutions of the compounds described herein which can contain antioxidants, buffers, bacteriostats and solutes which render the formulation isotonic with the blood of the intended recipient; and aqueous and non-aqueous sterile suspensions which can include suspending agents and thickening agents. Aqueous injection suspensions can contain substances which increase the viscosity of the suspension, such as sodium carboxymethyl cellulose, sorbitol, or dextran. Optionally, the suspension can also contain suitable stabilizers or agents which increase the solubility of the compounds to allow for the preparation of highly concentrated solutions.
[0073] The pharmaceutical compositions can also be formulated for rectal administration, e.g., suppositories or retention enema.
[0074] The pharmaceutical compositions can also be formulated in vaginal compositions as gels, suppositories, or as dendrimers conjugates.
[0075] The pharmaceutical compositions can be administered topically. Pharmaceutical compositions suitable for topical administration include liquid or semi-liquid preparations suitable for penetration through the skin such as gels, liniments, lotions, creams, ointments or pastes.Methods of Treatment
[0076] The disclosure also provides methods of modulating alpha-synuclein in a patient in need thereof. The inventors found that the compounds described herein bind to alpha-synuclein. In some embodiments, the compounds bind with high affinity to Asyn. The compounds disclosed herein also have a low affinity for Abeta.
[0077] The methods include administering an effective amount of a compound described herein to the patient. In some embodiments, the compound is of formula I. In other embodiments, the compound is of formula II.
[0078] An “effective amount” means an amount or dose sufficient to generally bring about the desired therapeutic benefit in patients in need of such treatment for the designateddisease, disorder, or condition. Effective amounts or doses of the compounds of the present disclosure may be ascertained by routine methods such as modeling, dose escalation studies or clinical trials, and by taking into consideration routine factors, e.g., the mode or route of administration or drug delivery, the pharmacokinetics of the compound, the severity and course of the disease, disorder, or condition, the subject's previous or ongoing therapy, the subject’s health status and response to drugs, and the judgment of the treating physician. An example of a dose is in the range of from about 0.001 to about 200 mg of compound per kg of subject's body weight per day, preferably about 0.05 to 100 mg / kg / day, or about 1 to 35 mg / kg / day, in single or divided dosage units (e.g., BID, TID, QID). For a 70-kg human, an illustrative range for a suitable dosage amount is from about 0.05 to about 7 g / day, or about 0.2 to about 2.5 g / day.
[0079] These effective amounts may be provided on regular schedule, ie., daily, weekly, monthly, or yearly basis or on an irregular schedule with varying administration days, weeks, months, etc. Alternatively, the effective amount to be administered may vary. In some embodiments, the effective amount for the first dose is higher than the effective amount for one or more of the subsequent doses. In other embodiments, the effective amount for the first dose is lower than the effective amount for one or more of the subsequent doses.
[0080] The disclosure also provides noninvasive imaging techniques for measuring alpha-synuclein aggregates. Thus, these techniques are valuable tools for evaluating the efficacy of antibodies in preventing the formation of lewy bodies (LB), lewy neurites (LN), glial cytoplasmic inclusions (GCI), or combinations thereof in Parkinson’s disease and multiple system atrophy (MSA).
[0081] The methods may also include performing imaging, such as positron emission tomography, on the patient. In some embodiments, imaging measures the amount of aggregated alpha-synuclein. In other embodiments, binding of compounds of the disclosure may be monitored and / or measured using imaging.
[0082] The compounds described herein also are useful in treating neurodegenerative disorders in a patient in need thereof. The methods include administering a pharmaceutical agent that clears aggregated alpha-synuclein from the brain of the patient; administering an effective amount of a compound described here to the patient; and performing positron emission tomography imaging on the patient. Examples of pharmaceutical agents that clear aggregated alpha-synuclein include monoclonal antibodies, such as humanized antibodies. For Example, the pharmaceutical agent is a humanizedmonoclonal antibody raised towards alpha synuclein and UCB0599, a small molecule inhibitor of alpha synuclein misfolding. See, e.g., Prasad, Current Therapies in Clinical Trials of Parkinson's Disease: A 2021 Update. 2021. 14(8); and Smit, Phase 1 / lb Studies of UCB0599, an Oral Inhibitor of a-Synuclein Misfolding, Including a Randomized Study in Parkinson's Disease. Movement Disorders, 2022. 37(10): p. 2045-2056, the disclosures of which are incorporated by reference herein.
[0083] In some embodiments, the neurodegenerative disorder is a synucleinopathy. The term “synucleinopathy” as used herein refers to neurodegenerative disorders that share a common pathologic lesion composed of aggregates of insoluble a-synuclein protein in selectively vulnerable populations of neurons and glia. In certain aspects, the neurodegenerative disorder is Parkinson’s disease, multiple system atrophy, dementia with lewy bodies, Shy-Drager syndrome, striatonigral degeneration, olivopontocerebellar atrophy, or neurodegeneration with brain iron accumulation, type I (adult neuroaxonal dystrophy or Hallervorden-Spatz syndrome). In other aspects, the neurodegenerative disorder is Parkinson’s disease. In further aspects, the neurodegenerative disorder is multiple system atrophy.
[0084] The compounds may also be used in detecting a neurodegenerative disorder. Thus, these methods include administering an effective amount of the compound to a subject and detecting the neurodegenerative disorder. The neurodegenerative disorder may be detected by performing imaging such as positron emission tomography. In some embodiments, the detection methods described herein may be performed using an isotopically-labeled compound described herein. In some embodiments, the detection methods are performed using a compound labeled with radioactive isotope. In other embodiments, the detection methods are performed using a compound labeled with18F. In further embodiments, the detection methods are performed using a compound labeled withnC. In yet other embodiments, the detection methods are performed using a compound labeled with123I.
[0085] Also provided herein are methods of monitoring treatment of neurodegenerative disorders in a subject by administering an antibody to the subject, administering an effective amount of a compound described herein to said subject, and performing positron emission tomography on the subject. In some embodiments, the monitoring methods described herein may be performed using an isotopically-labeled compound described herein.
[0086] The methods described herein may be performed by administering a compound described herein via a combination therapy in prior to, concurrently with, or subsequent to another medication such as an antibody. As used herein, the term “antibody” refers to a protein that includes at least one immunoglobulin variable domain or immunoglobulin variable domain sequence. For example, an antibody can include a heavy (H) chain variable region (abbreviated herein as VH), and a light (L) chain variable region (abbreviated herein as VL). In another example, an antibody includes two heavy (H) chain variable regions and two light (L) chain variable regions. The term “antibody” encompasses antigen-binding fragments of antibodies (e.g., single chain antibodies, Fab fragments, F(ab)2, a Fd fragment, a Fv fragments, and dAb fragments) as well as complete antibodies. In some embodiments, the antibody is a monoclonal antibody. In other embodiments, the antibody targets Ap aggregates. In further embodiments, the antibody is AN1792, gantenerumab, aducanumab, or bapineuzumab.
[0087] Such combination treatment may occur by administering compositions containing multiple active ingredients, as described above. In some embodiments, the compound and antibody are administered to the patient by one or more selected routes of administration sequentially. In other embodiments, an antibody is administered before treatment with a compound described herein. In further embodiments, an antibody is administered after treatment with a compound described herein. In still other embodiments, an antibody is administered during treatment with a compound described herein.
[0088] Aside from the antibody, the compounds described herein are optionally administered in methods with one or more other therapeutic ingredients. In some embodiments, the other therapeutic ingredient is known to treat a neurodegenerative disorder or reduces neuroinflammation. In other embodiments, the other therapeutic ingredient is amantadine, apomorphine, baclofen, carbidopa, carbidopa / levodopa, dantrolene, donepezil, entacapone, galantamine, levodopa, memantine, pramipexole, rasagiline, riluzole, rivastigmine, ropinirole, selegiline, tacrine, tetrabenazine, tizanidine, or tolcapone, or combinations thereof.
[0089] Desirably, the compounds disclosed herein have a low affinity for Ap. The term “low affinity” as used herein refers to the binding affinity between the compounds of the disclosure and Ap. In some embodiments, the compounds of the disclosure have less than an about 50% binding affinity to Ap. In other embodiments, the compounds of the disclosurehave less than an about 40, about 30, about 20, about 10, about 5, or about 1% binding affinity to Ap.Kits
[0090] Also provided herein are kits or packages containing a compound or composition described herein. The kits may be organized to indicate a single formulation or combination of formulations to be taken at each desired time. The composition may also be sub-divided to contain appropriate quantities of the compound. For example, the unit dosage can be packaged compositions, e.g., packeted powders, vials, ampoules, prefilled syringes or sachets containing liquids.
[0091] Suitably, the kit contains packaging or a container with the compound formulated for the desired delivery route. Optionally, the kit contains instructions on dosing and an insert regarding the compound. Optionally, the kit may further contain instructions for monitoring circulating levels of product and materials for performing such assays including, e.g., reagents, well plates, containers, markers or labels, and the like. Such kits are readily packaged in a manner suitable for treatment of a desired indication. For example, the kit may also contain instructions for use of the delivery device. Other suitable components to include in such kits will be readily apparent to one of skill in the art, taking into consideration the desired indication and the delivery route. The doses are repeated daily, weekly, or monthly, for a predetermined length of time or as prescribed.
[0092] The compound or composition described herein can be a single dose or for continuous or periodic discontinuous administration. For continuous administration, a package or kit can include the compound in each dosage unit (e.g., solution, lotion, tablet, pill, or other unit described above or utilized in drug delivery). When the compound is to be delivered with periodic discontinuation, a package or kit can include placebos during periods when the compound is not delivered. When varying concentrations of a composition, of the components of the composition, or of relative ratios of the compound or other agents within a composition over time is desired, a package or kit may contain a sequence of dosage units, so varying.
[0093] A number of packages or kits are known in the art for the use in dispensing pharmaceutical agents for oral use. In one embodiment, the package has indicators for each period. In another embodiment, the package is a labeled blister package, dial dispenser package, or bottle.
[0094] The packaging means of a kit may itself be geared for administration, such as an inhalant, syringe, pipette, eye dropper, or other such like apparatus, from which the formulation may be applied to an infected area of the body, such as the lungs, injected into a subject, or even applied to and mixed with the other components of the kit.
[0095] The compound or composition of these kits also may be provided in dried or lyophilized forms. When reagents or components are provided as a dried form, reconstitution generally is by the addition of a suitable solvent. It is envisioned that the solvent also may be provided in another packaging means.
[0096] The kits may include a means for containing the vials in close confinement for commercial sale such as, e.g., injection or blow-molded plastic containers into which the desired vials are retained.
[0097] Irrespective of the number or type of packages, the kits also may include, or be packaged with a separate instrument for assisting with the injection / administration or placement of the ultimate complex composition within the body of an animal. Such an instrument may be an inhalant, syringe, pipette, forceps, measuring spoon, eye dropper or any such medically approved delivery means. Other instrumentation includes devices that permit the reading or monitoring of reactions in vitro.
[0098] In some embodiments, a pharmaceutical kit is provided and contains a compound as described herein. The compound may be in the presence or absence of one or more of the pharmaceutically acceptable excipients described above. The kit may optionally contain an antibody and / or instructions for administering the antibody and the compound to a subject having cancer.
[0099] In further embodiments, a pharmaceutical kit is provided and contains an antibody in a first dosage unit, one or more of a compound selected from those described herein in a second dosage unit, and one or more of the pharmaceutically acceptable excipients described above in a third dosage unit. The kit may optionally contain instructions for administering the antibody and / or compound to a subject having cancer.Aspects
[0100] Aspect 1. A compound of Formula I:wherein: n is 1 or 2;R1to R4are H; or R1and R3are H and R2and R4are joined to form -Ci-ealk-; or R2and R4are H and R1and R3are joined to form -Ci-ealk-;R5is optionally substituted aryl or optionally substituted heteroaryl;X1is absent or -C(O)-;X2absent, O, or NH;R6is H, CN, Ci-ealkyl, Ci-ealk-OH, or optionally substituted phenyl; andR7and R8are, independently, H, halo, or NH2; or a pharmaceutically acceptable salt or isotopic variant thereof.
[0101] Aspect 2. The compound of Aspect 1, wherein n is 1.
[0102] Aspect 3. The compound of Aspect 1, wherein n is 2.
[0103] Aspect 4. The compound of any one of the preceding Aspects, wherein R1to R4are H.
[0104] Aspect 5. The compound of any one of Aspects 1-3, wherein R1and R3are H and R2and R4are joined to form -Ci-ealk-, such as -CH2CH2-.
[0105] Aspect 6. The compound of any one of Aspects 1-3, wherein R2and R4are H and R1and R3are joined to form -Ci-ealk-, such as -CH2CH2-.
[0106] Aspect 7. The compound of any one of the preceding Aspects, wherein R5is optionally substituted aryl, such as phenyl.
[0107] Aspect 8. The compound of any one of the preceding Aspects, wherein R5is optionally substituted heteroaryl such as a N-containing heteroaryl, or such as pyridyl, isoquinolinyl, benzoxazolyl, benzthiazolyl, or quinoxalinyl.
[0108] Aspect 9. The compound of Aspect 8, wherein R5is optionally substituted pyridyl.
[0109] Aspect 10. The compound of Aspect 8, wherein R5is optionally substituted isoquinolinyl.
[0110] Aspect 11. The compound of any one of the preceding Aspects, wherein X1is absent.
[0111] Aspect 12. The compound of any one of the preceding Aspects, wherein X1is -C(O)-.
[0112] Aspect 13. The compound of any one of the preceding Aspects, wherein X2is absent.
[0113] Aspect 14. The compound of any one of Aspects 1-12, wherein X2is O.
[0114] Aspect 15. The compound of any one of Aspects 1-12, wherein X2is NH.
[0115] Aspect 16. The compound of any one of the preceding Aspects, wherein R6is H.
[0116] Aspect 17. The compound of any one of Aspects 1-15, wherein R6is CN.
[0117] Aspect 18. The compound of any one of Aspects 1-15, wherein R6is Ci- ealkyl, such as methyl, ethyl, propyl, butyl, pentyl, or hexyl, or such as methyl.
[0118] Aspect 19. The compound of any one of Aspects 1-15, wherein R6is Ci- ealkOH, such as CH2OH, CH2CH2OH, propyl-OH, butyl-OH, pentyl-OH, or hexyl-OH.
[0119] Aspect 20. The compound of any one of Aspects 1-15, wherein R6is optionally substituted phenyl.
[0120] Aspect 21. The compound of any one of Aspects 1-15 or 20, wherein R6is, wherein R9is optionally substituted Ci-ealkyl, optionally substituted Ci- ealkoxy, halo, optionally substituted Ci-ehaloalkyl, or optionally substituted Ci-ehaloalkoxy.
[0121] Aspect 22. The compound of any one of the preceding Aspects, wherein R7is H.
[0122] Aspect 23. The compound of any one of Aspects 1-21, wherein R7is halo such as Cl, F, or Br, or such as F.
[0123] Aspect 24. The compound of any one of the preceding Aspects, wherein R7is H.
[0124] Aspect 25. The compound of any one of Aspects 1-21, wherein R7is NH2.
[0125] Aspect 26. The compound of any one of Aspects 1-21, wherein R8is halo such as Cl, F, or Br, or such as F.
[0126] Aspect 27. The compound of any one of Aspects 1-21, wherein R8is NH2.
[0127] Aspect 28. The compound of any one of the preceding Aspects, wherein the compound is of Formula I-A:
[0128] Aspect 29. The compound of any one of Aspects 1-21, wherein the compound is of Formula I-B:
[0129] Aspect 30. The compound of any one of Aspects 1-21, wherein the compound is of Formula I-C:
[0130] Aspect 31. The compound of any one Aspects 1-21, wherein the compound is of Formula I-D:
[0131] Aspect 32. The compound of any one of Aspects 1-21, wherein the compound is of Formula I-E:wherein, R10is Ci-ealkoxy, halo, Ci-6trihaloalkyl, or Ci-6trihaloalkoxy.
[0132] Aspect 33. The compound of Aspect 1, that is:4-amino-N-(4-fluorophenyl)-2-(4-(pyridin-2-yl)piperazin-l-yl)pyrimidine-5- carboxamide (34);2-hydroxy ethyl 4-amino-2-(4-(pyridin-2-yl)piperazin-l-yl)pyrimidine-5-carboxylate (37);4-amino-2-(4-(pyri din-2 -yl)piperazin-l-yl)-N-(4-(trifluoromethyl)phenyl)pyrimidine- 5-carboxamide (35);4-amino-2-(4-(pyri din-2 -yl)piperazin- 1 -yl)-N-(4-(trifluoromethoxy)phenyl)pyrimidine-5-carboxamide (36);2-(4-(pyridin-2-yl)piperazin- 1 -yl)pyrimidin-4-amine (40);4-amino-2-(4-(pyridin-2-yl)piperazin-l-yl)pyrimidine-5-carbonitrile (41);(4-amino-2-(4-(pyridin-2-yl)piperazin-l-yl)pyrimidin-5-yl)methanol (38);5-methyl-2-(4-(pyridin-2-yl)piperazin-l-yl)pyrimidin-4-amine (39); ethyl 4-amino-2-(3-(benzo[d]thiazol-2-yl)-3,8-diazabicyclo[3.2.1]octan-8- yl)pyrimidine-5-carboxylate (12); ethyl 4-amino-2-(4-(benzo[d]oxazol-2-yl)piperazin-l-yl)pyrimidine-5-carboxylate(10); ethyl 4-amino-2-(4-(benzo[d]thiazol-2-yl)piperazin-l-yl)pyrimidine-5-carboxylate(11);4-amino-2-(4-(benzo[d]oxazol-2-yl)piperazin-l-yl)-N-(4-methoxyphenyl)pyrimidine- 5-carboxamide (26);4-amino-2-(4-(benzo[d]thiazol-2-yl)piperazin-l-yl)-N-(4-methoxyphenyl)pyrimidine- 5-carboxamide (27) ; ethyl 4-amino-2-(4-(4-methoxyphenyl)piperazin-l-yl)pyrimidine-5-carboxylate (17); ethyl 4-amino-2-(4-(quinoxalin-2-yl)piperazin-l-yl)pyrimidine-5-carboxylate (16);4-amino-N-(4-methoxyphenyl)-2-(4-(4-methoxyphenyl)piperazin-l-yl)pyrimidine-5- carboxamide (33);4-amino-N-(4-methoxyphenyl)-2-(4-(quinoxalin-2-yl)piperazin-l-yl)pyrimidine-5- carboxamide (32);N-(4-methoxyphenyl)-2-(4-(pyridin-2-yl)piperazin-l-yl)pyrimidine-5-carboxamide (42); ethyl 4-amino-2-(4-(pyridin-2-yl)- 1 ,4-diazepan- 1 -yl)pyrimidine-5-carboxylate (7);4-amino-N-(4-methoxyphenyl)-2-(4-(pyridin-2-yl)- 1 ,4-diazepan- 1 -yl)pyrimidine-5- carboxamide (23); ethyl 4-amino-2-(4-(pyridin-2-yl)piperazin-l-yl)pyrimidine-5 -carboxylate (9); ethyl 4-amino-2-(8-(pyridin-2-yl)-3,8-diazabicyclo[3.2.1]octan-3-yl)pyrimidine-5- carb oxy late (4); ethyl 4-amino-2-(8-(isoquinolin-3-yl)-3,8-diazabicyclo[3.2.1]octan-3-yl)pyrimidine- 5-carboxylate (5); ethyl 4-amino-2-(8-(quinolin-3-yl)-3,8-diazabicyclo[3.2.1]octan-3-yl)pyrimidine-5- carb oxy late (6);4-amino-N-(4-methoxyphenyl)-2-(4-(pyridin-2-yl)piperazin-l-yl)pyrimidine-5- carboxamide (28); ethyl 4-amino-2-(3-(pyridin-2-yl)-3,8-diazabicyclo[3.2.1]octan-8-yl)pyrimidine-5- carb oxy late (1);4-amino-2-(8-(isoquinolin-3-yl)-3,8-diazabicyclo[3.2.1]octan-3-yl)-N-(4- methoxyphenyl)pyrimidine-5-carboxamide (21);4-amino-N-(4-methoxyphenyl)-2-(8-(quinolin-3-yl)-3,8-diazabicyclo[3.2.1]octan-3- yl)pyrimidine-5-carboxamide (22);4-amino-N-(4-methoxyphenyl)-2-(3-(pyridin-2-yl)-3,8-diazabicyclo[3.2.1]octan-8- yl)pyrimidine-5-carboxamide (18); ethyl 4-amino-2-(3-(isoquinolin-3-yl)-3,8-diazabicyclo[3.2.1]octan-8-yl)pyrimidine- 5-carboxylate (2); ethyl 4-amino-2-(3-(quinolin-3-yl)-3,8-diazabicyclo[3.2.1]octan-8-yl)pyrimidine-5- carb oxy late (3); ethyl 4-amino-2-(4-(quinolin-3-yl)-l,4-diazepan-l-yl)pyrimidine-5-carboxylate (8);4-amino-2-(3-(isoquinolin-3-yl)-3,8-diazabicyclo[3.2.1]octan-8-yl)-N-(4- methoxyphenyl)pyrimidine-5-carboxamide (19);4-amino-N-(4-methoxyphenyl)-2-(3-(quinolin-3-yl)-3,8-diazabicyclo[3.2.1]octan-8- yl)pyrimidine-5-carboxamide (20);4-amino-N-(4-methoxyphenyl)-2-(4-(quinolin-3 -yl)- 1 ,4-diazepan- 1 -yl)pyrimidine-5- carb oxami de (25);4-amino-2-(4-(isoquinolin-3 -yl)- 1 ,4-diazepan- 1 -yl)-N-(4-methoxyphenyl)pyrimidine- 5-carboxamide (24); ethyl 4-amino-2-(4-(quinolin-3-yl)piperazin-l-yl)pyrimidine-5-carboxylate (14);ethyl 4-amino-2-(4-(quinolin-2-yl)piperazin-l-yl)pyrimidine-5-carboxylate (15);4-amino-N-(4-methoxyphenyl)-2-(4-(quinolin-3-yl)piperazin-l-yl)pyrimidine-5- carboxamide (30);4-amino-N-(4-methoxyphenyl)-2-(4-(quinolin-2-yl)piperazin-l-yl)pyrimidine-5- carb oxami de (31); ethyl 4-amino-2-(4-(isoquinolin-3-yl)piperazin-l-yl)pyrimidine-5-carboxylate (13); or4-amino-2-(4-(isoquinolin-3-yl)piperazin-l-yl)-N-(4-methoxyphenyl)pyrimidine-5- carboxamide (29); or a pharmaceutically acceptable salt or isotopic variant thereof.
[0133] Aspect 34. The compound of any one of the preceding Aspects, that is an isotopic variant.
[0134] Aspect 35. The compound of Aspect 34, that is labeled with one or more of a non-radioactive isotope such as2H,13C, or15N, or such as2H, or such as13C, or such as15N.
[0135] Aspect 36. The compound of Aspect 34, that is labeled with a radioactive isotope, such as18F,nC, or123I, or such as18F, or such asnC, or such as123I.
[0136] Aspect 37. A pharmaceutical composition comprising one or more compounds of any one of Aspects 1-36 and a pharmaceutical excipient.
[0137] Aspect 38. A method of modulating alpha-synuclein in a patient in need thereof, comprising administering an effective amount of a compound of any one of Aspects 1-36 to the patient.
[0138] Aspect 39. The method of Aspect 38, wherein the compound binds to alpha-synuclein.
[0139] Aspect 40. The method of Aspect 38 or 39, further comprising performing positron emission tomography on the patient.
[0140] Aspect 41. A method of treating a neurodegenerative disorder in a patient in need thereof, comprising: administering a pharmaceutical agent that clears aggregated alpha-synuclein from the brain of the patient; administering an effective amount of a compound of any one of Aspects 1-36 to the patient; and performing positron emission tomography imaging on the patient.
[0141] Aspect 42. The method of Aspect 41, wherein the neurodegenerative disorder is a synucleinopathy such as Parkinson’s disease or multiple system atrophy.
[0142] v43. The method of Aspect 41 or 42, wherein the pharmaceutical agent is a monoclonal antibody.
[0143] Aspect 44. The method of any one of Aspects 41-43, wherein the imaging measures the amount of aggregated alpha-synuclein.
[0144] Aspect 45. The method of any one of Aspects 41-44, wherein the compound has a low affinity for Ap.
[0145] Aspect 46. A compound of Formula II:wherein:R20is optionally substituted Ci-ealkoxy or optionally substituted Ci-ehaloalkoxy;R21is H, optionally substituted Ci-ealkyl, optionally substituted Ci-ealkoxy, optionally substituted heteroaryl or optionally substituted aryl;Z2is CH or N; a, b, c, d, and e are, independently, 1 or 2;R22, R23, R24, and R25are H; or R23and R24are H and R22and R25are joined to form -Ci-ealk-; or R23and R25are H and R22and R24are joined to form -Ci- ealk-; or R22and R24are H and R23and R25are joined to form -Ci-ealk-; or R22and R25are H and R23and R24are joined to form -Ci-ealk-;R31, R32, R33, and R34are H; or R33and R34are H and R31and R32are joined to form a C3-8cycloalkyl; or R31and R32are H and R33and R34are joined to form a Cs-scycloalkyl; or a pharmaceutically acceptable salt isotopic variant thereof.
[0146] Aspect 47. The compound of Aspect 46, wherein R20is Ci-ealkoxy, such as OCH3.
[0147] Aspect 48. The compound of Aspect 46, wherein R20is Ci-ehaloalkoxy, such as Ci-efluoroalkoxy, or such as OCH2F or OCH2CH2F.
[0148] Aspect 49. The compound of any one of Aspects 46-48, wherein R21is H.
[0149] Aspect 50. The compound of any one of Aspects 46-48, wherein R21is Ci- ealkyl, such as methyl.
[0150] Aspect 51. The compound of any one of Aspects 46-48, wherein R21is Ci- ealkoxy, such as methoxy.
[0151] Aspect 52. The compound of any one of Aspects 46-48, wherein R21is optionally substituted aryl, such as phenyl.
[0152] Aspect 53. The compound of any one of Aspects 46-48, wherein R21is optionally substituted heteroaryl, such as a N-containing heteroaryl, or such as pyridyl, quinolinyl, or quinoxalinyl.
[0153] Aspect 54. The compound of any one of Aspects 46-53, wherein Z1is
[0154] Aspect 55. The compound of Aspect 54, wherein a, b, c, and d are 1.
[0155] Aspect 56. The compound of Aspect 54, wherein a and b are 1 and c and d are 2.
[0156] Aspect 57. The compound of Aspect 54, wherein a and c are 1 and b and d are 2.
[0157] Aspect 58. The compound of Aspect 54, wherein a, b, and d are 2 and c is1.
[0158] Aspect 59. The compound of any one of Aspects 46-58, wherein Z1is
[0159] Aspect 60. The compound of Aspect 59, wherein e is 1.
[0160] Aspect 61. The compound of Aspect 59, wherein e is 2.
[0161] Aspect 62. The compound of Aspect 59, wherein R22, R23, R24, and R25areH.
[0162] Aspect 63. The compound of Aspect 59, wherein R23and R24are H and R22and R25are joined to form -Ci-ealk-, such as -CH2-, -CH2CH2-, or CH2CH2CH2-.
[0163] Aspect 64. The compound of Aspect 59, wherein R23and R25are H and R22and R24are joined to form -Ci-ealk-, such as -CH2-, -CH2CH2-, or CH2CH2CH2-.
[0164] Aspect 65. The compound of Aspect 59, wherein R22and R24are H and R23and R25are joined to form -Ci-ealk-, such as -CH2-, -CH2CH2-, or CH2CH2CH2-.
[0165] Aspect 66. The compound of Aspect 59, wherein R22and R25are H and R23and R24are joined to form -Ci-ealk-, such as -CH2-, -CH2CH2-, or CH2CH2CH2-.
[0166] Aspect 67. The compound of any one of Aspects 46-58, wherein Z1is pect 68. The compound of any one of Aspects 46-58, wherein Z1is
[0168] Aspect 69. The compound of Aspect 68, wherein R31, R32, R33, and R34are H.
[0169] Aspect 70. The compound of Aspect 68, wherein R33and R34are H R31and R32are joined to form a Cs-scycloalkyl, such as cyclopropyl, cyclobutyl, cyclopentyl, or cyclohexyl.
[0170] Aspect 71. The compound of Aspect 68, wherein R31and R32are H and R33and R34are joined to form a Cs-scycloalkyl, such as cyclopropyl, cyclobutyl, cyclopentyl, or cyclohexyl.
[0171] Aspect 72. The compound of any one of Aspects 46-71, wherein Z2is CH.
[0172] Aspect 73. The compound of any one of Aspects 46-71, wherein Z2is N.
[0173] Aspect 74. The compound of Aspect 46, that is of formula II-A:
[0174] Aspect 75. The compound of Aspect 46, that is of formula II-B or II-C:
[0175] Aspect 76. The compound of Aspect 46, that is:4-methoxy-N-(4-(6-(pyridin-2-yl)-2,6-diazaspiro[3.3]heptan-2-yl)phenyl)benzamide(H7);4-methoxy-N-(4-(7-(pyridin-2-yl)-2,7-diazaspiro[3.5]nonan-2-yl)phenyl)benzamide (H8);4-methoxy-N-(4-(7-(3-nitrophenyl)-2,7-diazaspiro[3.5]nonan-2-yl)phenyl)benzamide (H9);4-methoxy-N-(4-(7-(pyridin-2-yl)-2,7-diazaspiro[4.4]nonan-2-yl)phenyl)benzamide (120);4-methoxy-N-(4-(5-(pyridin-2-yl)hexahydropyrrolo[3,4-b]pyrrol-l(2H)- yl)phenyl)benzamide (100);4-methoxy-N-(4-(2-(pyridin-2-yl)-2,8-diazaspiro[4.5]decan-8-yl)phenyl)benzamide (ioi);4-methoxy-N-(4-(5-(pyridin-2-yl)-2,5-diazabicyclo[2.2.1]heptan-2- yl)phenyl)benzamide (102);4-methoxy-N-(4-(3-(pyridin-2-yl)-3,8-diazabicyclo[3.2.1]octan-8- yl)phenyl)benzamide (103);4-methoxy-N-(4-(3-(quinolin-3-yl)-3,8-diazabicyclo[3.2.1]octan-8- yl)phenyl)benzamide (104);4-methoxy-N-(4-(3-(quinoxalin-2-yl)-3,8-diazabicyclo[3.2.1]octan-8- yl)phenyl)benzamide (105);4-methoxy-N-(4-(3-(pyridin-2-yl)-3,9-diazabicyclo[3.3.1]nonan-9- yl)phenyl)benzamide (106);4-methoxy-N-(4-(4-(pyridin-2-yl)- 1 ,4-diazepan- 1 -yl)phenyl)benzamide ( 107);N-(4-(4-(5-chloropyridin-2-yl)piperazin-l-yl)phenyl)-4-methoxybenzamide (108); 4-methoxy-N-(5-(4-(pyridin-2-yl)piperazin-l-yl)pyridin-2-yl)benzamide (109); 4-methoxy-N-(5-(3-(pyridin-2-yl)-3,8-diazabicyclo[3.2.1]octan-8-yl)pyridin-2- yl)benzamide (110);4-methoxy-N-(5-(4-(pyridin-2-yl)-l,4-diazepan-l-yl)pyridin-2-yl)benzamide (111);4-methoxy-N-(6-(3-(pyridin-2-yl)-3,8-diazabicyclo[3.2.1]octan-8-yl)pyridin-3- yl)benzamide (112);4-methoxy-N-(4-(4-methylpiperazin-l-yl)phenyl)benzamide (113);N-(4-(l-azaspiro[3.5]nonan-l-yl)phenyl)-4-methoxybenzamide (114);4-methoxy-N-(4-(3-methoxyazetidin-l-yl)phenyl)benzamide (115);4-(2-fluoroethoxy)-N-(4-(3-(pyridin-2-yl)-3,8-diazabicyclo[3.2.1]octan-8- yl)phenyl)benzamide (116); or a pharmaceutically acceptable salt or isotopic variant thereof.
[0176] Aspect 77. The compound of any one of Aspects 46-76, that is an isotopic variant.
[0177] Aspect 78. The compound of Aspect 77, that is labeled with one or more of a non-radioactive isotope such as2H,13C, or15N, or such as2H, or such as13C, or such as15N.
[0178] Aspect 79. The compound of Aspect 77, that is labeled with a radioactive isotope, such as18F,nC, or123I, or such as18F, or such asnC, or such as123I.
[0179] Aspect 80. A pharmaceutical composition comprising one or more compounds of any one of Aspects 46-79 and a pharmaceutical excipient.
[0180] Aspect 81. A method of modulating alpha-synuclein in a patient in need thereof, comprising administering an effective amount of a compound of any one of Aspects 46-79 to the patient.
[0181] Aspect 82. The method of Aspect 81, wherein the compound binds to alpha-synuclein.
[0182] Aspect 83. The method of Aspect 81 or 82, further comprising performing positron emission tomography on the patient.
[0183] Aspect 84. A method of treating a neurodegenerative disorder in a patient in need thereof, comprising: administering a pharmaceutical agent that clears aggregated alpha-synuclein from the brain of the patient; administering an effective amount of a compound of any one of Aspects 46-79 to the patient; and performing positron emission tomography imaging on the patient.
[0184] Aspect 85. The method of Aspect 84, wherein the neurodegenerative disorder is a synucleinopathy such as Parkinson’s disease or multiple system atrophy.
[0185] Aspect 86. The method of Aspect 84 or 885, wherein the pharmaceutical agent is a monoclonal antibody.
[0186] Aspect 87. The method of any one of Aspects 84-86, wherein the imaging measures the amount of aggregated alpha-synuclein.
[0187] Aspect 88. The method of any one of Aspects 84-87, wherein the compound has a low affinity for Ap.
[0188] This disclosure is further illustrated by the following examples, which should not be construed as limiting.Examples
[0189] Example 1: Synthesis of Quinoline Related compounds
[0190] l-(pyridin-2-yl)piperazine was purchased from Sigma- Aldrich. The amines for the synthesis of Compounds 10, 11, 15-17, 26, 27, and 31-33 were prepared as described in in Mach Org. Let. 2016, 18, 5272-5275.
[0191] The general process for the synthesis of secondary l-(pyridin-2- yl)piperazine analogs and related data.
[0192] Step a: Amine (3.0 mmol, 1.0 equiv.), corresponding aryl bromide (3.0 mmol, 1.0 equiv.), Pd2(dba)3 (1.0 mol%), Ruphos (2.0 mol%) and 'BuONa (4.0 equiv.) were mixed in a sealed vial and 1,4-di oxane (6 mL) was added. The mixture was kept stirring at 100 °C for 20 min. The mixture was diluted with DCM and filtered through a celite pad. The filtrate was condensed and the crude product was purified by flash column chromatography on silica gel, eluting with hexanes / ethyl acetate = 4: 1 to 2: 1 to afford the desired product.
[0193] Step b : The Boc-protected amine was dissolved in DCM (10 mL). HC1 in 1,4-di oxane (2 M, 4 mL) was added. The mixture was stirred at room temperature overnight. The solid was filtered out. The solid was collected and the crude products were used for the next step directly.
[0194] Example 2: / ‘c / 7- Butyl 3-(pyridin-2-yl)-3,8-diazabicyclo [3.2.1] octane-8- carboxylate. This compound was prepared using the procedure of Example 1. 'H NMR (400 MHz, CDCh) 5 8.17 (dd, J= 5.0, 1.8 Hz, 1H), 7.48 (t, J= 6.9 Hz, 1H), 6.63 (dd, J= 6.9, 5.0 Hz, 1H), 6.57 (d, J= 8.6 Hz, 1H), 4.36 (s, 2H), 3.96 (s, 1H), 3.82 (s, 1H), 3.09 (s, 2H), 1.95, 1.91 (m, 2H), 1.79-1.74 (m, 2H), 1.46 (s, 9H);13C NMR (101 MHz, CDCh) 5 159.7, 153.7, 147.2, 138.0, 113.3, 107.0, 79.9, 53.6, 52.8, 50.6, 28.6, 27.8. LCMS: 290 [M+H]+. White solid, 676 mg, 78%.
[0195] Example 3:Butyl 3-(isoquinolin-3-yl)-3,8- diazabicyclo[3.2.1]octane-8-carboxylate. This compound was prepared using the procedure of Example 1.XH NMR (400 MHz, CDCh) 5 8.92 (s, 1H), 7.77 (d, J= 8.2 Hz, 1H), 7.56 (d, J = 8.3 Hz, 1H), 7.49 (ddd, J= 8.3, 6.7, 1.3 Hz, 1H), 7.27-7.21 (m, 1H), 6.67 (s, 1H), 4.41 (s, 2H), 4.00 (d, J= 39.5 Hz, 2H), 3.12 (s, 2H), 2.04-1.76 (m, 4H), 1.49 (s, 9H);13C NMR (101 MHz, CDCh) 5 157.1, 153.8, 151.0, 138.9, 130.5, 127.7, 125.3, 123.6, 123.3, 98.4, 79.8, 53.8, 53.0, 51.3, 28.6. LCMS: 340 [M+H]+. White solid, 975 mg, 96%.
[0196] Example 4: tert-Butyl 3-(quinolin-3-yl)-3,8-diazabicyclo[3.2.1]octane-8- carboxylate. This compound was prepared using the procedure of Example 1. 1H NMR (400 MHz, CDCh) 5 8.75 (d, J = 2.9 Hz, 1H), 8.02-7.98 (m, 1H), 7.65 (dd, J = 7.9, 1.7 Hz, 1H), 7.52-7.43 (m, 2H), 7.27 (d, J = 3.0 Hz, 1H), 4.43 (s, 2H), 3.59-3.47 (m, 2H), 3.13 (s, 2H),2.07-1.86 (m, 4H), 1.49 (s, 9H);13C NMR (101 MHz, CDCh) 5 153.7, 144.7, 142.6, 142.2, 129.0, 128.6, 127.3, 126.5, 126.5, 116.0, 80.1, 28.6. LCMS: 340 [M+H]+. White solid, 975 mg, 96%.
[0197] Example 5: tert-Butyl 8-(pyridin-2-yl)-3,8-diazabicyclo[3.2.1]octane-3- carboxylate. This compound was prepared using the procedure of Example 1. 1H NMR (400 MHz, CDCh) 5 8.18-8.11 (m, 1H), 7.48-7.39 (m, 1H), 6.62-6.51 (m, 2H), 4.49 (s, 2H), 3.80 (d, J = 12.7 Hz, 1H), 3.65 (d, J = 12.7 Hz, 1H), 3.21 (d, J = 12.7 Hz, 1H), 3.11 (d, J =12.7 Hz, 1H), 2.00-1.91 (m, 2H), 1.82 (dd, J = 16.4, 7.5 Hz, 2H), 1.43 (s, 9H);13C NMR (101 MHz, CDCh) 5 157.2, 156.2, 148.6, 137.7, 113.2, 109.0, 79.7, 53.8, 53.4, 48.1, 46.8, 28.5, 27.1. LCMS: 290 [M+H]+. White solid, 736 mg, 86%.
[0198] Example 6: tert-Butyl 8-(isoquinolin-3-yl)-3,8- diazabicyclo[3.2.1]octane-3-carboxylate. This compound was prepared using the procedure of Example 1. 1H NMR (400 MHz, CDCh) 5 8.94 (s, 1H), 7.77 (d, J = 8.3 Hz, 1H), 7.57- 7.46 (m, 2H), 7.27-7.22 (m, 1H), 6.75 (s, 1H), 4.65 (d, J = 19.9 Hz, 2H), 3.86 (d, J = 12.8 Hz, 1H), 3.72 (d, J = 12.4 Hz, 1H), 3.30 (d, J = 12.8 Hz, 1H), 3.21 (d, J = 12.8 Hz, 1H), 2.07-2.02 (m, 2H), 1.88 (dd, J = 16.6, 7.7 Hz, 2H), 1.45 (s, 9H);13C NMR (101 MHz, CDCh) 5 156.2, 151.2, 139.1, 130.8, 127.8, 124.9, 123.4, 123.1, 100.9, 79.7, 54.3, 54.1, 47.9, 46.4, 28.4, 27.1, 27.0. LCMS: 340 [M+H]+. Light-yellow solid, 863 mg, 85%.
[0199] Example 7: tert-Butyl 8-(quinolin-3-yl)-3,8-diazabicyclo[3.2.1]octane-3- carboxylate. This compound was prepared using the procedure of Example 1. 1H NMR (400 MHz, CDCh) 5 8.69 (d, J = 3.0 Hz, 1H), 7.98-7.93 (m, 1H), 7.62-7.56 (m, 1H), 7.47- 7.41 (m, 2H), 7.24 (d, J = 2.7 Hz, 1H), 4.34 (d, J = 15.7 Hz, 2H), 3.83 (d, J = 12.9 Hz, 1H), 3.69 (d, J = 12.9 Hz, 1H), 3.33 (d, J = 12.9 Hz, 1H), 3.24 (d, J = 12.9 Hz, 1H), 2.10-2.05 (m, 2H), 1.90 (dd, J = 14.7, 7.3 Hz, 2H), 1.44 (s, 9H);13C NMR (101 MHz, CDCh) 5 156.1, 143.6, 142.2, 140.3, 129.3, 129.1, 127.2, 126.1, 125.9, 116.4, 80.0, 55.0, 54.8, 47.2, 45.8,28.5, 27.1, 26.9. LCMS: 340 [M+H]+. Light-yellow solid, 814 mg, 80%.
[0200] Example 8: tert-Butyl 8-(benzo[d]thiazol-2-yl)-3,8- diazabicyclo[3.2.1]octane-3-carboxylate. This compound was prepared using the procedure of Example 1. 1H NMR (400 MHz, CDCh) 5 7.60 (dd, J = 7.9, 1.2 Hz, 1H), 7.56 (d, J = 8.1 Hz, 1H), 7.32-7.28 (m, 1H), 7.11-7.06 (m, 1H), 4.37 (s, 2H), 3.79 (s, 2H), 3.43 (s, 2H), 2.01- 1.98 (m, 2H), 1.84-1.79 (m, 2H), 1.49 (s, 9H);13C NMR (101 MHz, CDCh) 5 169.8, 153.5,126.5, 126.3, 121.7, 120.8, 119.2, 111.4, 80.4, 53.8, 28.6, 27.5. LCMS: 346 [M+H]+. White solid, 640 mg, 62%.
[0201] Example 9: tert-Butyl 4-(pyridin-2-yl)-l,4-diazepane-l-carboxylate.This compound was prepared using the procedure of Example 1. 1H NMR (400 MHz, CDCh) 5 8.08 (d, J = 5.0 Hz, 1H), 7.37 (t, J = 7.9 Hz, 1H), 6.50-6.42 (m, 2H), 3.72 (t, J = 5.5 Hz, 2H), 3.65-3.48 (m, 4H), 3.28 (t, J = 6.1 Hz, 1H), 3.18 (t, J = 6.2 Hz, 1H), 1.94-1.88 (m, 2H), 1.36 (d, 9H).13C NMR (101 MHz, CDCh) 5 157.33, 157.28, 155.3, 155.1, 148.2, 148.1,137.4, 111.8, 105.63, 105.57, 79.4, 48.9, 48.5, 47.3, 47.1, 46.7, 46.2, 45.8, 28.4, 28.3, 25.3, 25.0. LCMS: 278 [M+H]+. Light-yellow oil, 673 mg, 81%.
[0202] Example 10: tert-Butyl 4-(isoquinolin-3-yl)-l,4-diazepane-l- carboxylate. This compound was prepared using the procedure of Example 1. 1H NMR (400 MHz, CDCh) 5 8.87 (s, 1H), 7.72 (dd, J = 8.2, 1.1 Hz, 1H), 7.51 (d, J = 8.5 Hz, 1H), 7.44 (ddd, J = 8.3, 6.6, 1.2 Hz, 1H), 7.16 (ddd, J = 8.1, 6.6, 1.2 Hz, 1H), 6.60 (d, J = 1.0 Hz, 1H), 3.88 (t, J = 5.4 Hz, 2H), 3.81-3.72 (m, 2H), 3.66-3.57 (m, 2H), 3.34 (t, J = 6.1 Hz, 1H), 3.23 (t, J = 6.2 Hz, 1H), 2.09-2.00 (m, 2H), 1.39 (d, 9H);13C NMR (101 MHz, CDCh) 5155.5, 155.2, 154.4, 151.4, 151.3, 139.2, 130.3, 127.8, 127.8, 124.9, 122.7, 122.3, 96.6, 96.4,79.5, 67.2, 49.6, 49.2, 47.7, 47.6, 47.0, 46.3, 46.0, 28.5, 28.4, 25.5, 24.9. LCMS: 328 [M+H]+. Light-yellow solid, 870 mg, 89%.
[0203] Example 11: tert-Butyl 4-(quinolin-3-yl)-l,4-diazepane-l-carboxylate. This compound was prepared using the procedure of Example 1. 1H NMR (400 MHz, CDCh) 5 8.66 (d, J = 3.0 Hz, 1H), 7.98-7.90 (m, 1H), 7.60 (q, J = 4.0 Hz, 1H), 7.44-7.36 (m, 2H), 7.14 (s, 1H), 3.76-3.58 (m, 6H), 3.35 (t, J = 6.0 Hz, 1H), 3.24 (t, J = 6.2 Hz, 1H), 2.04 (q, J = 6.3 Hz, 2H), 1.35 (d, 9H);13C NMR (101 MHz, CDCh) 5 155.4, 155.0, 141.2, 141.0, 140.3, 140.1, 129.6, 128.8, 127.1, 126.0, 125.2, 112.2, 112.1, 79.9, 50.5, 50.3, 49.0, 48.2, 46.4, 46.3, 45.8, 28.5, 28.3, 25.5, 25.0. LCMS: 328 [M+H]+. Light-yellow solid, 900 mg, 92%.
[0204] Example 12: tert-Butyl 4-(isoquinolin-3-yl)piperazine-l-carboxylate.This compound was prepared using the procedure of Example 1. 1H NMR (400 MHz, CDCh) 5 8.97 (s, 1H), 7.80 (dd, J = 8.3, 1.1 Hz, 1H), 7.60 (dd, J = 8.5, 1.1 Hz, 1H), 7.54 (t, J = 6.8 Hz, 1H), 7.30 (t, J = 6.8 Hz, 1H), 6.81 (s, 1H), 3.67-3.53 (m, 8H), 1.50 (s, 9H).13C NMR (101 MHz, CDCh) 5 154.8, 150.6, 139.0, 1131.2, 131.0, 127.8, 125.4, 124.0, 123.6, 100.1, 80.0, 46.4, 43.5, 28.5. LCMS: 314 [M+H]+. Light-yellow solid, 836 mg, 89%.
[0205] Example 13: tert-Butyl 4-(quinolin-3-yl)piperazine-l-carboxylate.This compound was prepared using the procedure of Example 1. 1H NMR (400 MHz, CDCh) 5 8.81-8.75 (m, 1H), 8.08-8.02 (m, 1H), 7.73-.67 (m, 1H), 7.59-7.45 (m, 2H), 7.42-7.38 (m, 1H), 3.65 (t, J = 5.0 Hz, 4H), 3.26 (s, 4H), 1.49 (s, 9H);13C NMR (101 MHz, CDCh) 5 144.7, 128.8, 128.3, 126.7, 118.2, 80.2, 49.3, 43.4, 28.4. LCMS: 314 [M+H]+. Light-yellow solid, 808 mg, 86%.
[0206] Example 14: General Process for Analogs of 4-Amino-N-(4- methoxyphenyl)-2-(4-(pyridin-2-yl)piperazin-l-yl)pyrimidine-5-carboxamide (28)
[0207] Step a: Ethyl 4-amino-2-chloropyrimidine-5-carboxylate (60 mg, 0.30 mmol) and the corresponding amine or the salt (0.45 mmol) was dissolved in 4 mL dry MeCN. EtsN (91 mg, 0.90 mmol) was added to the solution. The mixture was stirred at room temperature overnight. Removed the solvent and the crude product was purified by flash column chromatography on silica gel, eluting with hexanes / ethyl acetate (with 5% 7N NH3 in MeOH) (4: 1 to 1 : 1) to afford the desired product as a solid.
[0208] Step b: The product (0.20 mmol) from the last step was dissolved in EtOH and H2O (2 mL / 2 mL). The mixture was heated to 60 °C for 4 h. After cooling to room temperature, EtOH was removed under reduced pressure. 1 N HC1 was used to make the solution to pH = 7. The precipitated solid was filtered out and dried on a high vacuum for 12 h. The crude product was used for the next step without further purification.
[0209] Step c: A solution of the crude product above, DIPEA (77 mg, 0.6 mmol) and HBTU (0.21 mmol) in 4 mL DMF was stirred for 15 min at room temperature. 4- methoxyaniline (26 mg, 0.21 mmol) in DMF (1 mL) was added to the solution. The mixture was stirred at room temperature overnight. The mixture was washed with 1 N Na2CO3 solution and extracted with DCM (3^ 15 mL) and dried over Na2SO4. Removed the solvent and the residue was purified by flash column chromatography on silica gel, eluting with 5%MeOH in DCM to afford the desired product as a solid.
[0210] Example 15: Ethyl 4-amino-2-(3-(pyridin-2-yl)-3,8- diazabicyclo[3.2.1]octan-8-yl)pyrimidine-5-carboxylate (1).This compound was prepared using the procedure of Example 14 (R = pyridin-2-yl). 1H NMR (400 MHz, CDCh) 5 8.65 (s, 1H), 8.17 (d, J = 4.7 Hz, 1H), 7.75 (brsm, 1H), 7.51-7.45 (m, 1H), 6.64-6.63 (m, 1H), 6.56 (d, J = 8.6 Hz, 1H), 5.39 (brsm, 1H), 4.96 (s, 2H), 4.28 (q, J = 7.1 Hz, 2H), 3.96 (d, J = 11.8 Hz, 2H), 3.18 (d, J = 12.0 Hz, 2H), 2.05-1.97 (m, 2H), 1.92- 1.87 (m, 2H), 1.33 (t, J = 7.1 Hz, 3H);13C NMR (101 MHz, CDCh) 5 166.7, 163.6, 160.9, 159.8, 147.3, 138.0, 113.3, 106.9,96.5, 60.4, 53.2, 50.5, 27.5, 14.5. LCMS: 355 [M+H]+; HRMS (ESI) calculated for C18H23N6O2 + ([M+H+]) 355.1877, found: 355.1876. White solid, 54 mg, 51%.
[0211] Example 16: Ethyl 4-amino-2-(3-(isoquinolin-3-yl)-3,8- diazabicyclo [3.2.1] octan-8-yl)pyrimidine-5-car boxylate (2) .This compound was prepared using the procedure of Example 14 (R = isoquinolin-3-yl). 1H NMR (400 MHz, CDCh) 5 8.91 (s, 1H), 8.67 (s, 1H), 7.76 (d, J = 8.1 Hz, 1H), 7.55 (d, J = 8.3 Hz, 1H), 7.52-7.45 (m, 1H), 7.26-7.21 (m, 2H), 6.67 (s, 1H), 5.43 (brsm, 1H), 5.00 (s, 2H), 4.37-4.24 (m, 2H), 4.13-4.09 (m, 2H), 3.20 (dd, J = 11.8, 2.2 Hz, 2H), 2.08-1.95 (m, 4H), 1.35 (t, J = 7.1 Hz, 3H);13C NMR (101 MHz, CDCh) 5 166.4, 163.3, 157.1, 151.0, 149.2, 138.8, 130.5, 127.7, 125.3, 123.7, 123.4, 98.5, 96.6, 60.7, 53.9, 51.4, 27.6, 14.5.LCMS: 405 [M+H]+; HRMS (ESI) calculated for C22H25N6O2 + ([M+H+]) 405.2034, found: 405.2049. White solid, 61 mg, 50%.
[0212] Example 17: Ethyl 4-amino-2-(3-(quinolin-3-yl)-3,8- diazabicyclo [3.2.1] octan-8-yl)pyrimidine-5-car boxylate (3) .This compound was prepared using the procedure of Example 14 (R = quinolin-3-yl). 1H NMR (400 MHz, CDCh) 5 8.75 (s, 1H), 8.66 (s, 1H), 8.02 (d, J = 7.9 Hz, 1H), 7.83 (brsm, 1H), 7.64 (d, J = 7.8 Hz, 1H), 7.51-7.44 (m, 2H), 7.30 (s, 1H), 5.47 (brsm, 1H), 5.04 (s, 2H), 4.29 (q, J = 7.1 Hz, 2H), 3.60 (d, J = 11.0 Hz, 2H), 3.22 (d, J = 11.0 Hz, 2H), 2.06 (t, J = 10.9 Hz, 4H), 1.34 (t, J = 7.1 Hz, 3H);13C NMR (101 MHz, CDCh) 5 166.4, 163.4, 160.3, 144.6, 142.0, 141.5, 128.1, 127.3, 126.6, 126.4, 116.3, 96.6, 60.4, 53.3, 53.1, 27.7, 14.4. LCMS: 406 [M+H]+; HRMS (ESI) calculated for C22H25N6O2 + ([M+H+]) 405.2034, found: 405.2062. White solid, 68 mg, 56%.
[0213] Example 18: Ethyl 4-amino-2-(8-(pyridin-2-yl)-3,8- diazabicyclo [3.2.1] octan-3-yl)pyrimidine-5-car boxylate (4) .This compound was prepared using the procedure of Example 14 (R = pyridin-2-yl). 1H NMR (400 MHz, CDCh) 5 8.60 (s, 1H), 8.17 (d, J = 5.7 Hz, 1H), 7.65 (brsm, 1H), 7.47 (t, J = 7.8 Hz, 1H), 6.63 (d, J = 8.5 Hz, 1H), 6.61-6.56 (m, 1H), 5.33 (brsm, 1H), 4.61 (s, 2H), 4.48 (s, 2H),4.25 (q, J = 7.2 Hz, 2H), 3.25 (d, J = 13.0 Hz, 2H), 1.97 (dd, J = 8.8, 4.3 Hz, 2H), 1.84-1.80 (m, 2H), 1.31 (t, J = 7.1 Hz, 3H);13C NMR (101 MHz, CDCh) 5 166.8, 163.2, 163.1, 160.7, 156.9, 148.1, 137.9, 113.1, 96.0, 109.1, 96.1, 60.1, 54.0, 47.6, 27.1, 14.4.LCMS: 355 [M+H]+; HRMS (ESI) calculated for C18H23N6O2 + ([M+H+]) 355.1877, found: 355.1886. White solid, 81 mg, 76%.
[0214] Example 19: Ethyl 4-amino-2-(8-(isoquinolin-3-yl)-3,8- diazabicyclo [3.2.1] octan-3-yl)pyrimidine-5-car boxylate (5) .This compound was prepared using the procedure of Example 14 (R = isoquinolin-3-yl). 1H NMR (400 MHz, CDCh) 5 8.95 (s, 1H), 8.64 (s, 1H), 7.77 (d, J = 8.2 Hz, 1H), 7.56 (d, J = 8.3 Hz, 1H), 7.50 (t, J = 7.5 Hz, 1H), 7.27-7.23 (m, 1H), 6.81 (s, 1H), 5.40 (brsm, 1H), 4.75 (s, 2H), 4.53 (s, 2H), 4.28 (q, J = 7.1 Hz, 2H), 3.37 (s, 2H), 2.16-2.01 (m, 2H), 1.85-1.82 (m, 2H), 1.34 (t, J = 7.1 Hz, 3H);13C NMR (101 MHz, CDCh) 5 166.5, 162.9, 153.6, 151.7, 148.8, 138.9, 130.6, 127.8, 125.0, 123.4, 123.3, 100.8, 96.3, 60.3, 54.3, 47.6, 27.1, 14.4.LCMS: 405 [M+H]+; HRMS (ESI) calculated for C22H25N6O2+ ([M+H+]) 405.2034, found: 405.2059. White solid, 85 mg, 70%.
[0215] Example 20: Ethyl 4-amino-2-(8-(quinolin-3-yl)-3,8- diazabicyclo [3.2.1] octan-3-yl)pyrimidine-5-car boxylate (6) .This compound was prepared using the procedure of Example 14 (R = isoquinolin-3-yl). 1H NMR (400 MHz, CDCh) 5 8.74 (d, J = 2.8 Hz, 1H), 8.62 (s, 1H), 8.02 (s, 1H), 7.72 (brsm, 1H), 7.67-7.61 (m, 1H), 7.52-7.41 (m, 2H), 7.35 (s, 1H), 5.35 (brsm, 1H), 4.50 (s, 2H), 4.44 (s, 2H), 4.28 (q, J = 7.1 Hz, 2H), 3.36 (d, J = 13.2 Hz, 2H), 2.13-2.05 (m, 2H), 1.90-1.85 (m, 2H), 1.33 (t, J = 7.1 Hz, 3H);13C NMR (101 MHz, CDCh) 5 166.6, 163.0, 162.7, 160.4, 142.5, 140.3, 129.3, 128.2, 127.5, 127.4, 126.3, 126.1, 96.4, 60.3, 55.1, 46.6, 27.0, 14.4.LCMS: 405 [M+H]+; HRMS (ESI) calculated for C22H25N6O2 + ([M+H+]) 405.2034, found: 405.20942. White solid, 80 mg, 66%.
[0216] Example 21: Ethyl 4-amino-2-(4-(pyridin-2-yl)-l,4-diazepan-l- yl)pyrimidine-5-carboxylate (7).This compound was prepared using the procedure of Example 14 (R =pyridin-2-yl). 1H NMR (400 MHz, CDCh) 5 8.65 (s, 1H), 8.17-8.12 (m, 1H), 7.45 - 7.41 (m, 1H), 6.54-6.51 (m, 2H), 4.28 (q, J = 7.1 Hz, 2H), 3.97 (d, J = 16.7 Hz, 2H), 3.83 (t, J = 5.1 Hz, 2H), 3.66-3.58 (m, 4H), 2.10-2.04 (m, 2H), 1.34 (t, J = 7.1 Hz, 3H);13C NMR (101 MHz, CDCh) 5 167.1, 162.0, 157.6, 148.4, 137.5, 111.9, 105.8, 96.0, 60.2, 48.3, 46.6, 46.5, 14.5. LCMS: 343 [M+H]+;HRMS (ESI) calculated for C17H23N6O2 + ([M+H+]) 343.1877, found: 343.1870. White solid, 63 mg, 61%.
[0217] Example 22: Ethyl 4-amino-2-(4-(quinolin-3-yl)-l,4-diazepan-l- yl)pyrimidine-5-carboxylate (8).This compound was prepared using the procedure of Example 14 (R = quinolin-3-yl). 1H NMR (400 MHz, CDCh) 5 8.89 (s, 1H), 8.64 (s, 1H), 7.83 (brsm, 1H), 7.73 (d, J = 8.1 Hz, 1H), 7.53 (d, J = 8.4 Hz, 1H), 7.46 (ddd, J = 8.1, 6.6, 1.2 Hz, 1H), 7.18 (ddd, J = 8.0, 6.6, 1.2 Hz, 1H), 6.65 (s, 1H), 5.61 (brsm, 1H), 4.28 (q, J = 7.1 Hz, 2H), 4.12 -3.96 (m, 4H), 3.81- 3.60 (m, 4H), 2.17 (s, 2H), 1.33 (t, J = 7.1 Hz, 3H);13C NMR (101 MHz, CDCh) 5 166.3, 162.9, 159.8, 153.9, 151.1, 139.3, 130.5, 127.7, 124.9, 122.5, 96.8, 96.2, 60.5, 49.1, 48.5, 47.0, 46.8, 24.4, 24.1, 14.3. LCMS: 393 [M+H]+; HRMS (ESI) calculated for C21H25N6O2+ ([M+H+]) 393.2034, found: 393.2033. White solid, 89 mg, 76%.
[0218] Example 23: Ethyl 4-amino-2-(4-(pyridin-2-yl)piperazin-l- yl)pyrimidine-5-carboxylate (9).EtoH2NThis compound was prepared using the procedure of Example 14 (R = pyridin-2-yl). 1H NMR (400 MHz, DMSO-d6) 5 8.52 (s, 1H), 8.12 (ddd, J = 4.9, 2.0, 0.8 Hz, 1H), 7.55 (ddd, J = 8.9, 7.1, 2.0 Hz, 1H), 7.47 (s, 1H), 7.41 (s, 1H), 6.86 (d, J = 8.6 Hz, 1H), 6.66 (dd, J = 6.7, 4.5 Hz, 1H), 4.21 (q, J = 7.1 Hz, 2H), 1.26 (t, J = 7.1 Hz, 3H);13C NMR (101 MHz, DMSO- d6) 5 166.1, 162.9, 161.5, 160.6, 158.9, 147.7, 137.8, 113.4, 107.4, 95.1, 59.9, 44.5, 43.0, 14.4. LCMS: 329 [M+H]+; HRMS (ESI) calculated for C16H21N6O2 + ([M+H+]) 329.1721, found: 329.1745. White solid, 85 mg, 51%.
[0219] Example 24: Ethyl 4-amino-2-(4-(benzo[d]oxazol-2-yl)piperazin-l- yl)pyrimidine-5-carboxylate (10).This compound was prepared using the procedure of Example 14 (R = benzo[d]oxaol-2-yl). 1H NMR (400 MHz, CDCh) 5 8.67 (s, 1H), 7.76 (brsm, 1H), 7.38 (dd, J = 7.8, 1.2 Hz, 1H), 7.27 (dd, J = 9.3, 1.8 Hz, 1H), 7.18 (td, J = 7.7, 1.1 Hz, 1H), 7.04 (td, J = 7.7, 1.2 Hz, 1H), 5.33 (brsm, 1H), 4.30 (q, J = 7.1 Hz, 2H), 4.02 (t, J = 5.2 Hz, 4H), 3.80-3.70 (m, 4H), 1.35 (t, J = 7.1 Hz, 3H);13C NMR (101 MHz, CDCh) 5 166.7, 163.4, 162.2, 148.9, 143.1, 124.3, 121.1, 116.6, 109.0, 96.7, 60.4, 45.6, 43.3, 14.5. LCMS: 369 [M+H]+; HRMS (ESI) calculated for C18H21N6O3+ ([M+H+]) 369.1670, found: 369.1678. White solid, 84 mg, 77%.
[0220] Example 25: Ethyl 4-amino-2-(4-(benzo[d]thiazol-2-yl)piperazin-l- yl)pyrimidine-5-carboxylate (11).This compound was prepared using the procedure of Example 14 (R = benzo[d]thiazol-2-yl). 1H NMR (400 MHz, DMSO-d6) 5 8.54 (s, 1H), 7.78 (dd, J = 8.0, 1.2 Hz, 1H), 7.56-7.44 (m,3H), 7.29 (td, J = 8.2, 1.3 Hz, 1H), 7.08 (td, J = 7.6, 1.2 Hz, 1H), 4.22 (q, J = 7.1 Hz, 2H), 3.95 (t, J = 5.2 Hz, 4H), 3.65 (t, J = 5.2 Hz, 4H), 1.28 (t, J = 7.1 Hz, 3H);13C NMR (101 MHz, DMSO-d6) 5 168.1, 165.9, 162.8, 161.3, 160.5, 152.3, 130.4, 126.0, 121.3, 121.2, 118.6, 95.2, 59.7, 47.7, 42.5, 14.2. LCMS: 385 [M+H]+; HRMS (ESI) calculated for C18H21N6O2S+ ([M+H+]) 385.1441, found: 385.1452. White solid, 86 mg, 76%.
[0221] Example 26: Ethyl 4-amino-2-(3-(benzo[d]thiazol-2-yl)-3,8- diazabicyclo[3.2.1]octan-8-yl)pyrimidine-5-carboxylate (12).This compound was prepared using the procedure of Example 14 (R = benzo[d]thiazol-2-yl). 1H NMR (400 MHz, DMSO-d6) 5 8.55 (s, 1H), 7.75 (dd, J = 7.9, 1.2 Hz, 1H), 7.51 (s, 2H), 7.45 (d, J = 7.5 Hz, 1H), 7.27 (td, J = 7.7, 1.3 Hz, 1H), 7.06 (td, J = 7.6, 1.2 Hz, 1H), 4.88 (d, J = 22.3 Hz, 2H), 4.22 (q, J = 7.1 Hz, 2H), 3.85 (d, J = 12.0 Hz, 2H), 3.36 (d, J = 12.0 Hz, 2H), 1.98-1.94 (m, 2H), 1.81 (q, J = 6.7 Hz, 2H), 1.27 (t, J = 7.1 Hz, 3H);13C NMR (101 MHz, DMSO-d6) 5 169.0, 165.9, 163.1, 160.8, 159.9, 152.3, 130.0, 126.0, 121.1, 121.1, 118.5, 95.6, 59.7, 52.4, 26.7, 14.2. LCMS: 411 [M+H]+; HRMS (ESI) calculated for C20H23N6O2S+ ([M+H+]) 411.1598, found: 411.1605. White solid, 87 mg, 71%.
[0222] Example 27: Ethyl 4-amino-2-(4-(isoquinolin-3-yl)piperazin-l- yl)pyrimidine-5-carboxylate (13).This compound was prepared using the procedure of Example 14 (R = isoquinolin-3-yl). 1H NMR (400 MHz, CDCh) 5 8.97 (s, 1H), 8.69 (s, 1H), 7.85-7.76 (m, 1H), 7.55-7.51 (m, 1H), 7.32-7.28 (m, 1H), 6.82 (s, 1H), 4.31 (q, J = 7.1 Hz, 2H), 4.10 (s, 4H), 3.68 (t, J = 5.3 Hz, 4H), 1.36 (t, J = 7.1 Hz, 4H);13C NMR (101 MHz, CDCh) 5 163.0, 156.1, 151.1, 149.0, 138.8, 131.3, 130.6, 127.7, 125.4, 123.85, 123.79, 122.8, 99.6, 60.7, 46.2, 44.0, 14.3. LCMS: 379 [M+H]+; HRMS (ESI) calculated for C20H23N6O2 + ([M+H+]) 379.1877, found: 379.1911. White solid, 91 mg, 80%.
[0223] Example 28: Ethyl 4-amino-2-(4-(quinolin-3-yl)piperazin-l- yl)pyrimidine-5-carboxylate (14).This compound was prepared using the procedure of Example 14 (R = quinolin-3-yl). 1H NMR (400 MHz, CDCh) 5 8.83 (d, J = 2.8 Hz, 1H), 8.68 (s, 1H), 8.14 (s, 1H), 7.84 (brsm, 1H), 7.76 - 7.69 (m, 1H), 7.61 - 7.47 (m, 3H), 5.46 (brsm, 1H), 4.31 (q, J = 7.1, 2H), 4.13 (s, 4H), 3.37 (d, J = 5.3 Hz, 4H), 1.36 (t, J = 7.1 Hz, 3H);13C NMR (101 MHz, CDCh) 5 166.4, 163.2, 144.6, 142.6, 129.0, 127.9, 127.8, 127.6,127.4, 126.7, 96.6, 60.5, 49.0, 43.6, 14.4. LCMS: 379 [M+H]+; HRMS (ESI) calculated for C20H23N6O2+ ([M+H+]) 379.1877, found: 379.1911. White solid, 88 mg, 78%.
[0224] Example 29: Ethyl 4-amino-2-(4-(quinolin-2-yl)piperazin-l- yl)pyrimidine-5-carboxylate (15).This compound was prepared using the procedure of Example 14 (R = quinolin-2-yl). 1H NMR (400 MHz, CDCh) 5 8.67 (s, 1H), 7.95 (d, J = 9.1 Hz, 1H), 7.74 (brsm, 1H), 7.65-7.52 (m, 2H), 7.26 (d, J = 3.0 Hz, 1H), 7.01 (d, J = 9.2 Hz, 1H), 5.29 (brsm, 1H), 4.29 (q, J = 7.1 Hz, 2H), 4.11-3.97 (m, 4H), 3.86 (s, 4H), 1.35 (t, J = 7.1 Hz, 3H);13C NMR (101 MHz, CDCh) 5 166.9, 163.4, 161.9, 161.0, 130.1, 127.4, 123.1, 109.8, 96.4, 60.3, 45.5, 43.6, 14.5. LCMS: 379 [M+H]+; HRMS (ESI) calculated for C20H23N6O2 + ([M+H+]) 379.1877, found: 379.1905. Light-yellow solid, 93 mg, 82%.
[0225] Example 30: Ethyl 4-amino-2-(4-(quinoxalin-2-yl)piperazin-l- yl)pyrimidine-5-carboxylate (16).This compound was prepared using the procedure of Example 14 (R = quinoxalin-2-yl). 1H NMR (400 MHz, DMSO-d6) 5 8.75 (d, J = 1.8 Hz, 1H), 8.63 (d, J = 1.9 Hz, 1H), 8.55 (s, 1H), 7.91 (d, J = 9.3 Hz, 1H), 7.76 (dd, J = 9.4, 2.7 Hz, 1H), 7.48 (d, J = 7.5 Hz, 2H), 7.28 (d, J = 2.7 Hz, 1H), 4.22 (q, J = 7.1 Hz, 2H), 3.98 (t, J = 5.0 Hz, 4H), 3.47 (t, J = 5.2 Hz, 4H), 1.28 (t, J = 7.0 Hz, 3H);13C NMR (101 MHz, DMSO-d6) 5 165.9, 162.8, 161.3, 160.5, 151.4, 145.5, 144.1, 141.8, 137.4, 129.4, 122.3, 108.5, 95.0, 59.7, 47.4, 42.8, 14.2. LCMS: 380 [M+H]+; HRMS (ESI) calculated for C19H22N7O2 + ([M+H+]) 380.1829, found: 380.1861. Yellow solid, 90 mg, 80%.
[0226] Example 31: Ethyl 4-amino-2-(4-(4-methoxyphenyl)piperazin-l- yl)pyrimidine-5-carboxylate (17).This compound was prepared using the procedure of Example 14 (R = 4-methoxyphenyl). 1H NMR (400 MHz, DMSO-d6) 5 8.52 (s, 1H), 7.43 (d, J = 28.6 Hz, 2H), 7.00 - 6.86 (m, 4H), 4.22 (q, J = 7.1 Hz, 2H), 3.91 (t, J = 5.0 Hz, 4H), 3.80 (s, 3H), 2.97 (t, J = 5.0 Hz, 4H), 1.27 (t, J = 7.1 Hz, 3H);13C NMR (101 MHz, DMSO-d6) 5 165.9, 162.8, 161.3, 160.4, 152.1, 141.0, 122.8, 120.8, 118.4, 111.9, 94.8, 59.6, 55.4, 50.1, 43.4, 14.2. LCMS: 358 [M+H]+;HRMS (ESI) calculated for C18H24N5O3+ ([M+H+]) 358.1874, found: 358.1877. White solid, 87 mg, 82%.
[0227] Example 32: 4-Amino-N-(4-methoxyphenyl)-2-(3-(pyridin-2-yl)-3,8- diazabicyclo[3.2.1]octan-8-yl)pyrimidine-5-carboxamide (18).This compound was prepared using the procedure of Example 14 (R = pyridin-2-yl). 1HNMR (400 MHz, DMSO-d6) 5 9.79 (s, 1H), 8.63 (s, 1H), 8.13 (dd, J = 5.2, 1.9 Hz, 1H), 7.56(d, J = 8.9 Hz, 3H), 6.93 (d, J = 9.0 Hz, 2H), 6.78 (d, J = 8.7 Hz, 1H), 6.67 (dd, J = 7.0, 4.9 Hz, 1H), 4.90 (brsm, 2H), 4.05 (dd, J = 11.7, 2.5 Hz, 2H), 3.77 (s, 3H), 3.01 (dd, J = 12.1, 2.2 Hz, 2H), 1.94 (dd, J = 8.4, 4.2 Hz, 2H), 1.81 (t, J = 6.4 Hz, 2H);13C NMR (101 MHz, DMSO-d6) 5 165.8,163.6, 160.3, 160.2, 158.2, 155.9, 147.9, 137.8, 132.5, 122.8, 114.1, 113.4, 107.1, 100.0, 55.6, 53.0, 50.0, 27.5. LCMS: 432 [M+H]+; HRMS (ESI) calculated for C23H26N7O2 + ([M+H+]) 432.2142, found: 432.2149. White solid, 36 mg, 42% for 2 steps.
[0228] Example 33: 4-Amino-2-(3-(isoquinolin-3-yl)-3,8- diazabicyclo[3.2.1]octan-8-yl)-N-(4-methoxyphenyl)pyrimidine-5-carboxamide (19).This compound was prepared using the procedure of Example 14 (R = isoquinolin-3-yl). 1H NMR (400 MHz, DMSO-d6) 5 9.79 (s, 1H), 9.00 (s, 1H), 8.64 (s, 1H), 7.99 (s, 1H), 7.90 (d, J = 8.2 Hz, 1H), 7.68 (d, J = 8.5 Hz, 1H), 7.59-7.55 (m, 3H), 7.30 (t, J = 7.6 Hz, 1H), 6.94 (s, 2H), 4.96 (brsm, 2H), 4.15 (d, J = 11.9 Hz, 2H), 3.77 (s, 3H), 3.08 (d, J = 11.8 Hz, 2H), 1.97 (s, 2H), 1.87 (d, J = 7.7 Hz, 2H);13C NMR (101 MHz, DMSO-d6) 5 165.3, 163.1, 162.3, 159.8, 157.7, 156.8, 155.4, 150.7, 138.3, 132.0, 130.3, 127.5, 125.0, 122.9, 122.3, 113.7, 99.5, 97.7, 55.2, 52.6, 50.3, 27.1. LCMS: 482 [M+H]+; HRMS (ESI) calculated for C27H28N7O2+ ([M+H+]) 482.2299, found: 482.2288. Light-yellow solid, 48 mg, 50% for 2 steps.
[0229] Example 34: 4-Amino-N-(4-methoxyphenyl)-2-(3-(quinolin-3-yl)-3,8- diazabicyclo[3.2.1]octan-8-yl)pyrimidine-5-carboxamide (20).This compound was prepared using the procedure of Example 14 (R = quinolin-3-yl). 1H NMR (400 MHz, DMSO-d6) 5 9.80 (s, 1H), 8.90 (d, J = 2.8 Hz, 1H), 8.65 (s, 1H), 7.94 - 7.86 (m, 1H), 7.85-7.75 (m, 1H), 7.56 (d, J = 9.0 Hz, 2H), 7.52-7.47 (m, 3H), 6.93 (d, J = 9.0 Hz, 2H), 4.95 (brsm, 2H), 3.80 (dd, J = 11.4, 2.4 Hz, 2H), 3.77 (s, 3H), 3.07 (dd, J = 11.3, 2.2 Hz, 3H), 2.05-1.96 (m, 4H);13C NMR (101 MHz, DMSO-d6) 5 165.8, 163.6, 160.3, 158.2, 155.9, 145.1, 143.4, 142.2, 132.5, 129.1, 128.8, 127.2, 127.0, 126.0, 122.8, 114.9, 114.1,100.1, 55.6, 53.1, 52.6, 27.7. LCMS: 482 [M+H]+; HRMS (ESI) calculated for C27H28N7O2 + ([M+H+]) 482.2299, found: 482.2312. Light-yellow solid, 41 mg, 43% for 2 steps.
[0230] Example 35: 4-Amino-2-(8-(isoquinolin-3-yl)-3,8- diazabicyclo[3.2.1]octan-3-yl)-N-(4-methoxyphenyl)pyrimidine-5-carboxamide (21).This compound was prepared using the procedure of Example 14 (R = isoquinolin-3-yl). 1H NMR (400 MHz, DMSO-d6) 5 9.73 (s, 1H), 9.00 (s, 1H), 8.57 (s, 1H), 7.87 (dd, J = 8.3, 1.1 Hz, 1H), 7.64 (dd, J = 8.5, 1.1 Hz, 1H), 7.55-7.50 (m, 3H), 7.26 (ddd, J = 8.1, 6.7, 1.1 Hz, 1H), 7.09 (s, 1H), 6.89 (d, J = 9.1 Hz, 2H), 4.77 (brsm, 2H), 4.47 (d, J = 12.8 Hz, 2H), 3.73 (s, 3H), 3.20 (dd, J = 13.1, 2.0 Hz, 2H), 1.94 (dd, J = 8.4, 4.1 Hz, 2H), 1.72 (t, J = 6.7 Hz, 2H);13C NMR (101 MHz, DMSO-d6) 5 165.9, 163.1, 162.7, 157.7, 155.8, 154.2, 152.1, 138.9, 132.6, 130.9, 128.1, 125.3, 123.4, 123.3, 122.7, 114.1, 100.5, 99.5, 55.6, 54.0, 47.4, 27.2. LCMS: 482 [M+H]+; HRMS (ESI) calculated for C27H28N7O2+ ([M+H+]) 482.2299, found: 482.2278. Light-yellow solid, 51 mg, 53% for 2 steps.
[0231] Example 36: 4-Amino-N-(4-methoxyphenyl)-2-(8-(quinolin-3-yl)-3,8- diazabicyclo[3.2.1]octan-3-yl)pyrimidine-5-carboxamide (22).This compound was prepared using the procedure of Example 14 (R = quinolin-3-yl). 1H NMR (400 MHz, DMSO-d6) 5 9.73 (s, 1H), 8.87 (d, J = 2.9 Hz, 1H), 8.57 (s, 1H), 7.85 (dd, J = 7.7, 1.8 Hz, 1H), 7.76 - 7.71 (m, 1H), 7.61 (d, J = 2.8 Hz, 1H), 7.53 (d, J = 9.0 Hz, 2H), 7.47-7.43 (m, 2H), 6.89 (d, J = 9.0 Hz, 2H), 4.64 (s, 2H), 4.42 (d, J = 13.0 Hz, 2H), 3.73 (s, 3H), 3.24 (d, J = 12.9 Hz, 2H), 1.99 (d, J = 11.5 Hz, 3H), 1.73 (d, J = 7.4 Hz, 2H);13C NMR (101 MHz, DMSO-d6) 5 165.8, 163.1, 162.7, 157.7, 155.8, 144.2, 141.9, 140.8, 132.6, 129.6, 128.9, 127.2, 126.7, 125.7, 122.7, 116.0, 114.1, 99.6, 55.6, 54.6, 46.6, 27.1. LCMS: 482 [M+H]+; HRMS (ESI) calculated for C27H28N7O2 + ([M+H+]) 482.2299, found: 482.2299. Light-yellow solid, 42 mg, 44% for 2 steps.
[0232] Example 37: 4-Amino-N-(4-methoxyphenyl)-2-(4-(pyridin-2-yl)-l,4- diazepan-l-yl)pyrimidine-5-carboxamide (23).This compound was prepared using the procedure of Example 14 (R = pyridin-2-yl). 1H NMR (400 MHz, CDCh) 5 9.38 (brsm, 1H), 8.86 (s, 1H), 8.15 (d, J = 5.4 Hz, 1H), 7.63-7.52 (m, 3H), 6.84 (d, J = 9.1 Hz, 2H), 6.65 (dd, J = 11.6, 7.4 Hz, 2H), 4.04 (s, 4H), 3.78 (s, 3H), 3.70 (s, 4H), 2.08 (t, J = 6.7 Hz, 2H);13C NMR (101 MHz, CDCh) 5 163.1, 156.7, 130.8, 125.6, 123.3, 123.2, 114.8, 114.0, 112.2, 55.5, 48.3, 47.8, 29.7. LCMS: 420 [M+H]+; HRMS (ESI) calculated for C22H26N7O2 + ([M+H+]) 420.2142, found: 420.2153. White solid, 33 mg, 39% for 2 steps.
[0233] Example 38: 4-Amino-2-(4-(isoquinolin-3-yl)-l,4-diazepan-l-yl)-N-(4- methoxyphenyl)pyrimidine-5-carboxamide (24).This compound was prepared using the procedure of Example 14 (R = isoquinolin-3-yl). 1H NMR (400 MHz, DMSO-d6) 5 9.69 (s, 1H), 8.92 (s, 1H), 8.54 (s, 1H), 7.80 (d, J = 8.2 Hz, 1H), 7.61 (d, J = 8.3 Hz, 1H), 7.51 (d, J = 9.1 Hz, 2H), 7.49-7.44 (m, 1H), 7.17 (ddd, J = 8.0, 6.7, 1.1 Hz, 1H), 6.88 (d, J = 9.1 Hz, 2H), 6.84 (s, 1H), 3.96 (d, J = 18.3 Hz, 2H), 3.88 (s, 2H), 3.72 (s, 3H), 3.70 (d, J = 5-7 Hz, 2H), 3.63 (s, 2H), 2.08-1.95 (m, 2H);13C NMR (101 MHz, DMSO-d6) 5 165.9, 163.4, 161.3, 158.0, 155.8, 154.7, 151.6, 139.2, 132.6, 130.6, 128.0, 125.2, 122.7, 122.5, 114.1, 99.3, 96.4, 55.6, 47.3, 46.6, 46.1, 25.1. LCMS: 470 [M+H]+; HRMS (ESI) calculated for C26H28N7O2 + ([M+H+]) 470.2299, found: 470.2318. Light-yellow solid, 36 mg, 39% for 2 steps.
[0234] Example 39: 4-Amino-N-(4-methoxyphenyl)-2-(4-(quinolin-3-yl)-l,4- diazepan-l-yl)pyrimidine-5-carboxamide (25).This compound was prepared using the procedure of Example 14 (R = quinolin-3-yl). 1H NMR (400 MHz, DMSO-d6) 5 9.67 (s, 1H), 8.75 (d, J = 2.9 Hz, 1H), 8.53 (s, 1H), 7.79 (d, J = 8.0 Hz, 1H), 7.70 (d, J = 8.0 Hz, 1H), 7.50 (d, J = 9.0 Hz, 2H), 7.42-7.33 (m, 3H), 6.88 (d, J = 9.0 Hz, 2H), 4.00 (d, J = 14.9 Hz, 2H), 3.79 (t, J = 5.3 Hz, 2H), 3.72 (s, 3H), 3.69-3.59 (m, 4H), 2.07-1.97 (m, 2H);13C NMR (101 MHz, DMSO-d6) 5 165.4, 160.7, 157.5, 155.3, 140.4, 132.1, 129.3, 128.3, 126.5, 126.0, 124.3, 122.2, 113.6, 110.9, 98.9, 55.1, 47.5, 45.8, 28.8. LCMS: 470 [M+H]+; HRMS (ESI) calculated for C26H28N7O2 + ([M+H+]) 470.2299, found: 470.2297. Light-yellow solid, 38 mg, 40% for 2 steps.
[0235] Example 40: 4-Amino-2-(4-(benzo[d]oxazol-2-yl)piperazin-l-yl)-N-(4- methoxyphenyl)pyrimidine-5-carboxamide (26).This compound was prepared using the procedure of Example 14 (R = benzo[d]oxazol-2-yl). 1H NMR (400 MHz, DMSO-d6) 5 9.77 (s, 1H), 8.62 (s, 1H), 7.54 (d, J = 9.1 Hz, 2H), 7.42 (d, J = 7.7 Hz, 1H), 7.31 (d, J = 7.7 Hz, 1H), 7.17 (td, J = 7.7, 1.1 Hz, 1H), 7.04 (td, J = 7.7, 1.1 Hz, 1H), 6.90 (d, J = 9.1 Hz, 2H), 3.94 (t, J = 5.2 Hz, 4H), 3.73 (s, 3H), 3.68 (t, J = 5.2 Hz, 4H);13C NMR (101 MHZ, DMSO-d6) 5 165.3, 162.9, 161.8, 160.8, 157.4, 155.4, 148.3, 142.9, 132.0, 124.0, 122.3, 120.6, 115.9, 113.7, 108.9, 99.3, 55.2, 45.1, 42.5. LCMS: 446 [M+H]+; HRMS (ESI) calculated for C23H24N7O3 + ([M+H+]) 446.1935, found: 446.1941. White solid, 39 mg, 44% for 2 steps.
[0236] Example 41: 4-Amino-2-(4-(benzo[d]thiazol-2-yl)piperazin-l-yl)-N-(4- methoxyphenyl)pyrimidine-5-carboxamide (27).This compound was prepared using the procedure of Example 14 (R = benzo[d]thiazol-2-yl). 1H NMR (400 MHz, DMSO-d6) 5 9.77 (d, J = 3.9 Hz, 1H), 8.62 (d, J = 4.4 Hz, 1H), 7.79 (s,1H), 7.56-7.46 (m, 3H), 7.29 (d, J = 6.9 Hz, 1H), 7.09 (d, J = 7.0 Hz, 1H), 6.90 (s, 2H), 3.94 (s, 4H), 3.73 (s, 3H), 3.66 (s, 4H);13C NMR (101 MHz, DMSO-d6) 5 168.2, 165.3, 162.9,160.8, 157.5, 155.4, 152.4, 132.0, 130.4, 126.0, 122.3, 121.4, 121.2, 118.7, 113.7, 99.3, 55.2,47.8, 42.6. LCMS: 462 [M+H]+; HRMS (ESI) calculated for C23H24N7O2S+ ([M+H+]) 462.1707, found: 4621705. White solid, 48 mg, 51% for 2 steps.
[0237] Example 42: 4-Amino-N-(4-methoxyphenyl)-2-(4-(pyridin-2- yl)piperazin-l-yl)pyrimidine-5-carboxamide (28).This compound was prepared using the procedure of Example 14 (R = pyridin-2-yl). 1H NMR (400 MHz, DMSO-d6) 5 9.75 (s, 1H), 8.61 (s, 1H), 8.13 (d, J = 4.7 Hz, 1H), 7.64-7.45 (m, 4H), 6.95-6.85 (m, 3H), 6.66 (t, J = 5.9 Hz, 1H), 3.87 (t, J = 5.2 Hz, 4H), 3.73 (t, J = 1.5 Hz, 3H), 3.56 (t, J = 5.2 Hz, 4H);13C NMR (101 MHz, DMSO-d6) 5 165.4, 162.9, 160.9, 158.9, 157.4, 155.4, 147.6, 137.6, 132.0, 122.3, 113.7, 113.2, 107.2, 99.0, 55.2, 44.5, 42.9. LCMS: 406 [M+H]+; HRMS (ESI) calculated for C21H24N7O2 + ([M+H+]) 406.1986, found: 406.2014. White solid, 35 mg, 43%.
[0238] Example 43: 4-Amino-2-(4-(isoquinolin-3-yl)piperazin-l-yl)-N-(4- methoxyphenyl)pyrimidine-5-carboxamide (29).This compound was prepared using the procedure of Example 14 (R = isoquinolin-3-yl). 1H NMR (400 MHz, DMSO-d6) 5 9.76 (s, 1H), 9.01 (s, 1H), 8.63 (s, 1H), 7.89 (d, J = 8.2 Hz, 1H), 7.69 (d, J = 8.4 Hz, 1H), 7.58-7.52 (m, 3H), 7.29 (t, J = 7.5 Hz, 1H), 7.04 (s, 1H), 6.90 (d, J = 9.0 Hz, 2H), 3.94 (t, J = 5.2 Hz, 4H), 3.73 (s, 3H), 3.63 (t, J = 5.2 Hz, 4H);13C NMR(101 MHz, DMSO-d6) 5 165.8, 163.4, 161.4, 157.9, 156.5, 155.9, 151.4, 138.8, 132.5, 130.9,128.0, 125.6, 123.7, 123.5, 122.8, 114.1, 99.5, 99.0, 55.6, 45.8, 43.4. LCMS: 456 [M+H]+;HRMS (ESI) calculated for C25H26N7O2+ ([M+H+] 456.2142, found: 456.2133. Light-yellow solid, 44 mg, 48% for 2 steps.
[0239] Example 44: 4-Amino-N-(4-methoxyphenyl)-2-(4-(quinolin-3- yl)piperazin-l-yl)pyrimidine-5-carboxamide (30).This compound was prepared using the procedure of Example 14 (R = quinolin-3-yl). 1H NMR (400 MHz, DMSO-d6) 5 9.77 (s, 1H), 8.91 (d, J = 2.8 Hz, 1H), 8.62 (s, 1H), 7.91-7.85 (m, 1H), 7.82-7.76 (m, 1H), 7.59 (d, J = 2.9 Hz, 1H), 7.53 (d, J = 9.0 Hz, 2H), 7.51-7.48 (m, 2H), 6.89 (d, J = 9.0 Hz, 2H), 3.98 (t, J = 5.0 Hz, 4H), 3.36 (t, J = 5.0 Hz, 4H);13C NMR (101 MHz, DMSO-d6) 5 165.8, 163.4, 162.9, 161.3, 157.9, 155.9, 145.1, 145.0, 142.6, 132.4, 129.1, 128.8, 127.3, 127.2, 126.6, 122.8, 118.6, 116.5, 114.2, 99.6, 55.6, 48.7, 43.4. LCMS: 456 [M+H]+; HRMS (ESI) calculated for C25H26N7O2 + ([M+H+] 456.2142, found: 456.2152. Brown solid, 51 mg, 56% for 2 steps.
[0240] Example 45: 4-Amino-N-(4-methoxyphenyl)-2-(4-(quinolin-2- yl)piperazin-l-yl)pyrimidine-5-carboxamide (Compound 31).This compound was prepared using the procedure of Example 14 (R = quinolin-2-yl). 1H NMR (400 MHz, DMSO-d6) 5 9.75 (s, 1H), 8.63 (s, 1H), 8.08 (d, J = 9.1 Hz, 1H), 7.72 (dd, J = 8.2, 1.4 Hz, 1H), 7.61-7.57 (m, 1H), 7.56-7.51 (m, 3H), 7.30 (d, J = 9.0 Hz, 1H), 7.24 (ddd, J = 8.1, 6.7, 1.3 Hz, 1H), 6.90 (d, J = 9.0 Hz, 2H), 3.92 (dd, J = 6.9, 3.7 Hz, 4H), 3.78 (dd, J =6.8, 3.9 Hz, 4H), 3.73 (s, 3H);13C NMR (101 MHz, DMS0-d6) 5 165.8, 163.4, 161.4, 157.9,157.5, 155.9, 147.7, 137.9, 132.5, 129.9, 127.9, 126.5, 123.3, 122.7, 122.6, 114.1, 110.7,99.5, 55.6, 44.9, 43.5. LCMS: 456 [M+H]+; HRMS (ESI) calculated for C25H26N7O2 + ([M+H+]) 456.2142, found: 456.2165. Light-yellow solid, 46 mg, 50% for 2 steps.
[0241] Example 46: 4-Amino-N-(4-methoxyphenyl)-2-(4-(quinoxalin-2- yl)piperazin-l-yl)pyrimidine-5-carboxamide (32).This compound was prepared using the procedure of Example 14 (R = quinoxalin-2-yl). 1H NMR (400 MHz, DMSO-d6) 5 9.76 (s, 1H), 8.76 (d, J = 1.9 Hz, 1H), 8.65-8.60 (m, 2H), 7.92 (d, J = 9.3 Hz, 1H), 7.78 (dd, J = 9.3, 2.7 Hz, 1H), 7.54 (d, J = 8.9 Hz, 2H), 7.29 (d, J = 2.7 Hz, 1H), 6.90 (d, J = 8.9 Hz, 2H), 3.97 (t, J = 5.2 Hz, 4H), 3.73 (s, 3H), 3.48 (t, J = 5.2 Hz, 4H);13C NMR (101 MHz, DMSO-d6) 5 165.3, 162.9, 160.8, 157.5, 155.4, 151.5, 145.5, 144.1, 141.9, 137.4, 132.0, 129.5, 122.4, 122.3, 113.7, 108.6, 99.1, 55.2, 47.5, 42.8. LCMS: 462 [M+H]+; HRMS (ESI) calculated for C24H25N8O2 + ([M+H+]) 457.2095, found: 457.2098. Yellow solid, 48 mg, 51% for 2 steps.
[0242] Example 47: 4-Amino-N-(4-methoxyphenyl)-2-(4-(4- methoxyphenyl)piperazin-l-yl)pyrimidine-5-carboxamide (33).This compound was prepared using the procedure of Example 14 (R = 4-methoxyphenyl). 1H NMR (400 MHz, DMSO-d6) 5 9.74 (s, 1H), 8.61 (s, 1H), 7.55 (s, 3H), 6.96-6.88 (m, 5H), 3.90 (s, 4H), 3.81 (s, 3H), 3.73 (s, 3H), 2.98 (s, 4H); 13C NMR (101 MHz, DMSO-d6) 5165.4, 162.9, 160.8, 157.5, 155.4, 152.1, 141.1, 132.1, 122.8, 122.2, 120.8, 118.4, 113.7, 111.9, 98.9, 55.4, 55.2, 50.2, 43.4. LCMS: 457 [M+H]+; HRMS (ESI) calculated for C23H27N6O3 + ([M+H+]) 435.2139, found: 435.2151. White solid, 36 mg, 41% for 2 steps.
[0243] Example 48: Method for the synthesis of 4-Amino-N-(4-fluorophenyl)- 2-(4-(pyridin-2-yl)piperazin-l-yl)pyrimidine-5-carboxamide (34) and 4-Amino-2-(4- (pyridin-2-yl)piperazin-l-yl)-N-(4-(trifluoromethyl)phenyl)pyrimidine-5-carboxamide (35).R = F, CF3
[0244] Step a: Compound 9 (0.20 mmol) was dissolved in EtOH and H2O (2 mL / 2 mL). The mixture was heated to 60 °C for 4 h. After cooling to room temperature, EtOH was removed under reduced pressure. 1 N HC1 was used to make the solution to PH = 7. The precipitated solid was filtered out and dried on a high vacuum for 12 h. The crude product was used for the next step directly.
[0245] Step b: A solution of the crude product above, DIPEA (77 mg, 0.6 mmol) and HBTU (0.21 mmol) in DMF (4 mL) was stirred for 15 min. at room temperature. Corresponding amine (0.21 mmol) in DMF (1 mL) was added to the solution. The mixture was heated to 50 °C and stirred overnight. After cooling to room temperature, the mixture was washed with 1 N Na2CO3 solution and extracted with DCM (3^ 15 mL), and dried over Na2SO4. Removed the solvent and the residue was purified by flash column chromatography on silica gel, eluting with 5% MeOH in DCM to afford the desired product as a solid.
[0246] R = F: 4-Amino-N-(4-fluorophenyl)-2-(4-(pyridin-2-yl)piperazin-l- yl)pyrimidine-5-carboxamide (34). 1H NMR (400 MHz, DMSO-d6) 5 9.90 (s, 1H), 8.63 (s, 1H), 8.13 (ddd, J = 4.9, 2.1, 0.8 Hz, 1H), 7.70-7.62 (m, 2H), 7.56 (ddd, J = 8.9, 7.1, 2.0 Hz, 2H), 7.19-7.11 (m, 2H), 6.87 (d, J = 8.6 Hz, 1H), 6.66 (ddd, J = 7.1, 4.8, 0.8 Hz, 1H), 3.94- 3.82 (m, 4H), 3.60 - 3.51 (m, 4H);13C NMR (101 MHz, DMSO-d6) 5 165.6, 162.9, 160.9,158.9, 158.1 (d, J = 241.9 Hz), 157.7, 147.6, 137.6, 135.4, 122.4 (d, J = 7.8 Hz), 115.1 (d, J = 22.1 Hz), 113.2, 107.2, 98.8, 44.4, 42.9. LCMS: 394 [M+H]+; HRMS (ESI) calculated for C20H21FN7O+ ([M+H+]) 394.1786, found: 394.1782. White solid, 28 mg, 36%.
[0247] R = CF3: 4-Amino-2-(4-(pyridin-2-yl)piperazin-l-yl)-N-(4- (trifluoromethyl)phenyl)pyrimidine-5-carboxamide (35). 1H NMR (400 MHz, DMSO-d6) 5 10.16 (s, 1H), 8.68 (s, 1H), 8.18-8.12 (m, 2H), 7.90 (d, J = 8.5 Hz, 2H), 7.69 (d, J = 8.6 Hz, 2H), 7.61-7.55 (m, 3H), 6.90-6.86 (m, 2H), 6.70-6.66 (m, 2H), 3.90 (t, J = 5.4 Hz, 4H), 3.58 (t, J = 5.4 Hz, 4H);13C NMR (101 MHz, DMSO-d6) 5 166.5, 163.4, 159.4, 158.6, 148.1, 138.1, 126.3, 126.3, 120.5, 113.7, 107.7, 99.1, 44.9, 43.4. LCMS: 444 [M+H]+; HRMS (ESI) calculated for C21H21F3N7O2+ ([M+H+]) 444.1754, found: 444.1755. Light-yellow solid, 5 mg, 5%.
[0248] Example 49: Method for the synthesis of 4-Amino-2-(4-(pyridin-2- yl)piperazin-l-yl)-N-(4-(trifluoromethoxy)phenyl)pyrimidine-5-carboxamide (36)
[0249] Step a: Compound 9 (0.20 mmol) was dissolved in EtOH and H2O (2 mL / 2 mL). The mixture was heated to 60 °C for 4 h. After cooling to room temperature, EtOH was removed under reduced pressure. 1 N HC1 was used to make the solution to pH = 7. The precipitated solid was filtered out and dried on a high vacuum for 12 h. The crude product was used for the next step directly.
[0250] Step b: A solution of the crude product above, EtsN (0.6 mmol) and DMAP (0.02 mmol), and EDChHCl (0.21 mmol) in DMF (4 mL)was stirred for 15 min. at room temperature. 4-(Trifluoromethoxy)aniline (0.21 mmol) in DMF (1 mL) was added to the solution. The mixture was heated to 50 °C and stirred overnight. After cooling to room temperature, the mixture was washed with 1 N Na2COs solution and extracted with DCM (3 x 15 mL), and dried over Na2SO4. Removed the solvent and the residue was purified by flashcolumn chromatography on silica gel, eluting with 5%MeOH in DCM to afford the desired product as a solid.
[0251] 1H NMR (400 MHz, DMSO-d6) 5 10.02 (s, 1H), 8.64 (s, 1H), 8.13 (dd, J = 5.0, 2.0 Hz, 1H), 7.76 (d, J = 9.1 Hz, 2H), 7.56 (ddd, J = 8.9, 7.0, 2.0 Hz, 2H), 7.32 (d, J = 8.6 Hz, 2H), 6.87 (d, J = 8.6 Hz, 1H), 6.66 (dd, J = 7.1, 4.8 Hz, 1H), 3.88 (dd, J = 6.9, 3.8 Hz, 4H), 3.57 (dd, J = 6.4, 3.9 Hz, 4H);13C NMR (101 MHz, DMSO-d6) 5 166.2, 163.4, 161.4, 159.4, 158.4, 148.0, 144.1, 138.9, 138.1, 122.2, 121.8, 119.4, 113.7, 107.7, 99.2, 44.9, 43.4.LCMS: 460 [M+H]+; HRMS (ESI) calculated for C21H21F3N7O3 + ([M+H+]) 460.1703, found: 460.1711. Light-yellow solid, 32 mg, 36% for 2 steps.
[0252] Example 50: Methods for the synthesis of 2-Hydroxyethyl 4-amino-2-(4-(pyridin-2-yl)piperazin-l-yl)pyrimidine-5-carboxylate (37)
[0253] Step a: Compound 9 (0.20 mmol) was dissolved in EtOH and H2O (2 mL / 2 mL). The mixture was heated to 60 °C for 4 h. After cooling to room temperature, EtOH was removed under reduced pressure. 1 N HC1 was used to make the solution to pH = 7. The precipitated solid was filtered out and dried on a high vacuum for 12 h. The crude product was used for the next step directly.
[0254] Step b: A solution of the crude product above, EtsN (0.6 mmol) and DMAP (0.02 mmol), and EDCFHCl (0.21 mmol) in DMF (4 mL)was stirred for 15 min. at room temperature. Ethane- 1 ,2-diol (0.21 mmol) in DMF (1 mL) was added to the solution. The mixture was heated to 50 °C and stirred overnight. After cooling to room temperature, the mixture was washed with 1 N Na2COs solution and extracted with DCM (3x 15 mL), and dried over Na2SO4. Removed the solvent and the residue was purified by flash column chromatography on silica gel, eluting with 5%MeOH in DCM to afford the desired product as a solid.
[0255] 1H NMR (400 MHz, DMSO-d6) 5 8.61 (s, 1H), 8.13 (dd, J = 5.0, 2.0 Hz, 1H), 7.55 (ddd, J = 8.9, 7.0, 2.0 Hz, 1H), 7.44 (s, 2H), 6.86 (d, J = 8.6 Hz, 1H), 6.66 (dd, J = 7.1, 4.9 Hz, 1H), 4.89 (t, J = 5.7 Hz, 1H), 4.18 (t, J = 5.7 Hz, 2H), 3.90-3.87 (m, 4H), 3.66 (q, J = 5.4 Hz, 2H), 3.59-3.50 (m, 4H);13C NMR (101 MHz, DMSO-d6) 5 166.0, 162.8, 161.4, 160.8, 158.8, 147.6, 137.6, 113.2, 107.2, 94.9, 65.6, 59.1, 44.4, 42.9. LCMS: 345 [M+H]+; HRMS (ESI) calculated for C16H21N6O3 + ([M+H+]) 345.1670, found: 345.1677. White solid, 28 mg, 36% for 2 steps.
[0256] Example 51: Methods for the synthesis of (4-Amino-2-(4-(pyridin-2- yl)piperazin-l-yl)pyrimidin-5-yl)methanol (38)
[0257] A solution of ethyl 4-amino-2-(4-(pyridin-2-yl)piperazin-l-yl)pyrimidine- 5-carboxylate (9) (65 mg, 0.20 mmol) in THF (4 mL) was cooled to 0 °C. LiAlH4 (0.4 mL, 1 M in THF) was added to the solution. The mixture was warmed to room temperature and stirred overnight. 10% NH4Q was added to quench the reaction. The mixture was extracted with DCM (10 mL x 3). The combined solvents were dried with Na2SO4, and filtered through a celite pad. Removed the solvent and the crude product was purified by flash column chromatography on silica gel, eluting with 5%MeOH in DCM to afford the desired product as a white solid.
[0258] 1H NMR (400 MHz, CDCh) 5 8.19 (dd, J = 4.9, 1.9 Hz, 1H), 7.73 (s, 1H), 7.49 (ddd, J = 8.9, 7.1, 2.0 Hz, 1H), 6.69-6.61 (m, 2H), 5.35 (s, 2H), 4.47 (s, 2H), 3.88-3.85 (m, 4H), 3.59-3.57 (m, 4H);13C NMR (101 MHz, CDCh): 5 163.2, 159.4, 154.2, 148.0, 137.6, 113.5, 107.2, 106.1, 60.6, 45.1, 43.7. LCMS: 287 [M+H]+; HRMS (ESI) calculated for C14H19N6O+ ([M+H+]) 287.1615, found: 287.1627. White solid, 54 mg, 62%.
[0259] Example 52: Methods for the synthesis of 5-Methyl-2-(4-(pyridin-2- yl)piperazin-l-yl)pyrimidin-4-amine (39) and 2-(4-(Pyridin-2-yl)piperazin-l- yl)pyrimidin-4-amine (40)
[0260] Step a: A solution of 2-chloropyrimidin-4-amine (0.20 mmol), l-(pyridin- 2-yl)piperazine (0.22 mmol) and CS2CO3 (0.22 mmol) in DMF (3 mL) was heated to 110 °C overnight. Removed the solvent and the crude product was purified by flash column chromatography on silica gel, eluting with 5% MeOH in DCM to afford the desired product as a white solid.
[0261] 5-Methyl-2-(4-(pyridin-2-yl)piperazin-l-yl)pyrimidin-4-amine(Compound 39). as described above (R = CH3). 1H NMR (400 MHz, CDCI3) 5 8.20 (ddd, J = 4.9, 2.0, 0.9 Hz, 1H), 7.77 (s, 1H), 7.48 (ddd, J = 8.8, 7.1, 2.0 Hz, 1H), 6.67 (d, J = 8.6 Hz, 1H), 6.62 (ddd, J = 7.1, 4.9, 0.8 Hz, 1H), 4.69 (s, 2H), 3.90-3.77 (m, 4H), 3.63-3.55 (m, 4H), 1.95 (s, 3H);13C NMR (101 MHz, CDCh): 5 162.4, 160.9, 159.7, 155.3, 148.1, 137.6, 113.5, 107.3, 102.5, 45.2, 43.9, 13.0. LCMS: 271 [M+H]+; HRMS (ESI) calculated for C14H19N6 + ([M+H+] 271.1666, found: 271.1690. White solid, 60 mg, 73%.
[0262] 2-(4-(Pyridin-2-yl)piperazin-l-yl)pyrimidin-4-amine (40). This compound was prepared as described above (R = H). 1H NMR (400 MHz, CDCh) 5 8.20 (d, J = 4.9 Hz, 1H), 7.95 (d, J = 5.6 Hz, 1H), 7.49 (t, J = 7.9 Hz, 1H), 6.73-6.57 (m, 2H), 5.79 (d, J = 5.6 Hz, 1H), 4.66 (s, 2H), 3.89 (s, 4H), 3.60 (s, 4H);13C NMR (101 MHz, CDCh): 5 163.5, 161.8, 159.6, 156.7, 148.1, 137.7, 113.6, 107.3, 95.1, 45.2, 43.6. LCMS: 257 [M+H]+; HRMS (ESI) calculated for C13H17N6 + ([M+H+] 257.1509, found: 257.1523. White solid, 41 mg, 16%.
[0263] Example 53: Methods for the synthesis of 4-Amino-2-(4-(pyridin-2- yl)piperazin-l-yl)pyrimidine-5-carbonitrile (41)
[0264] 4 -Amino-2-chloropyrimidine-5-carbonitrile (46 mg, 0.30 mmol) and 1- (pyridin-2-yl)piperazine (0.45 mmol) was dissolved in 4 mL dry MeCN. EtsN (91 mg, 0.90 mmol) was added to the solution. The mixture was stirred at room temperature overnight. Removed the solvent and the crude product was purified by flash column chromatography on silica gel, eluting with hexanes / ethyl acetate (with 5% 7N NH3 in MeOH) (4: 1 to 1 : 1) to afford the desired product as a white solid.
[0265] 1H NMR (400 MHz, DMSO-d6) 5 8.29 (s, 1H), 8.12 (ddd, J = 4.9, 2.1, 0.8 Hz, 1H), 7.55 (ddd, J = 8.9, 7.0, 2.0 Hz, 1H), 7.29 (s, 2H), 6.86 (d, J = 8.6 Hz, 1H), 6.73-6.58(m, 1H), 3.85 (t, J = 5.3 Hz, 4H), 3.59-3.50 (m, 4H);13C NMR (101 MHz, DMSO-d6: 5 162.8, 161.9, 160.7, 158.8, 147.5, 137.6, 117.2, 113.2, 107.2, 78.5, 44.3, 42.8. LCMS: 282 [M+H]+; HRMS (ESI) calculated for CuHieN? + ([M+H+]) 282.1462, found: 282.1460. White solid, 76 mg, 90%.
[0266] Example 54: Methods for the synthesis of N-(4-Methoxyphenyl)-2-(4- (pyridin-2-yl)piperazin-l-yl)pyrimidine-5-carboxamide (42)
[0267] Step a: A solution of ethyl 2-chloropyrimidine-5-carboxylic acid (317 mg, 2.0 mmol) in DCM (6 mL) was cooled to 0 °C under N2. SOCh (357 mg, 3.0 mmol) was added to the solution. The mixture was stirred for 3 h at room temperature. The extra SOCh was removed under vacuum. The residue was dissolved in 6 mL DCM. 4-methoxyaniline (246 mg, 2.0 mmol) was added to the mixture. The mixture was stirred at room temperature overnight. 10 mL saturated NaHCOs was added to quench the reaction. The mixture was extracted with DCM 3 times. Combine the organic phase and dried with Na2SO4. Removed the solvents and the crude product was purified by flash column chromatography on silica gel, eluting with 5%MeOH in DCM to afford the desired product as a white solid.
[0268] Step b: 2-chloro-N-(4-methoxyphenyl)pyrimidine-5-carboxamide (52 mg, 0.20 mmol) and l-(pyridin-2-yl)piperazine (32 mg, 0.20 mmol) was dissolved in 4 mL dry MeCN. EtsN (30 mg, 0.30 mmol) was added to the solution. The mixture was stirred at room temperature overnight. Removed the solvent and the crude product was purified by flash column chromatography on silica gel, eluting with hexanes / ethyl acetate (with 5% 7N NH3 in MeOH) (4: 1 to 1 : 1) to afford the desired product as a white solid.
[0269] 1H NMR (400 MHz, DMSO-d6) 5 9.99 (s, 1H), 8.91 (s, 2H), 8.14 (dd, J = 4.9, 2.0 Hz, 1H), 7.62 (d, J = 9.0 Hz, 2H), 7.59-7.54 (m, 1H), 6.92 (d, J = 9.0 Hz, 2H), 6.88 (d, J = 8.7 Hz, 1H), 6.67 (dd, J = 7.1, 4.9 Hz, 1H), 3.96 (t, J = 5.3 Hz, 4H), 3.74 (s, 3H), 3.62 (t, J = 5.3 Hz, 4H);13C NMR (101 MHz, DMSO-d6) 5 162.2, 161.4, 158.8, 158.0, 155.5, 147.6, 137.7, 132.0, 121.9, 116.7, 113.8, 113.3, 107.3, 55.2, 44.3, 43.2. LCMS: 391 [M+H]+;HRMS (ESI) calculated for C21H23N6O2+ ([M+H]+) 391.1877, found: 391.1879. White solid, 59 mg, 76%.
[0270] Example 55: 2-Chloro-N-(4-methoxyphenyl)pyrimidine-5-carboxamide (43).
[0271] This compound was prepared as described herein. 1H NMR (400 MHz, DMSO-d6) 5 10.50 (s, 1H), 9.21 (s, 2H), 7.65 (d, J = 9.0 Hz, 2H), 6.96 (d, J = 9.0 Hz, 2H), 3.75 (s, 3H);13C NMR (101 MHz, DMSO-d6) 5 162.2, 161.1, 160.1, 156.5, 131.8, 128.1, 122.4, 114.4, 55.7. LCMS: 264 [M+H]+. White solid, 101 mg, 19%.
[0272] Example 56: 4-methoxy-N-(4-(6-(pyridin-2-yl)-2,6- diazaspiro[3.3]heptan-2-yl)phenyl)benzamide (117)
[0273] This compound was prepared as described herein. Purification by flash chromatography using 0% to 50% EtOAc / n-Hexane with gradient elution and CH2CI2 / 7N NH3 in MeOH = 40: 1 gave 4-methoxy-N-(4-(6-(pyridin-2-yl)-2,6-diazaspiro[3.3]heptan-2- yl)phenyl)benzamide (30 mg, 52% yield) as a white solid. (1H NMR, 400 MHz, DMSO-d6): 5 = 9.83 (s, 1H), 8.07 (dd, JI = 5.0 Hz, J2 = 1.0 Hz, 1H), 7.93 (d, J = 8.8 Hz, 2H), 7.55 (d, J = 8.8 Hz, 2H), 7.03 (ddd, JI = 8.2 Hz, J2 = 7.1 Hz, J3 = 1.9 Hz, 1H), 7.03 (d, J = 8.8 Hz, 2H), 6.64 (dd, JI = 6.8 Hz, J2 = 5.2 Hz, 1H), 6.45 (d, J = 8.8 Hz, 2H), 6.39 (d, J = 8.3 Hz, 1H), 4.10 (s, 4H), 3.96 (s, 4H), 3.83 (s, 3H);13C NMR, 100 MHz, DMSO-d6: 5 = 164.2, 161.6, 160.4, 148.1, 147.7, 137.0, 129.9, 129.3, 127.2, 121.8, 113.5, 112.9, 111.5, 106.0, 62.0, 60.5, 55.3, 34.1; ESI-MS m / z calculated for C24H26N4O2 + [M+2H]+ 402.5; found 402.7 HRMS (ESI) for C24H25N4O2 + [M+H]+ 401.1978; found 401.1979
[0274] Example 57: 4-methoxy-N-(4-(7-(pyridin-2-yl)-2,7- diazaspiro[3.5]nonan-2-yl)phenyl)benzamide (118)
[0275] This compound was prepared as described herein. Purification by flash chromatography using 0% to 50% EtOAc / n-Hexane with gradient elution and CH2CI2 / 7N NH3 in MeOH = 40: 1 gave 4-methoxy-N-(4-(7-(pyridin-2-yl)-2,7-diazaspiro[3.5]nonan-2- yl)phenyl)benzamide (103 mg, 75% yield) as a white solid. (1H NMR, 400 MHz, DMSO- d6): 5 = 9.81 (s, 1H), 8.10 (dd, JI = 4.8 Hz, J2 = 1.4 Hz, 1H), 7.93 (dt, JI = 8.8 Hz, J2 = 2.8 Hz, 2H), 7.53 (d, J = 8.8 Hz, 2H), 7.50 (ddd, JI = 8.7 Hz, J2 = 6.9 Hz, J3 = 2.0 Hz, 1H), 7.03 (dt, JI = 8.9 Hz, J2 = 2.9 Hz, 2H), 6.84 (d, J = 8.6 Hz, 1H), 6.59 (dd, JI = 6.8 Hz, J2 = 5.3 Hz, 1H), 6.42 (d, J = 8.9 Hz, 2H), 3.83 (s, 3H) 3.59 (s, 4H), 3.53 (t, J = 5.3 Hz, 4H), 1.78 (t, J = 5.4 Hz, 4H);13C NMR, 100 MHz, DMSO-d6: 5 = 164.2, 161.6, 158.8, 148.4, 147.6, 137.4, 129.4, 129.3, 127.2, 121.9, 113.5, 112.4, 111.0, 107.1, 61.6, 55.3, 42.0, 34.7, 34.5; ESI-MS m / z calculated for C26H30N4O2 + [M+2H]+ 430.6; found 430.6
[0276] Example 58: 4-methoxy-N-(4-(7-(3-nitrophenyl)-2,7- diazaspiro[3.5]nonan-2-yl)phenyl)benzamide (119)
[0277] This compound was prepared as described herein. Purification by flash chromatography using 0% to 50% EtOAc / n-Hexane with gradient elution and CH2CI2 / 7N NH3 in MeOH = 40: 1 gave 4-methoxy-N-(4-(7-(3-nitrophenyl)-2,7-diazaspiro[3.5]nonan-2- yl)phenyl)benzamide (97 mg, 59% yield) as a yellow solid. (1H NMR, 400 MHz, DMSO- d6): 5 = 9.82 (s, 1H), 7.94 (d, J = 8.8 Hz, 2H), 7.68 (t, J = 2.2 Hz, 1H), 7.57-7.53 (m, 3H), 7.49-7.43 (m, 2H), 7.04 (d, J = 8.9 Hz, 2H), 6.43 (d, J = 8.8 Hz, 2H), 3.83 (s, 3H), 3.61 (s, 4H), 3.33 (t, J = 5.4 Hz, 4H), 1.88 (t, J = 5.3 Hz, 4H);13C NMR, 100 MHz, DMSO-d6: 5 =164.2, 161.6, 151.5, 148.9, 148.4, 130.1, 129.4, 129.3, 127.2, 121.9, 121.7, 113.5, 112.3, 111.0, 108.6, 61.5, 55.3, 45.2, 34.5, 34.0; ESI-MS m / z calculated for C27H29N4O4 + [M+H]+ 473.6; found 473.6
[0278] Example 59: 4-methoxy-N-(4-(7-(pyridin-2-yl)-2,7- diazaspiro [4.4] nonan-2-yl)phenyl)benzamide (120)
[0279] This compound was prepared as described herein. Purification by flash chromatography using 0% to 50% EtOAc / n-Hexane with gradient elution and CH2CI2 / 7N NH3 in MeOH = 40: 1 gave 4-methoxy-N-(4-(7-(pyridin-2-yl)-2,7-diazaspiro[4.4]nonan-2- yl)phenyl)benzamide (18 mg, 79% yield) as a white solid. (1H NMR, 400 MHz, DMSO-d6): 5 = 9.79 (s, 1H), 8.05 (dd, JI = 4.9 Hz, J2 = 1.3 Hz, 1H), 7.94 (dt, JI = 8.8 Hz, J2 = 2.8 Hz, 2H), 7.54 (d, J = 8.9 Hz, 2H), 7.47 (ddd, JI = 8.6 Hz, J2 = 6.9 Hz, J3 = 2.0 Hz, 1H), 7. 03 (dt, JI = 8.8 Hz, J2 = 2.9 Hz, 2H), 6.55-6.51 (m, 3H), 6.44 (d, J = 8.5 Hz, 1H), 3.83 (s, 3H), 3.51 (t, J = 7.0 Hz, 2H), 3.46-3.35 (m, 4H), 3.26 (dd, JI = 12.2 Hz, J2 = 9.4 Hz, 2H), 2.07-1.97 (m, 4H);13C NMR, 100 MHZ, DMSO-d6: 5 = 164.0, 161.5, 156.9, 147.8, 144.4, 136.9, 129.3, 128.1, 127.3, 122.1, 113.4, 111.2, 106.2, 57.2, 56.0, 55.3, 54.9, 48.0, 47.0, 45.7, 34.8, 34.7; ESI-MS m / z calculated for C26H30N4O2 + [M+2H]+ 430.6; found 430.5 HRMS (ESI) for C26H29N4O2 + [M+H]+ 429.2291; found 429.2285
[0280] Example 60: 4-methoxy-N-(4-(5-(pyridin-2-yl)hexahydropyrrolo[3,4- b]pyrrol-l(2H)-yl)phenyl)benzamide (100)
[0281] This compound was prepared as described herein. Purification by flash chromatography using 0% to 50% EtOAc / n-Hexane with gradient elution and CH2CI2 / 7N NH3 in MeOH = 40: 1 gave 4-methoxy-N-(4-(5-(pyridin-2-yl)hexahydropyrrolo[3,4-b]pyrrol- l(2H)-yl)phenyl)benzamide (9 mg, 26% yield) as a yellow solid. (1H NMR, 400 MHz, DMSO-d6): 5 = 9.83 (s, 1H), 8.05 (dd, JI = 4.9 Hz, J2 = 1.3 Hz, 1H), 7.95 (dt, JI = 8.8 Hz, J2 = 2.8 Hz, 2H), 7.57 (d, J = 8.9 Hz, 2H), 7.47 (ddd, JI = 8.6 Hz, J2 = 7.0 Hz, J3 = 2.0 Hz, 1H), 7.04 (dt, JI = 8.9 Hz, J2 = 2.8 Hz, 2H), 6.59-6.55 (m, 3H), 6.48 (d, J = 8.5 Hz, 1H), 4.29(td, JI = 6.7 Hz, J2 = 2.6 Hz, 1H), 3.83 (s, 3H), 3.70 (dd, JI = 11.2 Hz, J2 = 6.2 Hz, 1H), 3.58 (dd, JI = 10.6 Hz, J2 = 8.0 Hz, 1H), 3.51 (dt, JI = 9.0 Hz, J2 = 6.9 Hz, 1H), 3.44 (dd, JI = 11.2 Hz, J2 = 2.6 Hz, 1H), 3.38 (dd, JI = 10.6 Hz, J2 = 4.6 Hz, 1H), 3.31-3.28 (m, 1H), 3.20- 3.11 (m, 1H), 2.23-2.14 (m, 1H), 2.00-1.87 (m, 1H);13C NMR, 100 MHz, DMSO-d6: 5 = 164.1, 161.5, 157.4, 147.8, 143.4, 137.0, 129.3, 128.6, 127.3, 122.1, 113.4, 112.0, 111.8, 106.9, 62.0, 55.3, 54.9, 52.3, 50.8, 48.0, 41.7, 29.5; ESI-MS m / z calculated for C25H28N4O2 + [M+2H]+ 416.5; found 416.4 HRMS (ESI) for C25H27N4O2 + [M+H]+ 415.2134; found 415.2141
[0282] Example 61: 4-methoxy-N-(4-(2-(pyridin-2-yl)-2,8- diazaspiro[4.5]decan-8-yl)phenyl)benzamide (101)
[0283] This compound was prepared as described herein. Purification by flash chromatography using 0% to 50% EtOAc / n-Hexane with gradient elution and CH2CI2 / 7N NH3 in MeOH = 40: 1 gave 4-methoxy-N-(4-(2-(pyridin-2-yl)-2,8-diazaspiro[4.5]decan-8- yl)phenyl)benzamide (12 mg, 25% yield) as a white solid. (1H NMR, 400 MHz, DMSO-d6): 5 = 9.87 (s, 1H), 8.04 (dd, JI = 5.0 Hz, J2 = 1.3 Hz, 1H), 7.94 (dt, JI = 8.9 Hz, J2 = 2.8 Hz, 2H), 7.59 (d, J = 9.1 Hz, 2H), 7.46 (ddd, JI = 9.0 Hz, J2 = 7.0 Hz, J3 = 2.0 Hz, 1H), 7.04 (dt, JI = 8.9 Hz, J2 = 2.8 Hz, 2H), 6.94 (d, J = 9.1 Hz, 2H), 6.52 (dd, JI = 6.6 Hz, J2 = 5.1 Hz, 1H), 6.43 (d, J = 8.5 Hz, 1H), 3.83 (s, 3H), 3.45 (t, J = 7.0 Hz, 2H), 3.31 (s, 2H), 3.24-3.19 (m, 2H), 3.13-3.07 (m, 2H), 1.88 (t, J = 7.0 Hz, 2H), 1.73-1.63, 4H) (13C NMR, 100 MHz, DMSO-d6): 5 = 164.3, 161.6, 157.0, 147.8, 147.6, 136.8, 131.0, 129.4, 127.2, 121.5, 115.9, 113.5, 111.0, 106.2, 56.1, 55.4, 54.9, 46.6, 44.7, 35.2, 34.2, 30.7; ESI-MS m / z calculated for C27H31N4O2 + [M+H]+ 443.6; found 443.5 HRMS (ESI) for C27H31N4O2 + [M+H]+ 443.2447; found 443.2457
[0284] Example 62: 4-methoxy-N-(4-(5-(pyridin-2-yl)-2,5- diazabicyclo[2.2.1]heptan-2-yl)phenyl)benzamide (102)
[0285] This compound was prepared as described herein. Purification by flash chromatography using 0% to 50% EtOAc / n-Hexane with gradient elution and CH2CI2 / 7N NH3 in MeOH = 40: 1 gave 4-methoxy-N-(4-(5-(pyridin-2-yl)-2,5-diazabicyclo[2.2.1]heptan- 2-yl)phenyl)benzamide (25 mg, 45% yield) as a white solid. (1H NMR, 400 MHz, DMSO- d6): 5 = 9.78 (s, 1H), 8.02 (dd, JI = 5.0 Hz, J2 = 1.2 Hz, 1H), 7.92 (dt, JI = 8.8 Hz, J2 = 2.6 Hz, 2H), 7.51 (d, J = 8.9 Hz, 2H), 7.43 (ddd, JI = 8.6 Hz, J2 = 7.0 Hz, J3 = 1.9 Hz, 1H), 7.03 (dt, JI = 8.8 Hz, J2 = 2.8 Hz, 2H), 6.57 (d, J = 9.0 Hz, 2H), 6.52 (dd, JI = 6.5 Hz, J2 = 5.1 Hz, 1H), 6.46 (d, J = 8.5 Hz, 1H), 4.85 (s, 1H), 4.59 (s, 1H), 3.83 (s, 3H), 3.61 (dd, JI = 8.8 Hz, J2 = 1.8 Hz, 1H), 3.51 (dd, JI = 9.5 Hz, J2 = 1.5 Hz, 1H), 3.32 (d, J = 11.5 Hz, 2H), 2.97 (d, J = 8.9 Hz, 1H), 2.04 (dd, JI = 14.7 Hz, J2 = 9.4 Hz, 2H);13C NMR, 100 MHz, DMSO- d6: 5 = 164.1, 161.5, 156.8, 147.8, 143.5, 137.1, 129.3, 128.7, 127.3, 123.0, 113.5, 112.4, 111.8, 106.9, 56.8, 56.1, 55.9, 55.4, 52.4, 37.2; ESI-MS m / z calculated for C24H26N4O2 + [M+2H]+ 402.5; found 402.4 HRMS (ESI) for C24H25N4O2 + [M+H]+ 401.1978; found 401.2000
[0286] Example 63: 4-methoxy-N-(4-(3-(pyridin-2-yl)-3,8- diazabicyclo[3.2.1]octan-8-yl)phenyl)benzamide (103)
[0287] This compound was prepared as described herein. Purification by flash chromatography using 0% to 50% EtOAc / n-Hexane with gradient elution and CH2CI2 / 7N NH3 in MeOH = 40: 1 gave 4-methoxy-N-(4-(3-(pyridin-2-yl)-3,8-diazabicyclo[3.2.1]octan-8- yl)phenyl)benzamide (960 mg, 63% yield) as a white solid. (1H NMR, 400 MHz, DMSO- d6): 5 = 9.83 (s, 1H), 8.07 (dd, JI = 4.9 Hz, J2 = 1.3 Hz, 1H), 7.92 (dt, JI = 8.8 Hz, J2 = 2.8 Hz, 2H), 7.58 (d, J = 9.0 Hz, 2H), 7.49 (ddd, JI = 8.7 Hz, J2 = 7.0 Hz, J3 = 2.0 Hz, 1H), 7.03 (dt, JI = 8.9 Hz, J2 = 2.9 Hz, 2H), 6.92 (d, J = 9.1 Hz, 2H), 6.68 (d, J = 8.6 Hz, 1H), 6.61 (dd, JI = 6.7 Hz, J2 = 5.0 Hz, 1H), 4.40 (s, 2H), 3.83 (s, 3H), 3.61 (d, J = 10.7 Hz, 2H), 3.11 (d, J = 10.7 Hz, 2H), 1.95 (t, J = 4.0 Hz, 2H), 1.77 (q, J = 5.9 Hz, 2H);13C NMR, 100 MHz, DMSO-d6: 5 = 164.2, 161.6, 159.9, 147.4, 143.0, 137.2, 129.8, 129.3, 127.2, 122.0, 115.5, 113.5, 112.7, 106.3, 55.4, 53.9, 46.8, 27.2; ESI-MS m / z calculated for C25H28N4O2 + [M+2H]+ 416.5; found 416.5 HRMS (ESI) for C25H27N4O2 + [M+H]+ 415.2134; found 415.2148
[0288] Example 64: 4-methoxy-N-(4-(3-(quinolin-3-yl)-3,8- diazabicyclo[3.2.1]octan-8-yl)phenyl)benzamide (104)
[0289] This compound was prepared as described herein. Purification by flash chromatography using 0% to 50% EtOAc / n-Hexane with gradient elution and CH2CI2 / 7N NH3 in MeOH = 40: 1 gave 4-methoxy-N-(4-(3-(quinolin-3-yl)-3,8-diazabicyclo[3.2.1]octan- 8-yl)phenyl)benzamide (69 mg, 74% yield) as a yellow solid. (1H NMR, 400 MHz, DMSO- d6): 5 = 9.84 (s, 1H), 8.83 (d, J = 2.9 Hz, 1H), 7.92 (dt, JI = 8.9 Hz, J2 = 2.8 Hz, 2H), 7.85- 7.81 (m, 1H), 7.74-7.71 (m, 1H), 7.59 (d, J = 9.0 Hz, 2H), 7.44-7.42 (m, 2H), 7.39 (d, J = 2.8 Hz, 1H), 7.03 (dt, JI = 8.9 Hz, J2 = 2.9 Hz, 2H), 6.95 (d, J = 9.1 Hz, 2H), 4.46 (s, 2H), 3.82 (s, 3H), 3.56 (d, J = 10.0 Hz, 2H), 3.16 (d, J = 10.4 Hz, 2H), 2.02-1.94 (m, 4H);13C NMR, 100 MHz, DMSO-d6: 5 = 164.2, 161.6, 144.7, 142.9, 142.5, 141.6, 129.9, 129.3, 128.6,128.3, 127.2, 126.6, 126.5, 125.3, 122.0, 115.6, 113.7, 113.5, 55.4, 54.9, 54.1, 49.1, 27.3; ESI-MS m / z calculated for C29H30N4O2+ [M+2H]+ 466.6; found 466.4 HRMS (ESI) for C29H29N4O2+ [M+H]+ 465.2291; found 465.2300
[0290] Example 65: 4-methoxy-N-(4-(3-(quinoxalin-2-yl)-3,8- diazabicyclo[3.2.1]octan-8-yl)phenyl)benzamide (105)
[0291] This compound was prepared as described herein. Purification by flash chromatography using CH2CI2 / 7N NH3 in MeOH = 40: 1 gave 4-methoxy-N-(4-(3- (quinoxalin-2-yl)-3,8-diazabicyclo[3.2.1]octan-8-yl)phenyl)benzamide (36 mg, 52%) as a yellow solid. (1H NMR, 400 MHz, DMSO-d6): 5 = 9.85 (s, 1H), 8.73 (s, 1H), 7.92 (d, J = 2.8 Hz, 2H), 7.81 (d, J = 8.0 Hz, 1H), 7.62-7.58 (m, 4H), 7.40-7.36 (m, 1H), 7.03 (dt, JI = 8.9 Hz, J2 = 2.8 Hz, 2H), 6.97 (d, J = 9.0 Hz, 2H), 4.47 (s, 2H), 4.12 (d, J = 11.7 Hz, 2H), 3.82 (s, 3H), 3.36 (d, J = 11.5 Hz, 2H), 1.98 (t, J = 4.2 Hz, 2H), 1.82 (q, J = 5.9 Hz, 2H);13C NMR, 100 MHz, DMSO-d6: 5 = 164.2, 161.6, 153.1, 142.8, 141.0, 136.4, 136.3, 130.0, 129.9,129.3, 128.3, 127.2, 125.9, 124.2, 122.1, 122.0, 115.6, 113.4, 55.3, 54.9, 53.9, 46.3, 26.9;ESI-MS m / z calculated for C28H29N5O2 + [M+2H]+ 467.6; found 467.5 HRMS (ESI) for C28H28N5O2 + [M+H]+ 466.2243; found 466.2240
[0292] Example 66: 4-methoxy-N-(4-(3-(pyridin-2-yl)-3,9- diazabicyclo[3.3.1]nonan-9-yl)phenyl)benzamide (106)
[0293] This compound was prepared as described herein. Purification by flash chromatography using 0% to 50% EtOAc / n-Hexane with gradient elution and CH2CI2 / 7N NH3 in MeOH = 40: 1 gave 4-methoxy-N-(4-(3-(pyridin-2-yl)-3,9-diazabicyclo[3.3.1]nonan- 9-yl)phenyl)benzamide (7 mg, 19% yield) as a white solid. (1H NMR, 400 MHz, DMSO-d6): 5 = 9.88 (s, 1H), 8.13 (dd, JI = 4.9 Hz, J2 = 1.4 Hz, 1H), 7.95 (dt, JI = 8.9 Hz, J2 = 2.8 Hz, 2H), 7.61 (d, J = 9.0 Hz, 2H), 7.54 (ddd, JI = 8.7 Hz, J2 = 6.9 Hz, J3 = 2.0 Hz, 1H), 7.05 (dt, JI = 8.9 Hz, J2 = 2.8 Hz, 2H), 6.93 (d, J = 9.1 Hz, 2H), 6.87 (d, J = 8.7 Hz, 1H), 6.58 (dd, JI = 6.9 Hz, J2 = 5.0 Hz, 1H), 4.64 (s, 2H), 3.84 (s, 3H), 3.77 (d, J = 11.0 Hz, 2H), 2.97 (dd, JI = 11.4 Hz, J2 = 3.2 Hz, 2H), 2.48-2.42 (m, 1H), 1.80 (d, J = 6.2 Hz, 4H), 1.50-1.47 (m, 1H);13C NMR, 100 MHZ, DMSO-d6: 5 = 164.2, 161.6, 157.4, 147.9, 146.8, 137.6, 130.5, 129.4, 127.2, 121.6, 114.4, 113.5, 112.1, 107.0, 55.4, 51.9, 46.5, 27.8, 19.8; ESI-MS m / z calculated for C26H30N4O2 + [M+2H]+ 430.6; found 430.5 HRMS (ESI) for C26H29N4O2+ [M+H]+ 429.2291; found 429.2291
[0294] Example 67: 4-methoxy-N-(4-(4-(pyridin-2-yl)-l,4-diazepan-l- yl)phenyl)benzamide (107)
[0295] This compound was prepared as described herein. Purification by flash chromatography using 0% to 50% EtOAc / n-Hexane with gradient elution and CH2CI2 / 7N NH3 in MeOH = 40: 1 gave 4-methoxy-N-(4-(4-(pyridin-2-yl)-l,4-diazepan-l- yl)phenyl)benzamide (24 mg, 40% yield) as a white solid. (1H NMR, 400 MHz, DMSO-d6): 5 = 9.77 (s, 1H), 8.05 (dd, JI = 4.9 Hz, J2 = 1.4 Hz, 1H), 7.92 (dt, JI = 8.8 Hz, J2 = 2.8 Hz, 2H), 7.52 (d, J = 9.0 Hz, 2H), 7.46 (ddd, JI = 8.7 Hz, J2 = 6.9 Hz, J3 = 2.0 Hz, 1H), 7.03 (dt,JI = 8.9 Hz, J2 = 2.9 Hz, 2H), 6.73 (d, J = 9.1 Hz, 2H), 6.66 (d, J = 8.6 Hz, 1H), 6.51 (dd, JI = 6.9 Hz, J2 = 5.1 Hz, 1H), 3.83 (s, 3H), 3.81 (t, J = 5.7 Hz, 2H), 3.59 (t, J = 5.2 Hz, 2H), 3.48 (t, J = 6.0 Hz, 2H), 3.40 (t, J = 5.9 Hz, 2H), 2.00-1.94 (m, 2H);13C NMR, 100 MHz, DMSO-d6: 5 = 164.1, 161.5, 157.1, 147.8, 143.8, 137.4, 129.3, 128.2, 127.3, 122.3, 113.5, 111.34, 111.29, 105.6, 55.4, 48.8, 47.2, 46.1, 45.6, 23.8; ESI-MS m / z calculated for C24H28N4O2+ [M+2H]+ 404.5; found 404.5 HRMS (ESI) for C24H27N4O2+ [M+H]+ 403.2134; found 403.2117
[0296] Example 68: N-(4-(4-(5-chloropyridin-2-yl)piperazin-l-yl)phenyl)-4- methoxybenzamide (108)
[0297] This compound was prepared as described herein. Purification by flash chromatography using 0% to 50% EtOAc / n-Hexane with gradient elution and CH2CI2 / 7N NH3 in MeOH = 40: 1 gave N-(4-(4-(5-chloropyridin-2-yl)piperazin-l-yl)phenyl)-4- methoxybenzamide (20 mg, 34% yield) as a white solid. (1H NMR, 400 MHz, DMSO-d6): 5 = 9.91 (s, 1H), 8.14 (d, J = 2.7 Hz, 1H), 7.94 (dt, JI = 8.9 Hz, J2 = 2.8 Hz, 2H), 7.62 (dd, JI = 9.1 Hz, J2 = 2.4 Hz, 3H), 7.04 (dt, JI = 8.9 Hz, J2 = 2.8 Hz, 2H), 6.98 (d, J = 9.1 Hz, 2H), 6.95 (d, J = 9.2 Hz, 1H), 3.83 (s, 3H), 3.63 (t, J = 4.8 Hz, 2H), 3.19 (t, J = 5.1 Hz, 2H);13C NMR, 100 MHz, DMSO-d6: 5 = 164.3, 161.7, 157.5, 147.2, 145.6, 137.2, 131.6, 129.4, 127.1, 121.4, 119.0, 116.0, 113.5, 108.6, 55.4, 48.5, 44.7; ESI-MS m / z calculated for C23H24CIN4O2 + [M+H]+ 423.9; found 423.4 HRMS (ESI) for C23H24CIN4O2 + [M+H]+ 423.1588; found 423.1598
[0298] Example 69: 4-methoxy-N-(5-(4-(pyridin-2-yl)piperazin-l-yl)pyridin-2- yl)benzamide (109)
[0299] This compound was prepared as described herein. Purification by flash chromatography using 0% to 50% EtOAc / n-Hexane with gradient elution and CH2CI2 / 7N NH3 in MeOH = 40: 1 gave 4-methoxy-N-(5-(4-(pyridin-2-yl)piperazin-l-yl)pyridin-2-yl)benzamide (42 mg, 63% yield) as a white solid. (1H NMR, 400 MHz, DMSO-d6): 5 = 10.42 (s, 1H), 8.15-8.12 (m, 2H), 8.05-8.02 (m, 3H), 7.56 (ddd, JI = 8.7 Hz, J2 = 7.0 Hz, J3 = 2.0 Hz, 1H), 7.51 (dd, JI = 9.1 Hz, J2 = 3.0 Hz, 1H), 7.02 (d, J = 8.8 Hz, 2H), 6.91 (d, J = 8.6 Hz, 1H), 6.67 (dd, JI = 7.0 Hz, J2 = 5.0 Hz, 1H), 3.83 (s, 3H), 3.65 (t, J = 4.8 Hz, 2H), 3.26 (t, J = 5.1 Hz, 2H);13C NMR (100 MHz, DMSO-d6): 5 = 174.2, 171.6, 168.6, 157.2, 154.4, 153.4, 147.2, 145.0, 139.4, 136.0, 134.8, 124.8, 123.2, 122.9, 117.0, 65.0, 57.8, 54.1; ESI-MS m / z calculated for C22H24N5O2 + [M+H]+ 390.5; found 390.4 HRMS (ESI) for C22H24N5O2 + [M+H]+ 390.1930; found 390.1929
[0300] Example 70: 4-methoxy-N-(5-(3-(pyridin-2-yl)-3,8- diazabicyclo[3.2.1]octan-8-yl)pyridin-2-yl)benzamide (110)
[0301] This compound was prepared as described herein. Purification by flash chromatography using 0% to 50% EtOAc / n-Hexane with gradient elution and CH2CI2 / 7N NH3 in MeOH = 40: 1 gave 4-methoxy-N-(5-(3-(pyridin-2-yl)-3,8-diazabicyclo[3.2.1]octan-8- yl)pyridin-2-yl)benzamide (17 mg, 23% yield) as a yellow oil. (1H NMR, 400 MHz, MeOD): 5 = 8.05 (dd, JI = 4.9 Hz, J2 = 1.3 Hz, 2H), 7.98 (d, J = 8.9 Hz, 1H), 7.93 (d, J = 8.8 Hz, 2H), 7.53 (ddd, JI = 8.7 Hz, J2 = 7.0 Hz, J3 = 1.9 Hz, 1H), 7.46 (dd, JI = 9.1 Hz, J2 = 2.4 Hz, 1H), 7.03 (d, J = 8.8 Hz, 2H), 6.72 (d, J = 8.7 Hz, 1H), 6.66 (dd, JI = 6.9 Hz, J2 = 5.2 Hz, 1H), 4.44 (brs, 2H), 3.86 (s, 3H), 3.80 (dd, JI = 12.2 Hz, J2 = 1.4 Hz, 2H), 3.21 (d, J = 11.6 Hz, 2H), 2.06 (t, J = 4.0 Hz, 2H), 1.91 (d, J = 5.8 Hz, 2H) (13C NMR, 100 MHz, DMSO-d6): 5 = 167.8, 164.5, 161.7, 158.3, 148.2, 144.3, 139.3, 136.7, 130.7, 126.8, 114.5, 109.4, 108.6, 56.3, 56.1, 28.5; ESI-MS m / z calculated for C24H26N5O2 + [M+H]+ 416.5; found 416.4 HRMS (ESI) for C24H26N5O2+ [M+H]+ 416.2087; found 416.2087.
[0302] Example 71: 4-methoxy-N-(5-(4-(pyridin-2-yl)-l,4-diazepan-l- yl)pyridin-2-yl)benzamide (111)
[0303] This compound was prepared as described herein. Purification by flash chromatography using 0% to 50% EtOAc / n-Hexane with gradient elution and CH2CI2 / 7N NH3 in MeOH = 40: 1 gave 4-methoxy-N-(5-(4-(pyridin-2-yl)-l,4-diazepan-l-yl)pyridin-2- yl)benzamide (60 mg, 68% yield) as a white solid. 1H NMR (400 MHz, MeOD): 5 = 8.00 (d, J = 4.4 Hz, 1H), 7.92 (d, J = 8.7 Hz, 2H), 7.86 (d, J = 9.0 Hz, 2H), 7.47 (ddd, JI = 8.9 Hz, J2 = 6.7 Hz, J3 = 1.4 Hz, 1H), 7.26 (dd, JI = 9.1 Hz, J2 = 2.9 Hz, 1H), 7.02 (d, J = 8.7 Hz, 2H), 6.68 (d, J = 8.7 Hz, 1H), 6.54 (t, J = 5.9 Hz, 1H), 3.88 (t, J = 4.9 Hz, 5H), 3.69 (t, J = 5.5 Hz, 2H), 3.57 (t, J = 6.0 Hz, 2H), 3.51 (t, J = 6.0 Hz, 2H), 2.09-2.03 (m, 2H);13C NMR, 100 MHz, MeOD: 5 = 167.8, 164.4, 158.8, 148.5, 143.0, 142.5, 139.4, 132.3, 130.6, 122.4, 118.3, 115.0, 113.1, 107.8, 56.1, 54.9, 47.9, 47.7, 25.0; ESI-MS m / z calculated for C23H26N5O2 + [M+H]+ 404.5; found 404.4 HRMS (ESI) for C23H26N5O2 + [M+H]+ 404.2087; found 404.2084
[0304] Example 72: 4-methoxy-N-(6-(3-(pyridin-2-yl)-3,8- diazabicyclo[3.2.1]octan-8-yl)pyridin-3-yl)benzamide (112)
[0305] This compound was prepared as described herein. Purification by flash chromatography using 0% to 50% EtOAc / n-Hexane with gradient elution and CH2CI2 / 7N NH3 in MeOH = 40: 1 gave 4-methoxy-N-(6-(3-(pyridin-2-yl)-3,8-diazabicyclo[3.2.1]octan-8- yl)pyri din-3 -yl)benzamide (83 mg, 13% yield) as a white solid. (1H NMR, 400 MHz, DMSO-d6): 5 = 9.95 (s, 1H), 8.45 (d, J = 2.6 Hz, 1H), 8.08 (dd, JI = 4.8 Hz, J2 = 1.4 Hz, 1H), 7.94 (dt, JI = 8.8 Hz, J2 = 2.9 Hz, 2H), 7.90 (dd, JI = 9.0 Hz, J2 = 2.6 Hz, 1H), 7.49 (ddd, JI = 8.7 Hz, J2 = 7.0 Hz, J3 = 2.0 Hz, 1H), 7.05 (dt, JI = 8.9 Hz, J2 = 2.9 Hz, 2H), 6.91 (d, J = 9.0 Hz, 1H), 6.70 (d, J = 8.6 Hz, 1H), 6.61 (dd, JI = 6.7 Hz, J2 = 5.0 Hz, 1H), 4.67 (s, 2H), 3.88 (dd, JI = 12.2 Hz, J2 = 1.8 Hz, 2H), 3.83 (s, 3H), 3.05 (dd, JI = 11.9 Hz, J2 = 1.5 Hz, 2H), 1.92 (t, J = 4.0 Hz, 2H), 1.77 (q, J = 5.7 Hz, 2H);13C NMR, 100 MHz, DMSO-d6: 5 = 164.5, 161.8, 159.8, 153.9, 147.4, 140.8, 137.2, 131.3, 129.4, 126.7, 126.6, 113.5, 112.7, 108.7, 106.4, 55.4, 55.2, 48.0, 27.1; ESI-MS m / z calculated for C24H27N5O2 + [M+2H]+ 417.5; found 417.5 HRMS (ESI) for C24H26N5O2 + [M+H]+ 416.2087; found 416.2087
[0306] Example 73: 4-methoxy-N-(4-(4-methylpiperazin-l- yl)phenyl)benzamide (113)
[0307] This compound was prepared as described herein. Purification by flash chromatography using 0% to 50% EtOAc / n-Hexane with gradient elution and CH2CI2 / 7N NH3 in MeOH = 40: 1 gave 4-methoxy-N-(4-(4-methylpiperazin-l-yl)phenyl)benzamide (5 mg, 8% yield) as a white solid. (1H NMR, 400 MHz, MeOD): 5 = 7.89 (dt, JI = 8.8 Hz, J2 = 2.8 Hz, 2H), 7.53 (d, J = 9.0 Hz, 2H), 7.02 (dt, JI = 8.8 Hz, J2 = 2.9 Hz, 2H), 6.98 (dt, JI = 9.0 Hz, J2 = 3.2 Hz, 2H), 3.86 (s, 3H), 3.19 (t, J = 4.8 Hz, 4H), 2.63 (t, J = 5.0 Hz, 4H), 2.35 (s, 3H) (13C NMR, 100 MHz, MeOD): 5 = 164.2, 149.8, 132.8, 132.4, 130.6, 128.4, 123.8, 117.9, 114.9, 56.14, 56.09, 50.5, 46.2; ESI-MS m / z calculated for C19H25N3O2 + [M+2H]+ 327.4; found 327.4
[0308] Example 74: N-(4-(l-azaspiro[3.5]nonan-l-yl)phenyl)-4- methoxybenzamide
[0309] This compound was prepared as described herein. Purification by flash chromatography using 0% to 50% EtOAc / n-Hexane with gradient elution and CH2CI2 / 7N NH3 in MeOH = 40: 1 gave N-(4-(l-azaspiro[3.5]nonan-l-yl)phenyl)-4-methoxybenzamide (9 mg, 11% yield) as a white waxy solid. (1H NMR, 400 MHz, MeOD): 5 = 7.88 (dt, JI = 8.8 Hz, J2 = 2.8 Hz, 2H), 7.40 (d, J = 8.8 Hz, 2H), 7.01 (dt, JI = 8.9 Hz, J2 2.9 Hz, 2H), 6.56 (dt, JI = 8.9 Hz, J2 = 3.0 Hz, 2H), 3.86 (s, 3H), 3.65 (t, J = 7.2 Hz, 2H), 2.10 (t, J = 7.2 Hz, 2H), 1.92 (td, JI = 12.8 Hz, J2 = 1.7 Hz, 2H), 1.80 -1.71 (m, 4H), 1.41-1.28 (m, 3H), 1.20 (tt, JI = 12.0 Hz, J2 = 4.1 Hz, 1H).13C NMR, 100 MHz, MeOD: 5 = 164.1, 147.5, 130.5, 130.4, 128.5, 124.1, 115.1, 114.9, 72.2, 56.1, 46.5, 36.6, 29.6, 26.8, 24.4; ESI-MS m / z calculated for C22H28N2O2+[M+2H]+ 352.5; found 352.5
[0310] Example 75: 4-methoxy-N-(4-(3-methoxyazetidin-l- yl)phenyl)benzamide (115)
[0311] This compound was prepared as described herein. Purification by flash chromatography using 0% to 50% EtOAc / n-Hexane with gradient elution and CH2CI2 / 7N NH3 in MeOH = 40: 1 gave 4-methoxy-N-(4-(3-methoxyazetidin-l-yl)phenyl)benzamide (85 mg, 49% yield) as a white solid. (1H NMR, 400 MHz, DMSO-d6): 5 = 9.83 (s, 1H), 7.93 (dt, JI = 8.8 Hz, J2 = 2.8 Hz, 2H), 7.54 (d, J = 8.8 Hz, 2H), 7.04 (dt, JI = 8.9 Hz, J2 = 2.8 Hz, 2H), 6.44 (dt, JI = 8.8 Hz, J2 = 2.9 Hz, 2H), 4.33-4.28 (m, 1H), 4.03 (t, J = 7.5 Hz, 2H), 3.83 (s, 3H), 3.55 (dd, JI = 8.2 Hz, J2 = 4.5 Hz, 2H), 3.24 (s, 3H);13C NMR, 100 MHz, DMSO- d6: 5 = 164.2, 161.6, 148.2, 129.8, 129.3, 127.2, 121.8, 113.5, 111.4, 69.3, 58.8, 55.4, 55.3; ESI-MS m / z calculated for CI8H22N2O3+[M+2H]+ 314.4; found 314.4
[0312] Example 76: 4-(2-fluoroethoxy)-N-(4-(3-(pyridin-2-yl)-3,8- diazabicyclo[3.2.1]octan-8-yl)phenyl)benzamide (116)
[0313] This compound was prepared as described herein. Purification by flash chromatography using 0% to 50% EtOAc / n-Hexane with gradient elution and CH2CI2 / 7N NH3 in MeOH = 40: 1 gave 4-(2-fluoroethoxy)-N-(4-(3-(pyridin-2-yl)-3,8- diazabicyclo[3.2.1]octan-8-yl)phenyl)benzamide (10 mg, 72% yield) as a white solid. (1H NMR, 400 MHz, DMSO-d6): 5 = 9.84 (s, 1H), 8.07 (dd, JI = 4.8 Hz, J2 = 1.4 Hz, 1H), 7.93 (d, J = 8.8 Hz, 2H), 7.58 (d, J = 9.0 Hz, 2H), 7.49 (ddd, JI = 8.7 Hz, J2 = 7.0 Hz, J3 = 2.0 Hz, 1H), 7.07 (d, J = 8.8 Hz, 2H), 6.92 (d, J = 8.6 Hz, 2H), 6.68 (d, J = 8.6 Hz, 1H), 6.61 (dd, JI = 6.9 Hz, J2 = 5.0 Hz, 1H), 4.83 (t, J = 3.8 Hz, 1H), 4.71 (t, J = 3.8 Hz, 1H), 4.40 (s, 2H), 4.36 (t, J = 3.8 Hz, 1H), 4.28 (t, J = 3.9 Hz, 1H), 3.76 (d, J = 11.0 Hz, 2H), 3.11 (d, J = 10.8 Hz, 2H), 1.95 (t, J = 3.9 Hz, 2H), 1.77 (q, J = 5.9 Hz, 2H);13C NMR, 100 MHz, DMSO-d6: 5 = 164.1, 160.5, 159.9, 147.4, 143.0, 137.2, 129.8, 129.3, 127.6, 122.0, 115.5, 114.0, 112.7, 106.3, 82.8, 81.2, 67.3, 67.1, 53.9, 46.8, 27.2; ESI-MS m / z calculated for C26H29FN4O2+[M+2H]+ 448.5; found 448.6 HRMS (ESI) for C26H28FN4O2+[M+H]+ 447.2196; found 447.2183
[0314] Example 77: Ethyl 4-amino-2-(4-(pyridin-4-yl)piperazin-l- yl)pyrimidine-5-carboxylate (117)
[0315] This compound was prepared using the procedures described herein. 'H NMR (400 MHz, DMSO) 5 8.53 (s, 1H), 8.34 (d, J = 2.9 Hz, 1H), 8.02 (dd, J = 4.5, 1.3 Hz, 1H), 7.46 (d, J = 13.0 Hz, 2H), 7.36 (ddd, J = 8.5, 3.0, 1.4 Hz, 1H), 7.23 (dd, J = 8.5, 4.5 Hz, 1H), 4.22 (q, J = 7.1 Hz, 2H), 3.93 (t, J = 5.1 Hz, 4H), 3.25 (t, J = 5.2 Hz, 4H), 1.27 (t, J = 7.1 Hz, 3H); 13C NMR (101 MHz, DMSO) 5 165.9, 162.8, 161.3, 160.5, 146.6, 140.0, 138.1, 123.5, 122.1, 95.0, 59.7, 47.5, 42.8, 14.2. LCMS: 329 [M+H]+; HRMS (ESI) calculated for Ci6H2iN6O2+([M+H+]) 329.1721, found: 329.1726. White solid, 55 mg, 56%.
[0316] Example 78: 4-Amino-N-(4-methoxyphenyl)-2-(4-(pyridin-3- yl)piperazin-l-yl)pyrimidine-5-carboxamide (118)
[0317] This compound was prepared using the procedures described herein. 'H NMR (400 MHz, DMSO) 5 9.74 (s, 1H), 8.62 (s, 1H), 8.35 (d, J = 2.9 Hz, 1H), 8.02 (d, J =4.4 Hz, 1H), 7.54 (d, J = 9.1 Hz, 3H), 7.37 (ddd, J = 8.6, 3.0, 1.4 Hz, 1H), 7.23 (dd, J = 8.5,4.5 Hz, 1H), 6.89 (d, J = 9.1 Hz, 2H), 3.92 (t, J = 5.2 Hz, 4H), 3.73 (s, 3H), 3.25 (t, J = 5.3 Hz, 4H);13C NMR (101 MHZ, DMSO) 5 165.3, 162.9, 160.8, 157.4, 155.4, 146.7, 140.0, 138.1, 132.0, 123.5, 122.2, 122.1, 113.7, 99.1, 55.2, 47.6, 42.8. LCMS: 406 [M+H]+; HRMS (ESI) calculated for C2iH24N7O2+([M+H+]) 406.1986, found: 406.1998. White solid, 32 mg, 39%.
[0318] Example 79: Ethyl 4-amino-2-(4-(pyrimidin-2-yl)piperazin-l- yl)pyrimidine-5-carboxylate (119)
[0319] This compound was prepared using the procedures described herein. 'H NMR (400 MHz, DMSO) 5 8.53 (s, 1H), 8.38 (d, J = 4.7 Hz, 2H), 7.46 (d, J = 9.5 Hz, 2H), 6.65 (t, J = 4.7 Hz, 1H), 4.22 (q, J = 7.1 Hz, 2H), 3.86 (dd, J = 6.9, 3.8 Hz, 4H), 3.79 (dd, J = 7.1, 3.9 Hz, 4H), 1.27 (t, J = 7.1 Hz, 3H);13C NMR (101 MHz, DMSO) 5 165.9, 162.8, 161.4, 161.1, 160.4, 157.9, 110.3, 95.0, 59.7, 43.1, 43.0, 14.2. LCMS: 330 [M+H]+; HRMS (ESI) calculated for CI5H2ON702+([M+H+]) 330.1673, found: 330.1667. White solid, 67 mg, 68%.
[0320] Example 80: 4-Amino-N-(4-methoxyphenyl)-2-(4-(pyrimidin-2- yl)piperazin-l-yl)pyrimidine-5-carboxamide (120)
[0321] This compound was prepared using the procedures described herein.1H NMR (400 MHz, DMSO) 5 9.74 (s, 1H), 8.61 (s, 1H), 8.39 (d, J = 4.8 Hz, 2H), 7.53 (d, J = 9.1 Hz, 3H), 6.89 (d, J = 9.0 Hz, 2H), 6.66 (t, J = 4.7 Hz, 1H), 3.85 (d, J = 4.9 Hz, 4H), 3.82- 3.77 (m, 4H), 3.73 (s, 3H);13C NMR (101 MHz, DMSO) 5 165.8, 163.4, 161.7, 161.4, 158.5, 157.9, 155.9, 132.5, 122.8, 114.1, 110.8, 99.5, 55.6, 43.6, 43.4. LCMS: 407 [M+H]+; HRMS (ESI) calculated for oH^NsO ([M+H+]) 407.1938, found: 407.1968. White solid, 47 mg, 58%.
[0322] Example 81: Ethyl 4-amino-2-(4-(pyrazin-2-yl)piperazin-l- yl)pyrimidine-5-carboxylate (121)
[0323] This compound was prepared using the procedures described herein. 'H NMR (400 MHz, DMSO) 5 8.53 (s, 1H), 8.36 (d, J = 1.6 Hz, 1H), 8.10 (dd, J = 2.6, 1.5 Hz, 1H), 7.86 (d, J = 2.6 Hz, 1H), 7.47 (d, J = 7.2 Hz, 2H), 4.22 (q, J = 7.1 Hz, 2H), 3.91-3.88 (m,4H), 3.67-3.62 (m, 4H), 1.27 (t, J = 7.1 Hz, 3H);13C NMR (101 MHz, DMSO) 5 165.9, 162.8, 161.3, 160.5, 154.5, 141.4, 132.6, 131.4, 95.0, 59.7, 43.7, 42.7, 14.2. LCMS: 330 [M+H]+; HRMS (ESI) calculated for CI5H2ON702+([M+H+]) 330.1673, found: 330.1693. White solid, 70 mg, 71%.
[0324] Example 82: 4-Amino-N-(4-methoxyphenyl)-2-(4-(pyrazin-2- yl)piperazin-l-yl)pyrimidine-5-carboxamide (122)
[0325] This compound was prepared using the procedures described herein. 'H NMR (400 MHz, DMSO) 5 9.75 (s, 1H), 8.62 (s, 1H), 8.37 (d, J = 1.6 Hz, 1H), 8.11 (dd, J = 2.6, 1.5 Hz, 1H), 7.86 (d, J = 2.6 Hz, 1H), 7.54 (d, J = 9.1 Hz, 3H), 6.89 (d, J = 9.1 Hz, 2H), 3.93-3.86 (m, 4H), 3.73 (s, 3H), 3.68-3.62 (m, 4H);13C NMR (101 MHz, DMSO) 5 165.3, 162.9, 160.8, 157.4, 155.4, 154.6, 141.4, 132.6, 132.0, 131.4, 122.3, 113.7, 99.1, 55.1, 43.7, 42.7. LCMS: 407 [M+H]+; HRMS (ESI) calculated for C2oH23N802+([M+H+]) 407.1938, found: 407.1956. White solid, 45 mg, 55%.
[0326] Example 83: Ethyl 4-amino-2-(4-(thiazol-2-yl)piperazin-l- yl)pyrimidine-5-carboxylate (123)
[0327] This compound was prepared using the procedures described herein. 'H NMR (400 MHz, DMSO) 5 8.53 (s, 1H), 7.47 (d, J = 5.8 Hz, 2H), 7.18 (d, J = 3.6 Hz, 1H), 6.87 (d, J = 3.6 Hz, 1H), 4.22 (q, J = 7.1 Hz, 2H), 3.91 (t, J = 5.2 Hz, 4H), 3.50-3.43 (m, 4H), 1.27 (t, J = 7.1 Hz, 3H);13C NMR (101 MHz, DMSO) 5 171.3, 165.9, 162.8, 161.3, 160.5, 139.4, 108.3, 95.2, 59.7, 48.0, 42.4, 14.2. LCMS: 335 [M+H]+; HRMS (ESI) calculated for CI4HI9N6O2S+([M+H+]) 335.1285, found: 335.1304. White solid, 57 mg, 57%.
[0328] Example 84: 4-Amino-N-(4-methoxyphenyl)-2-(4-(thiazol-2- yl)piperazin-l-yl)pyrimidine-5-carboxamide (124)
[0329] This compound was prepared using the procedures described herein. 'H NMR (400 MHz, DMSO) 5 9.75 (s, 1H), 8.61 (s, 1H), 7.53 (d, J = 9.0 Hz, 3H), 7.19 (d, J = 3.6 Hz, 1H), 6.93-6.85 (m, 3H), 3.91 (t, J = 5.3 Hz, 4H), 3.73 (s, 3H), 3.47 (t, J = 5.2 Hz, 4H);13C NMR (101 MHz, DMSO) 5 171.4, 165.3, 162.9, 160.8, 157.4, 155.4, 139.4, 132.0, 122.3, 113.7, 108.3, 99.2, 55.2, 48.1, 42.4. LCMS: 412 [M+H]+; HRMS (ESI) calculated for CI9H22N7O2S+([M+H+]) 412.1550, found: 412.1566. White solid, 57 mg, 70%.
[0330] Example 85: Ethyl 4-amino-2-(3-(benzo[d]thiazol-2-yl)-3,8- diazabicyclo[3.2.1]octan-8-yl)pyrimidine-5-carboxylate (125)
[0331] This compound was prepared using the procedures described herein. 'H NMR (400 MHz, DMSO-d6) 5 8.55 (s, 1H), 7.75 (dd, J = 7.9, 1.2 Hz, 1H), 7.51 (s, 2H), 7.45 (d, J = 7.5 Hz, 1H), 7.27 (td, J = 7.7, 1.3 Hz, 1H), 7.06 (td, J = 7.6, 1.2 Hz, 1H), 4.88 (d, J = 22.3 Hz, 2H), 4.22 (q, J = 7.1 Hz, 2H), 3.85 (d, J = 12.0 Hz, 2H), 3.36 (d, J = 12.0 Hz, 2H), 1.98-1.94 (m, 2H), 1.81 (q, J = 6.7 Hz, 2H), 1.27 (t, J = 7.1 Hz, 3H); 13C NMR (101 MHz, DMSO-d6) 5 169.0, 165.9, 163.1, 160.8, 159.9, 152.3, 130.0, 126.0, 121.1, 121.1, 118.5, 95.6, 59.7, 52.4, 26.7, 14.2. LCMS: 411 [M+H]+; HRMS (ESI) calculated for C20H23N6O2S+ ([M+H+]) 411.1598, found: 411.1605. White solid, 87 mg, 71%.
[0332] Example 86: 4-Amino-N-(4-methoxyphenyl)-2-(8-(quinolin-3-yl)-3,8- diazabicyclo[3.2.1]octan-3-yl)pyrimidine-5-carboxamide (126)
[0333] 1H NMR (400 MHz, DMSO-d6) 5 9.73 (s, 1H), 8.87 (d, J = 2.9 Hz, 1H),8.57 (s, 1H), 7.85 (dd, J = 7.7, 1.8 Hz, 1H), 7.76 - 7.71 (m, 1H), 7.61 (d, J = 2.8 Hz, 1H),7.53 (d, J = 9.0 Hz, 2H), 7.47-7.43 (m, 2H), 6.89 (d, J = 9.0 Hz, 2H), 4.64 (s, 2H), 4.42 (d, J = 13.0 Hz, 2H), 3.73 (s, 3H), 3.24 (d, J = 12.9 Hz, 2H), 1.99 (d, J = 11.5 Hz, 3H), 1.73 (d, J = 7.4 Hz, 2H);13C NMR (101 MHz, DMSO-d6) 5 165.8, 163.1, 162.7, 157.7, 155.8, 144.2, 141.9, 140.8, 132.6, 129.6, 128.9, 127.2, 126.7, 125.7, 122.7, 116.0, 114.1, 99.6, 55.6, 54.6, 46.6, 27.1. LCMS: 482 [M+H]+; HRMS (ESI) calculated for C27H28N7O2+([M+H+]) 482.2299, found: 482.2299. Light-yellow solid, 42 mg, 44% for 2 steps.
[0334] Example 87: 4-amino-N-(2-fluoro-4-methoxyphenyl)-2-(4-(pyridin-2- yl)piperazin-l-yl)pyrimidine-5-carboxamide (127)
[0335] 1H NMR (400 MHz, DMSO) 5 9.58 (s, 1H), 8.65 (s, 1H), 8.13 (dd, J = 5.3, 1.9 Hz, 1H), 7.58-7.54 (m, 3H), 7.32 (t, J = 8.9 Hz, 1H), 6.96-6.83 (m, 2H), 6.77 (dd, J = 8.9,2.3 Hz, 1H), 6.66 (dd, J = 7.1, 4.9 Hz, 1H), 3.87 (t, J = 5.3 Hz, 4H), 3.77 (s, 3H), 3.56 (t, J =5.3 Hz, 4H);13C NMR (101 MHz, DMSO) 5 165.8, 162.9, 160.9, 158.9, 158.2 (d, J = 228.4 Hz), 157.8, 156.9 (d, J = 7.3 Hz), 147.6, 137.6, 128.6 (d, J = 3.4 Hz), 118.0 (d, J = 13.0 Hz), 113.2, 109.7 (d, J = 3.1 Hz), 107.2, 101.9 (d, J = 23.9 Hz), 98.2, 55.7, 44.4, 42.9. LCMS: 424 [M+H]+; HRMS (ESI) calculated for C2IH23FN7O2+([M+H+]) 424.1892, found: 424.1887. White solid, 42 mg, 50%.
[0336] Example 88: 4-amino-N-(3-fluoro-4-methoxyphenyl)-2-(4-(pyridin-2- yl)piperazin-l-yl)pyrimidine-5-carboxamide (128)
[0337] 1H NMR (400 MHz, DMSO) 5 9.86 (s, 1H), 8.61 (s, 1H), 8.13 (dd, J = 4.9, 1.7 Hz, 1H), 7.70-7.47 (m, 4H), 7.36 (ddd, J = 9.0, 2.6, 1.4 Hz, 1H), 7.12 (t, J = 9.3 Hz, 1H), 6.87 (d, J = 8.6 Hz, 1H), 6.66 (dd, J = 7.1, 4.9 Hz, 1H), 3.90-3.84 (m, 4H), 3.81 (s, 3H), 3.60-3.54 (m, 4H);13C NMR (101 MHz, DMSO) 5 165.5, 162.8, 160.9, 158.9, 159.9, 157.6, 154.9 (d, J = 3.0 Hz), 151.9, 147.5, 137.6, 116.4 (d, J = 3.0 Hz), 113.8, 113.2, 109.0, 107.2, 98.8, 56.2, 44.4, 42.9.LCMS: 424 [M+H]+; HRMS (ESI) calculated for C2iH23FN7O2+([M+H+]) 424.1892, found: 424.1906. White solid, 45 mg, 53%.
[0338] Example 89: 2-Hydroxyethyl 4-amino-2-(4-(pyridin-2-yl)piperazin-l- yl)pyrimidine-5-carboxylate (129)
[0339] 1H NMR (400 MHz, DMSO-d6) 5 8.61 (s, 1H), 8.13 (dd, J = 5.0, 2.0 Hz, 1H), 7.55 (ddd, J = 8.9, 7.0, 2.0 Hz, 1H), 7.44 (s, 2H), 6.86 (d, J = 8.6 Hz, 1H), 6.66 (dd, J = 7.1, 4.9 Hz, 1H), 4.89 (t, J = 5.7 Hz, 1H), 4.18 (t, J = 5.7 Hz, 2H), 3.90-3.87 (m, 4H), 3.66 (q, J = 5.4 Hz, 2H), 3.59-3.50 (m, 4H);13C NMR (101 MHz, DMSO-d6) 5 166.0, 162.8, 161.4, 160.8, 158.8, 147.6, 137.6, 113.2, 107.2, 94.9, 65.6, 59.1, 44.4, 42.9. LCMS: 345 [M+H]+; HRMS (ESI) calculated for Ci6H2iN6O3+([M+H+]) 345.1670, found: 345.1677. White solid, 28 mg, 36% for 2 steps.
[0340] Example 90: N-(4-Methoxyphenyl)-2-(4-(pyridin-2-yl)piperazin-l- yl)pyrimidine-5-carboxamide (130)
[0341] 1H NMR (400 MHz, DMSO-d6) 5 9.99 (s, 1H), 8.91 (s, 2H), 8.14 (dd, J = 4.9, 2.0 Hz, 1H), 7.62 (d, J = 9.0 Hz, 2H), 7.59-7.54 (m, 1H), 6.92 (d, J = 9.0 Hz, 2H), 6.88 (d, J = 8.7 Hz, 1H), 6.67 (dd, J = 7.1, 4.9 Hz, 1H), 3.96 (t, J = 5.3 Hz, 4H), 3.74 (s, 3H), 3.62 (t, J = 5.3 Hz, 4H);13C NMR (101 MHz, DMSO-d6) 5 162.2, 161.4, 158.8, 158.0, 155.5, 147.6, 137.7, 132.0, 121.9, 116.7, 113.8, 113.3, 107.3, 55.2, 44.3, 43.2. LCMS: 391 [M+H]+; HRMS (ESI) calculated for C2IH23N6O2+([M+H+]) 391.1877, found: 391.1879. White solid, 59 mg, 76%.
[0342] Example 91: 4-Amino-N-(4-hydroxyphenyl)-2-(4-(pyridin-2- yl)piperazin-l-yl)pyrimidine-5-carboxamide (131)
[0343] 1H NMR (400 MHz, DMSO-d6) 5 9.66 (s, 1H), 9.22 (s, 1H), 8.59 (s, 1H), 8.13 (ddd, J = 5.0, 2.0, 0.8 Hz, 1H), 7.56 (ddd, J = 8.9, 7.1, 2.0 Hz, 1H), 7.39 (d, J = 8.9 Hz, 2H), 6.87 (d, J = 8.6 Hz, 1H), 6.71 (d, J = 8.9 Hz, 2H), 6.66 (ddd, J = 7.2, 4.8, 0.8 Hz, 1H), 3.89-3.83 (m, 4H), 3.59-3.52 (m, 4H);13C NMR (101 MHz, DMSO-d6) 5 165.2, 162.9, 160.9, 158.9, 157.3, 153.5, 147.6, 137.6, 130.5, 122.6, 114.9, 113.2, 107.3, 99.1, 44.5, 42.9. LCMS: 392 [M+H]+. White solid, 41 mg, 53%.
[0344] Example 92: 4-Amino-N-(4-(2-fluoroethoxy)phenyl)-2-(4-(pyridin-2- yl)piperazin-l-yl)pyrimidine-5-carboxamide (132)
[0345] 1H NMR (400 MHz, DMSO-d6) 5 9.76 (s, 1H), 8.61 (s, 1H), 8.13 (ddd, J = 4.9, 2.0, 0.8 Hz, 1H), 7.57-7.53 (m, 3H), 6.93 (d, J = 9.1 Hz, 2H), 6.87 (d, J = 8.6 Hz, 1H), 6.66 (ddd, J = 7.1, 4.9, 0.8 Hz, 1H), 4.81-4.77 (m, 1H), 4.69-4.65 (m, 1H), 4.26-4.22 (m, 1H), 4.18-4.14 (m, 1H), 3.90-3.84 (m, 4H), 3.59-3.54 (m, 4H);13C NMR (101 MHz, DMSO-d6) 5 165.4, 162.9, 160.9, 158.9, 157.5, 154.2, 147.6, 137.6, 132.4, 122.2, 114.4, 113.2, 107.2, 99.0, 82.2 (d, J = 166.7 Hz), 67.2 (d, J = 19.0 Hz), 44.4, 42.9. LCMS: 438 [M+H]+; HRMS (ESI) calculated for C22H25FN7O2+([M+H+]) 438.2048, found: 438.2044. White solid, 30 mg, 68%.
[0346] Example 93: 4-Amino-2-(4-(benzo[d]oxazol-2-yl)piperazin-l-yl)-N-(4- (2-fluoroethoxy)phenyl)pyrimidine-5-carboxamide (133)
[0347] 1H NMR (400 MHz, DMSO-d6) 5 9.78 (s, 1H), 8.63 (s, 1H), 7.65-7.49 (m, 3H), 7.42 (d, J = 8.0 Hz, 1H), 7.31 (d, J = 7.7 Hz, 1H), 7.17 (td, J = 7.7, 1.2 Hz, 1H), 7.04 (td, J = 7.7, 1.2 Hz, 1H), 6.93 (d, J = 9.0 Hz, 2H), 4.81-4.76 (m, 1H), 4.69-4.65 (m, 1H), 4.26- 4.22 (m, 1H), 4.19-4.15 (m, 1H), 3.98-3.90 (m, 4H), 3.69-3.67(m, 4H);13C NMR (101 MHz, DMSO-d6) 5 165.3, 162.9, 161.8, 160.8, 157.5, 154.2, 148.3, 142.9, 132.4, 124.0, 122.3, 120.6, 115.9, 114.4, 108.9, 99.3, 82.2 (d, J = 166.4 Hz), 67.2 (d, J = 19.0 Hz), 45.0, 42.5. LCMS: 478 [M+H]+; HRMS (ESI) calculated for C24H25FN7O3+([M+H+]) 478.1997, found: 478.2007. White solid, 34 mg, 72%.
[0348] Example 94: 4-Amino-N-(4-(3-fluoro-2-hydroxypropoxy)phenyl)-2-(4- (pyridin-2-yl)piperazin-l-yl)pyrimidine-5-carboxamide (134), (S)-4-amino-N-(4-(3- fluoro-2-hydroxypropoxy)phenyl)-2-(4-(pyridin-2-yl)piperazin-l-yl)pyrimidine-5- carboxamide (135), (R)-4-amino-N-(4-(3-fluoro-2-hydroxypropoxy)phenyl)-2-(4- (pyridin-2-yl)piperazin-l-yl)pyrimidine-5-carboxamide (136)
[0349] 1H NMR (400 MHz, DMSO-d6) 5 9.75 (s, 1H), 8.61 (s, 1H), 8.13 (ddd, J = 4.9, 2.0, 0.8 Hz, 1H), 7.59-7.51 (m, 4H), 6.93-6.85 (m, 3H), 6.68-6.64 (m, 1H), 5.42 (d, J = 5.2 Hz, 1H), 4.59-4.38 (m, 2H), 4.04-3.93 (m, 3H), 3.90-3.83 (m, 4H), 3.59-3.52 (m, 4H);13C NMR (101 MHz, DMSO-d6) 5 165.4, 162.9, 160.9, 158.9, 157.4, 154.5, 147.6, 137.6, 132.3, 122.2, 114.4, 113.2, 107.2, 99.0, 84.4 (d, J = 168.2 Hz), 68.3 (d, J = 7.9 Hz), 67.7 (d, J = 19.0 Hz), 44.4, 42.9. 134: LCMS: 468 [M+H]+; HRMS (ESI) calculated for C23H27FN7O3+([M+H+]) 468.2154, found: 468.2155. White solid, 24 mg, 53%; 135: LCMS: 468 [M+H]+; HRMS (ESI) calculated for C23H27FN7O3+([M+H+]) 468.2154, found: 468.2155. White solid, 28 mg, 61%; 136: LCMS: 468 [M+H]+; HRMS (ESI) calculated for C23H27FN7O3+([M+H+]) 468.2154, found: 468.2185. White solid, 27 mg, 58%.
[0350] Example 95: Assays
[0351] Competition binding assays were performed with [3H]BF2846 and [3H]PIB ure affinity to Asyn and Ap. See, Table 1.
[0352] Ka and Bmax values of [3H]-Compound 113 were obtained from a panel of postmortem brain samples (e.g., PD, MSA, corticobasal degeneration (CBD), progressive supranuclear palsy (PSP), Alzheimer's disease (AD)). Nuclear emulsion autoradiography identified the distribution of [3H]-Compound 113 on PD and MSA tissues for aggregated Asyn, which was confirmed by antibody staining. Dynamic whole body PET images of [nC]- Compound 113 in non-human primate were obtained over 90 min. In in vitro binding assays, Compound 113 exhibited high binding affinity for Asyn (6.1 ± 2.1 nM) and low binding affinity at Ap fibrils (33-115 nM). In the tissue binding study, [3H]-Compound 113 exhibited high specific binding to all the investigated tissues (Kd = 5.1 nM for PD tissue; 4.5 nM for MSA; 18 nM for CBD, and 7.1 nM for PSP and 3.2 for AD). Interestingly, [3H]-Compound 113 had higher binding to pathologic Asyn in MSA compared to PD brain sections in autoradiography, suggesting [3H]-Compound 113 may be specific for MSA Asyn. In AD tissue, Compound 113 competed poorly with [3H]PiB (Ki=120 nM) for Ap, indicating high affinity binding of Compound 113 to AD tau only. The high affinity of [3H]-Compound 113 to AD, CBD and PSP may reflect binding to a novel binding site on aggregated tau since it could not be blocked with the tau ligands PI-2620, JNJ-067, PM-PBB3, and GTP-1 in homogenate binding and autoradiography studies. The non-human primate PET study confirmed that ["C]-Compound 113 had good brain uptake (SUV ~1.6) and rapid washout (2 : 60 min ratio -3.0).
[0353] Thus, [nC]-Compound 113 displayed binding to Asyn fibrils with low nM binding affinity. Tissue binding and autoradiography studies demonstrated [3H]-Compound 113 can bind to Asyn in postmortem tissue, particularly Asyn aggregates in MSA. Binding in CBD and PSP may indicate binding to a new site in aggregated tau. Whole body PET confirmed the favorable in vivo properties of ["C]-Compound 113 for brain imaging.
[0354] The contents of all references, patent applications, patents, and published patent applications, as well as the Figures, cited throughout this application are hereby incorporated by reference.
[0355] Those skilled in the art will recognize, or be able to ascertain using no more than routine experimentation, many equivalents to the specific embodiments of the disclosure described herein. Such equivalents are intended to be encompassed by the following claims.
Claims
What is Claimed is:
1. A compound of Formula I:wherein: n is 1 or 2;R1to R4are H; or R1and R3are H and R2and R4are joined to form -Ci-ealk-; or R2and R4are H and R1and R3are joined to form -Ci-ealk-;R5is optionally substituted aryl or optionally substituted heteroaryl;X1is absent or -C(O)-;X2absent, O, or NH;R6is H, CN, Ci-ealkyl, Ci-ealk-OH, or optionally substituted phenyl; and R7and R8are, independently, H, halo, or NH2; or a pharmaceutically acceptable salt or isotopic variant thereof.
2. The compound of claim 1, wherein n is 1.
3. The compound of claim 1, wherein n is 2.
4. The compound of any one of the preceding claims, wherein R1to R4are H.
5. The compound of any one of claims 1-3, wherein R1and R3are H and R2and R4are joined to form -Ci-ealk-, such as -CH2CH2-; or R2and R4are H and R1and R3are joined to form -Ci-ealk-, such as -CH2CH2-.
6. The compound of any one of the preceding claims, wherein R5is optionally substituted aryl, such as phenyl.
7. The compound of any one of the preceding claims, wherein R5is optionally substituted heteroaryl such as a N-containing heteroaryl, or such as pyridyl, isoquinolinyl, benzoxazolyl, benzthiazolyl, or quinoxalinyl, or such as optionally substituted pyridyl, or such as optionally substituted isoquinolinyl.
8. The compound of any one of the preceding claims, wherein X1and / or X2is absent.
9. The compound of any one of claims 1-7, wherein X1is -C(O)-.
10. The compound of any one of claims 1-7, wherein X2is O.
11. The compound of any one of claims 1-7, wherein X2is NH.
12. The compound of any one of the preceding claims, wherein R6and / or R7is H.
13. The compound of any one of claims 1-11, wherein R6is CN.
14. The compound of any one of claims 1-11, wherein R6is Ci-ealkyl, such as methyl, ethyl, propyl, butyl, pentyl, or hexyl, or such as methyl.
15. The compound of any one of claims 1-11, wherein R6is Ci-ealkOH, such as CH2OH, CH2CH2OH, propyl-OH, butyl-OH, pentyl-OH, or hexyl-OH.The compound of any one of claims 1-11, wherein R6is optionally substituted phenyl, such as, wherein R9is optionally substituted Ci-ealkyl, optionally substituted Ci-ealkoxy, halo, optionally substituted Ci-ehaloalkyl, or optionally substituted Ci-ehaloalkoxy.
16. The compound of any one of claims 1-15, wherein R7and / or R8is halo such as Cl, F, or Br, or such as F.
17. The compound of any one of claims 1-15, wherein R7and / or R8is NH2.
18. The compound of any one of the preceding claims, wherein the compound is of Formula I-A, I-B, I-C, I-D, or I-E:wherein, R10is Ci-ealkoxy, halo, Ci-6trihaloalkyl, or Ci-6trihaloalkoxy.
19. The compound of claim 1, that is:4-amino-N-(4-fluorophenyl)-2-(4-(pyridin-2-yl)piperazin-l-yl)pyrimidine-5- carboxamide (34);2-hydroxy ethyl 4-amino-2-(4-(pyridin-2-yl)piperazin-l-yl)pyrimidine-5-carboxylate (37);4-amino-2-(4-(pyri din-2 -yl)piperazin-l-yl)-N-(4-(trifluoromethyl)phenyl)pyrimidine- 5-carboxamide (35);4-amino-2-(4-(pyri din-2 -yl)piperazin- 1 -yl)-N-(4-(trifluoromethoxy)phenyl)pyrimidine-5-carboxamide (36);2-(4-(pyridin-2-yl)piperazin- 1 -yl)pyrimidin-4-amine (40);4-amino-2-(4-(pyridin-2-yl)piperazin-l-yl)pyrimidine-5-carbonitrile (41);(4-amino-2-(4-(pyridin-2-yl)piperazin-l-yl)pyrimidin-5-yl)methanol (38);5-methyl-2-(4-(pyridin-2-yl)piperazin-l-yl)pyrimidin-4-amine (39);ethyl 4-amino-2-(3-(benzo[d]thiazol-2-yl)-3,8-diazabicyclo[3.2.1]octan-8- yl)pyrimidine-5-carboxylate (12); ethyl 4-amino-2-(4-(benzo[d]oxazol-2-yl)piperazin-l-yl)pyrimidine-5-carboxylate(10); ethyl 4-amino-2-(4-(benzo[d]thiazol-2-yl)piperazin-l-yl)pyrimidine-5-carboxylate(11);4-amino-2-(4-(benzo[d]oxazol-2-yl)piperazin-l-yl)-N-(4-methoxyphenyl)pyrimidine- 5-carboxamide (26);4-amino-2-(4-(benzo[d]thiazol-2-yl)piperazin-l-yl)-N-(4-methoxyphenyl)pyrimidine- 5-carboxamide (27); ethyl 4-amino-2-(4-(4-methoxyphenyl)piperazin-l-yl)pyrimidine-5-carboxylate (17); ethyl 4-amino-2-(4-(quinoxalin-2-yl)piperazin-l-yl)pyrimidine-5-carboxylate (16);4-amino-N-(4-methoxyphenyl)-2-(4-(4-methoxyphenyl)piperazin-l-yl)pyrimidine-5- carboxamide (33);4-amino-N-(4-methoxyphenyl)-2-(4-(quinoxalin-2-yl)piperazin-l-yl)pyrimidine-5- carb oxami de (32);N-(4-methoxyphenyl)-2-(4-(pyridin-2-yl)piperazin-l-yl)pyrimidine-5-carboxamide (42); ethyl 4-amino-2-(4-(pyridin-2-yl)- 1 ,4-diazepan- 1 -yl)pyrimidine-5-carboxylate (7);4-amino-N-(4-methoxyphenyl)-2-(4-(pyridin-2-yl)- 1 ,4-diazepan- 1 -yl)pyrimidine-5- carboxamide (23); ethyl 4-amino-2-(4-(pyridin-2-yl)piperazin-l-yl)pyrimidine-5 -carboxylate (9); ethyl 4-amino-2-(8-(pyridin-2-yl)-3,8-diazabicyclo[3.2.1]octan-3-yl)pyrimidine-5- carb oxy late (4); ethyl 4-amino-2-(8-(isoquinolin-3-yl)-3,8-diazabicyclo[3.2.1]octan-3-yl)pyrimidine- 5-carboxylate (5); ethyl 4-amino-2-(8-(quinolin-3-yl)-3,8-diazabicyclo[3.2.1]octan-3-yl)pyrimidine-5- carb oxy late (6);4-amino-N-(4-methoxyphenyl)-2-(4-(pyridin-2-yl)piperazin-l-yl)pyrimidine-5- carboxamide (28); ethyl 4-amino-2-(3-(pyridin-2-yl)-3,8-diazabicyclo[3.2.1]octan-8-yl)pyrimidine-5- carb oxy late (1);4-amino-2-(8-(isoquinolin-3-yl)-3,8-diazabicyclo[3.2.1]octan-3-yl)-N-(4- methoxyphenyl)pyrimidine-5-carboxamide (21);4-amino-N-(4-methoxyphenyl)-2-(8-(quinolin-3-yl)-3,8-diazabicyclo[3.2.1]octan-3- yl)pyrimidine-5-carboxamide (22);4-amino-N-(4-methoxyphenyl)-2-(3-(pyridin-2-yl)-3,8-diazabicyclo[3.2.1]octan-8- yl)pyrimidine-5-carboxamide (18); ethyl 4-amino-2-(3-(isoquinolin-3-yl)-3,8-diazabicyclo[3.2.1]octan-8-yl)pyrimidine- 5-carboxylate (2); ethyl 4-amino-2-(3-(quinolin-3-yl)-3,8-diazabicyclo[3.2.1]octan-8-yl)pyrimidine-5- carb oxy late (3); ethyl 4-amino-2-(4-(quinolin-3-yl)-l,4-diazepan-l-yl)pyrimidine-5-carboxylate (8);4-amino-2-(3-(isoquinolin-3-yl)-3,8-diazabicyclo[3.2.1]octan-8-yl)-N-(4- methoxyphenyl)pyrimidine-5-carboxamide (19);4-amino-N-(4-methoxyphenyl)-2-(3-(quinolin-3-yl)-3,8-diazabicyclo[3.2.1]octan-8- yl)pyrimidine-5-carboxamide (20);4-amino-N-(4-methoxyphenyl)-2-(4-(quinolin-3 -yl)- 1 ,4-diazepan- 1 -yl)pyrimidine-5- carb oxami de (25);4-amino-2-(4-(isoquinolin-3 -yl)- 1 ,4-diazepan- 1 -yl)-N-(4-methoxyphenyl)pyrimidine- 5-carboxamide (24); ethyl 4-amino-2-(4-(quinolin-3-yl)piperazin-l-yl)pyrimidine-5-carboxylate (14); ethyl 4-amino-2-(4-(quinolin-2-yl)piperazin-l-yl)pyrimidine-5-carboxylate (15);4-amino-N-(4-methoxyphenyl)-2-(4-(quinolin-3-yl)piperazin-l-yl)pyrimidine-5- carboxamide (30);4-amino-N-(4-methoxyphenyl)-2-(4-(quinolin-2-yl)piperazin-l-yl)pyrimidine-5- carboxamide (31); ethyl 4-amino-2-(4-(isoquinolin-3-yl)piperazin-l-yl)pyrimidine-5-carboxylate (13);4-amino-2-(4-(isoquinolin-3-yl)piperazin-l-yl)-N-(4-methoxyphenyl)pyrimidine-5- carboxamide (29); ethyl 4-amino-2-(4-(pyridin-4-yl)piperazin-l-yl)pyrimidine-5-carboxylate (117);4-amino-N-(4-methoxyphenyl)-2-(4-(pyridin-3-yl)piperazin-l-yl)pyrimidine-5- carboxamide (118); ethyl 4-amino-2-(4-(pyrimidin-2-yl)piperazin-l-yl)pyrimidine-5-carboxylate (119);4-amino-N-(4-methoxyphenyl)-2-(4-(pyrimidin-2-yl)piperazin-l-yl)pyrimidine-5- carboxamide (120); ethyl 4-amino-2-(4-(pyrazin-2-yl)piperazin-l-yl)pyrimidine-5-carboxylate (121);4-amino-N-(4-methoxyphenyl)-2-(4-(pyrazin-2-yl)piperazin-l-yl)pyrimidine-5- carboxamide (122); ethyl 4-amino-2-(4-(thiazol-2-yl)piperazin-l-yl)pyrimidine-5 -carboxylate (123);4-amino-N-(4-methoxyphenyl)-2-(4-(thiazol-2-yl)piperazin-l-yl)pyrimidine-5- carb oxami de (124); ethyl 4-amino-2-(3-(benzo[d]thiazol-2-yl)-3,8-diazabicyclo[3.2.1]octan-8- yl)pyrimidine-5-carboxylate (125);4-amino-N-(4-methoxyphenyl)-2-(8-(quinolin-3-yl)-3,8-diazabicyclo[3.2.1]octan-3- yl)pyrimidine-5-carboxamide (126);4-amino-N-(2-fluoro-4-methoxyphenyl)-2-(4-(pyri din-2 -yl)piperazin-l-yl)pyrimidine- 5-carboxamide (127);4-amino-N-(3-fluoro-4-methoxyphenyl)-2-(4-(pyri din-2 -yl)piperazin-l -yl)pyrimidine- 5-carboxamide (128);2-hydroxy ethyl 4-amino-2-(4-(pyridin-2-yl)piperazin-l-yl)pyrimidine-5-carboxylate(129);N-(4-methoxyphenyl)-2-(4-(pyridin-2-yl)piperazin-l-yl)pyrimidine-5-carboxamide(130);4-amino-N-(4-hydroxyphenyl)-2-(4-(pyridin-2-yl)piperazin-l-yl)pyrimidine-5- carb oxami de (131);4-amino-N-(4-(2-fluoroethoxy)phenyl)-2-(4-(pyridin-2-yl)piperazin-l-yl)pyrimidine- 5-carboxamide (132); or4-amino-2-(4-(benzo[d]oxazol-2-yl)piperazin-l-yl)-N-(4-(2- fluoroethoxy)phenyl)pyrimidine-5-carboxamide (133); or a pharmaceutically acceptable salt or isotopic variant thereof.
20. A compound of Formula II:wherein:R20is optionally substituted Ci-ealkoxy or optionally substituted Ci-ehaloalkoxy;R21is H, optionally substituted Ci-ealkyl, optionally substituted Ci-ealkoxy, optionally substituted heteroaryl or optionally substituted aryl;Z2is CH or N; a, b, c, d, and e are, independently, 1 or 2;R22, R23, R24, and R25are H; or R23and R24are H and R22and R25are joined to form -Ci-ealk-; or R23and R25are H and R22and R24are joined to form -Ci- ealk-; or R22and R24are H and R23and R25are joined to form -Ci-ealk-; or R22and R25are H and R23and R24are joined to form -Ci-ealk-;R31, R32, R33, and R34are H; or R33and R34are H and R31and R32are joined to form a C3-8cycloalkyl; or R31and R32are H and R33and R34are joined to form a Cs-scycloalkyl; or a pharmaceutically acceptable salt isotopic variant thereof.
21. The compound of claim 20, wherein R20and / or R21is Ci-ealkoxy, such as OCH3.
22. The compound of claim 20, wherein R20is Ci-ehaloalkoxy, such as Ci-efluoroalkoxy, or such as OCH2F or OCH2CH2F.
23. The compound of any one of claims 20-22, wherein R21is H.
24. The compound of any one of claims 20-22, wherein R21is Ci-ealkyl, such as methyl.
25. The compound of any one of claims 20-22, wherein R21is optionally substituted aryl such as phenyl.
26. The compound of any one of claims 20-22, wherein R21is optionally substituted heteroaryl, such as a N-containing heteroaryl, or such as pyridyl, quinolinyl, or quinoxalinyl.
27. The compound of any one of claims 20-26, wherein Z1isThe compound of claim 27, wherein a, b, c, and d are 1; or a and b are 1 and c and d are 2; or a and c are 1 and b and d are 2; or a, b, and d are 2 and c is 1.
28. The compound of any one of claims 20-27, wherein29. The compound of claim 28, wherein e is 1 or 2.
30. The compound of claim 28, wherein R22, R23, R24, and R25are H.
31. The compound of claim 28, wherein R23and R24are H and R22and R25are joined to form -Ci-ealk-, such as -CH2-, -CH2CH2-, or CH2CH2CH2-; or R23and R25are H and R22and R24are joined to form -Ci-ealk-, such as -CH2-, -CH2CH2-, or CH2CH2CH2-.
32. The compound of claim 28, wherein R22and R24are H and R23and R25are joined to form -Ci-ealk-, such as -CH2-, -CH2CH2-, or CH2CH2CH2-; or R22and R25are H and R23and R24are joined to form -Ci-ealk-, such as -CH2-, -CH2CH2-, or CH2CH2CH2-.
33. The compound of any one of claims 20-27, wherein Z1is34. The compound of any one of claims 20-27, wherein Z1is35. The compound of claim 34, wherein R31, R32, R33, and R34are H.
36. The compound of claim 34, wherein R33and R34are H R31and R32are joined to form a Cs-scycloalkyl, such as cyclopropyl, cyclobutyl, cyclopentyl, or cyclohexyl; or R31and R32are H and R33and R34are joined to form a C3-8cycloalkyl, such as cyclopropyl, cyclobutyl, cyclopentyl, or cyclohexyl.
37. The compound of any one of claims 20-36, wherein Z2is CH.
38. The compound of any one of claims 20-36, wherein Z2is N.
39. The compound of claim 20, that is of formula II-A, II-B, or III-C:
40. The compound of claim 20, that is:4-methoxy-N-(4-(6-(pyridin-2-yl)-2,6-diazaspiro[3.3]heptan-2-yl)phenyl)benzamide (H7);4-methoxy-N-(4-(7-(pyridin-2-yl)-2,7-diazaspiro[3.5]nonan-2-yl)phenyl)benzamide (H8);4-methoxy-N-(4-(7-(3-nitrophenyl)-2,7-diazaspiro[3.5]nonan-2-yl)phenyl)benzamide (H9);4-methoxy-N-(4-(7-(pyridin-2-yl)-2,7-diazaspiro[4.4]nonan-2-yl)phenyl)benzamide (120);4-methoxy-N-(4-(5-(pyridin-2-yl)hexahydropyrrolo[3,4-b]pyrrol-l(2H)- yl)phenyl)benzamide (100);4-methoxy-N-(4-(2-(pyridin-2-yl)-2,8-diazaspiro[4.5]decan-8-yl)phenyl)benzamide (ioi);4-methoxy-N-(4-(5-(pyridin-2-yl)-2,5-diazabicyclo[2.2.1]heptan-2- yl)phenyl)benzamide (102);4-methoxy-N-(4-(3-(pyridin-2-yl)-3,8-diazabicyclo[3.2.1]octan-8- yl)phenyl)benzamide (103);4-methoxy-N-(4-(3-(quinolin-3-yl)-3,8-diazabicyclo[3.2.1]octan-8- yl)phenyl)benzamide (104);4-methoxy-N-(4-(3-(quinoxalin-2-yl)-3,8-diazabicyclo[3.2.1]octan-8- yl)phenyl)benzamide (105);4-methoxy-N-(4-(3-(pyridin-2-yl)-3,9-diazabicyclo[3.3.1]nonan-9- yl)phenyl)benzamide (106);4-methoxy-N-(4-(4-(pyridin-2-yl)- 1 ,4-diazepan- 1 -yl)phenyl)benzamide ( 107); N-(4-(4-(5-chloropyridin-2-yl)piperazin-l-yl)phenyl)-4-methoxybenzamide (108);4-methoxy-N-(5-(4-(pyridin-2-yl)piperazin-l-yl)pyridin-2-yl)benzamide (109);4-methoxy-N-(5-(3-(pyridin-2-yl)-3,8-diazabicyclo[3.2.1]octan-8-yl)pyridin-2- yl)benzamide (110);4-methoxy-N-(5-(4-(pyridin-2-yl)-l,4-diazepan-l-yl)pyridin-2-yl)benzamide (111);4-methoxy-N-(6-(3-(pyridin-2-yl)-3,8-diazabicyclo[3.2.1]octan-8-yl)pyridin-3- yl)benzamide (112);4-methoxy-N-(4-(4-methylpiperazin-l-yl)phenyl)benzamide (113);N-(4-(l-azaspiro[3.5]nonan-l-yl)phenyl)-4-methoxybenzamide (114); 4-methoxy-N-(4-(3-methoxyazetidin-l-yl)phenyl)benzamide (115);4-(2-fluoroethoxy)-N-(4-(3-(pyridin-2-yl)-3,8-diazabicyclo[3.2.1]octan-8- yl)phenyl)benzamide (116); or a pharmaceutically acceptable salt or isotopic variant thereof.
41. The compound of any one of claims 1-40, that is an isotopic variant.
42. The compound of claim 41, that is labeled with one or more of a non-radioactive isotope such as2H,13C, or15N, or such as2H, or such as13C, or such as15N; or labeled with a radioactive isotope, such as18F,nC, or123I, or such as18F, or such as nC, or such as123I.
43. A pharmaceutical composition comprising one or more compounds of any one of claims 1-42 and a pharmaceutical excipient.
44. A method of modulating alpha-synuclein in a patient in need thereof, comprising administering an effective amount of a compound of any one of claims 1-42 to the patient.
45. The method of claim 44, wherein the compound binds to alpha-synuclein.
46. The method of claim 44 or 45, further comprising performing positron emission tomography on the patient.
47. A method of treating a neurodegenerative disorder in a patient in need thereof, comprising: administering a pharmaceutical agent that clears aggregated alpha-synuclein from the brain of the patient; administering an effective amount of a compound of any one of claims 1-42 to the patient; and performing positron emission tomography imaging on the patient.
48. The method of claim 47, wherein the neurodegenerative disorder is a synucleinopathy such as Parkinson’s disease or multiple system atrophy.
49. The method of claim 47 or 48, wherein the pharmaceutical agent is a monoclonal antibody.
50. The method of any one of claims 47-49, wherein the imaging measures the amount of aggregated alpha-synuclein.
51. The method of any one of claims 47-50, wherein the compound has a low affinity for Ap.
Citation Information
Patent Citations
1,4-di (heterocyclic substituted) piperazines
US2459367A
2-(Piperazinyl)-4-pyrimioinamines
US4333937A
Bis-heteroaryl derivatives as modulators of protein aggregation
WO2018138086A1
Radiolabeled compounds
WO2019121661A1
